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Thesis abstract 
The development and optimisation of conditions for oxidative Wacker-type cyclisations 
followed by establishing the reaction scope are reported. Building upon the achievements in 
the field of oxidative Wacker-type reactions that has recently gathered interest, 
hydroxylamines 1 and hydrazines 2 were converted to isoxazolidines 3 and pyrazolidines 4 
respectively (Scheme 1). 
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Scheme 1 
 
Secondary hydroxylamines cyclised yielding syn-isoxazolidines with excellent 
diastereoselectivities, whereas secondary hydrazines cyclised yielding anti-pyrazolidines but 
still maintained a high level of diastereoselectivity.  Isoxazolidine 5 was successfully 
transformed to the corresponding amino alcohol 6, which was further converted to amino 
sugar derivatives 7 (Scheme 2). 
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1. Literature Review 
1.1. Introduction 
Electron-rich alkenes are typically unsusceptible to nucleophilic attack; complexation to an 
electrophilic transition metal, such as PtII, PdII or FeII, unlocks the potential for such a 
nucleophilic attack to occur. Palladium, which can exist in 3 interconvertible oxidation states: 
Pd0, PdII and PdIV, is known for its role in a range of well established reactions and is more 
often than not the first choice for activating unsaturated alkenes.1 Palladium is a versatile 
metal with its unique properties derived from the ability to form both d8 and d10 complexes at 
the +2 and 0 oxidation states respectively.2 
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Scheme 1.1 
 
The Wacker process, in which ethylene is converted to acetaldehyde by a Pd catalysed 
aerobic oxidation (Scheme 1.1), was developed in 1959 at Wacker Chemie.3 Many regard this 
development as the starting point for decades of research and development into many other 
Pd catalysed reactions. Whilst the Wacker process is regarded the origin of this field of 
chemistry, the discovery really dates back to 1894 when Phillips observed a stoichiometric 
2 
 
oxidation of ethylene using aqueous PdII salts.4 However, it was the Wacker process that 
really set the precedent for this chemistry with the use of a CuII co-catalyst in the presence of 
molecular oxygen, allowing for the use of catalytic amounts of palladium. 
The reaction proceeds via a β-hydroxyethyl-PdII intermediate 1.1 (Scheme 1.1) formed from 
the addition of hydroxide and palladium across the C-C double bond. This addition across the 
double bond has been labelled “Nucleopalladation”, where the nucleo represents the 
nucleophile; a label which is often changed to fit the nucelophile in use. In the case of the 
Wacker oxidation, the term is hydroxypalladation as hydroxide is the nucleophile. 
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Since the Wacker process was established there have been numerous examples demonstrating 
that PdII can catalyse the addition of different nucleophiles to alkenes. These demonstrate a 
range of intermolecular and intramolecular transformations, the most common being 
oxidative and non-oxidative C-O, C-N and C-C bond forming reactions.5 Research groups 
have also taken advantage of the highly reactive PdII-alkyl intermediates, demonstrating the 
ability of the moiety to subsequently participate in a wide range of reactions (Scheme 1.2).5 
The large range of nucleophiles, coupled with the possibility for further functionalisation 
allow for access to a range of synthetically useful building blocks. This area of synthetic 
organic chemistry has developed vastly over the past half century and still remains very much 
active today. New methodology is being developed, with research groups striving for lower 
catalyst loadings, milder conditions and stereochemical control over newly formed bonds.  
 
 
1.2. Mechanism of Aminopalladation 
Mechanistically, the nucleopalladation step is not as simple as it may first appear. It has been 
shown that two pathways exist, in which the addition of palladium and a nucleophile across a 
double bond can occur (Scheme 1.3). 
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The difference in the two pathways stem from whether the nucleophile coordinates to the Pd, 
before the addition takes place, or not. In the case of trans-nucleopalladation, the nucleophile 
does not coordinate before the addition step, it approaches from the opposite face to the PdII. 
After the addition takes place the newly formed bonds are trans- (anti-) with respect to each 
other. As for cis-nucleopalladation, the nucleophile coordinates to the Pd catalyst before the 
addition takes place. The nucleophile bound Pd then interacts with the alkene, and now the 
addition across the double bond occurs. The nucleophile migrates from the Pd to the alkene, 
and the resulting alkyl-Pd species has the newly formed bonds in a cis- (syn-) configuration.  
Understanding these two pathways is important from a stereochemical standpoint; control 
over the nucleopalladation step could have a big influence on the stereochemistry of newly 
formed bonds. In some cases both pathways have been shown to operate in parallel, when the 
energy barriers associated with each manifold are extremely similar.6 
 
1.2.1. Early Studies 
Early studies into the hydroxypalladation step of the Wacker process were carried out by 
Henry, providing evidence for a cis-hydroxypalladation pathway.7 Based upon kinetic 
analysis and rate law determination of the reaction, Henry suggested that hydroxide bound to 
palladium (cis) would undergo the alkene addition faster than that of the Pd-alkene species 
(trans).7 
Soon after these initial findings, several groups observed that under modified Wacker 
conditions the pathway would primarily proceed via trans-hydroxypalladation.8 These studies 
were designed to yield products that could easily be analysed based on stereochemical 
outcome. Henry and co-workers later reported that the change in reaction conditions led to 
the change in stereochemical pathway.9 Recent computational studies have provided further 
evidence for this theory.10 
Around the same time as the studies into hydroxypalladation of the Wacker and related 
reactions, various research groups began to study the stereochemical pathways involved in 
palladium catalysed amination reactions. Åkermark, Bӓckvall and Zetterberg reacted 
secondary amines with 2-butene. The aminated Pd-alkyl species 1.2 could be reacted further 
with NH(Me)2 or LiAlD4 to yield products that could be isolated and subjected to deuterium 
5 
 
studies to determine what stereochemical course was taken. They found that trans-AP was 
operating (Scheme 1.4).11 
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Scheme 1.4 
Taniguchi and co-workers isolated a Pd-alkyl intermediate 1.3 via an intramolecular alkene 
addition of enamide 1.4. The tricyclic product was isolated with stereochemistry indicative of 
a cis-AP mechanism. β-Hydride elimination is prevented as the Pd and β-H are in a trans-
configuration (Scheme 1.5).12 
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These early studies into nucleopalladation are important and show how the pathway can 
easily be altered. However, taking into account the sensitive nature of the nucleopalladation 
step, these earlier studies could not provide an accurate account of what transpires in a 
catalytic process.  
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Recently however, studies into catalytic amination reactions have gathered momentum. 
Recent studies have been primarily focused on understanding the mechanistic aspects of the 
catalytic aminopalladation step and how it is influenced by different factors, i.e. conditions, 
catalysts and the nature of the substrates. 
 
1.2.2. Oxidative Wacker-type Amination 
Oxidative amination is the sequence where an alkene undergoes aminopalladation and 
subsequent β-hydride elimination to furnish a product that contains a new C-N bond but 
retains the alkene functionality, albeit in a different position. Catalysed by an electrophilic 
PdII species, the aminopalladation step in this type of transformation can be unpredictable. 
Several groups have attempted to gain an understanding of what governs the two pathways. 
Stahl and co-workers reported the synthesis of a C2-symmetrical pyrrolidine via a palladium 
catalysed oxidative amination of norbornene and TsNH2 (Scheme 1.6).13 
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Through X-ray crystallography the group found that the pyrrolidine contained the nitrogen 
atom in a cis-configuration on the exo-faces of the alkenes. They suggested that intermediate 
1.5 could be formed via a cis-AP on the first equivalent of norbornene, and then proposed a 
mechanistic pathway, leading to the formation of 1.6 (Scheme 1.7, pathway A). Pathway A 
involves a Heck-type addition of the Pd-alkyl intermediate 1.5 into the alkene of a second 
norbornene equivalent, followed by C-N coupling with elimination of palladium to furnish 
1.6. In a recent review, Stahl suggested an alternate pathway that could also give rise to 1.6 
(Scheme 1.7, pathway B).14 Pathway B proceeds slightly differently with a 4-membered Pd-N 
intermediate 1.7 forming before the insertion of the second norbornene molecule. Addition of 
7 
 
the second olefin to the Pd-N bond yields a 6-membered intermediate 1.8, containing both Pd 
and N bridging atoms. Subsequent C-C reductive elimination leads to the product 1.6. Both 
pathways are mechanistically viable and both account for the formation of product 1.6 from a 
cis-aminopalladation. 
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Two years after this report, Liu and Stahl published findings on the mechanistic studies of an 
intramolecular aminopalladation. Using a range of known oxidative amination conditions, 
they set out to determine the effect of different catalyst systems on the aminopalladation 
pathway.15 A deuterated substrate 1.9 was designed to probe different aminopalladation 
pathways. The product structures 1.10-1.13 could easily be identified to determine the 
dominant aminopalladation route (Scheme 1.8). During the cis-AP pathway in Scheme 1.8, 
1.11 is formed from β-hydride elimination of 1.14, and 1.10 is formed from β-hydride 
elimination, reinsertion of Pd-H and another β-hydride elimination. As the Pd and β-D atoms 
are in an anti-conformation as a result of cis-AP, the D atom remains unchanged. For the 
trans-AP pathway, the Pd and β-D are in a syn-configuration, so this time β-deuteride 
elimination can occur. The two products 1.12 and 1.13 are then formed via the same way as 
for the cis-AP pathway, with loss and shift of D respectively. 
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When the substrate 1.9 was submitted to the different catalyst systems, the results showed 
that cis-AP is dominant (Table 1.1, entries 1-4), with the exception of the NHC catalyst 
system of Pd(IMes)(TFA)2)/BzOH (Table 1.1, entry 5), which showed a 1:1 mixture of cis- 
and trans-pathway products. It was observed that this system was the only one operating 
under acidic conditions, in the presence of BzOH, where as the others are under basic 
conditions, from either exogenous base or a basic anionic ligand. 
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Scheme 1.8 
 
With this observation came the hope of seemingly being able to direct the course of the 
aminopalladation pathway. So with this they screened various acid and base additives with 
the NHC catalyst system (Table 1.2). 
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Table 1.1 
Ts
N
Ts
N
Ts
N
Ts
N
D D
D
cis-AP
products
trans-AP
products
D
TsHN catalyst
O2 (1 atm)
toluene, 80 °C
 
 Catalyst Yield (%) Product ratios - cis:trans 
1 Pd(OAc)2/DMSO 70 100 (100:0)              :                    0 
2 Pd(OAc)2/py 84 100 (98:2)                :                    0 
3 Pd(TFA)2/py 85 100 (88:12)              :                    0 
4 Pd(TFA)2/(−)-sparteine 37 100 (59:41)              :                    0 
5 Pd(IMes(TFA)2)/BzOH 60 51 (43:8)                  :                    49 (37:12) 
 
 
Table 1.2 
Ts
N
Ts
N
Ts
N
Ts
N
D D
D
cis-AP
products
trans-AP
products
D
TsHN
 
 Additive (pKa) Yield (%) of cis-AP  
(ratio of products) 
Yield (%) of trans-AP  
(ratio of products) 
1 None 39 (38:10) 20 (26:6) 
2 AcOH (4.76) 36 (49:8) 26 (34:7) 
3 BzOH (4.20) 31 (43:8) 29 (37:12) 
4 CF3CO2H (-0.25) 4 (ND) 9 (ND) 
5 NaOAc 68 (87:13) 0 
6 Na2CO3 71 (89:11) 0 
Reaction conditions: 1.9 (0.05 mmol), (IMes)Pd-(O2CCF3)2(OH2) (2.5 μmol), additive (AcOH and BzOH, 20 
mol %; CF3CO2H, 1 eq.; Na2CO3, 2 eq.), O2 (1 atm), toluene (0.5 mL), 80 °C, 72 h. ND = Not determined. 
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In the absence of additives both cis- and trans-AP products were obtained, favouring the cis-
products 2:1 (Table 1.2, entry 1). With increase in the strength of the added acid, the relative 
ratio of cis: trans-AP decreases, from 1.5:1 for AcOH to 1:2 for TFA (Table 1.2, entries 2-4). 
When base was used as the additive the cis-AP pathway was operating exclusively and the 
products were achieved in an improved yield (Table 1.2, entries 5-6). These observations 
seem to suggest that the dominant aminopalladation pathway is influenced by the pH of the 
reaction mixture. 
Following this, Stahl and co-workers investigated how the acidity of the nitrogen nucleophile 
tethered to the substrate would affect the stereochemical course of the reaction. With the pKa 
of TsNH2 ≈ 15.1, NsNH2 ≈ 13.9 and RCONHTs ≈ 9 (all in DMSO), it was expected that 
substrates bearing more acidic nitrogen atoms would show a different preference for 
stereochemical outcome of the aminopalladation step (Figure 1.1).  
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1.15 1.16  
Figure 1.1 
 
First the Ns derivative 1.15 was subjected to the catalyst screen (Table 1.3), which gave 
exclusively cis-AP products for all catalyst systems, including the acidic NHC/BzOH system. 
From this observation it would seem that increasing the acidity of the nucleophile increases 
the preference for cis-AP. 
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Table 1.3a 
Ns
N
Ns
N
Ns
N
Ns
N
D D
D
cis-AP
products
trans-AP
products
D
NsHN catalyst
O2 (1 atm)
toluene, 80 °C
 
 Catalyst Yield (%) Product ratios - cis:transb 
1 Pd(OAc)2/DMSO 74 100 (100:0)              :                    0 
2 Pd(OAc)2/py 91 100 (100:2)              :                    0 
3 Pd(TFA)2/py 86 100 (90:10)              :                    0 
4c Pd(IMes(TFA)2)/BzOH 78 100 (82:18)              :                    0 
(a) Reaction conditions: 5 mol % Pd, 33 μmol scale, 80 °C, 24 h. (b) Determined by 1H NMR spectroscopy      
(c) 32 h. 
 
However, an even more acidic sulfonamide 1.16 gave rise to a more complex and unexpected 
set of results (Table 1.4). 
 
Table 1.4a 
Ts
N
Ts
N
Ts
N
Ts
N
D D
D
cis-AP
products
trans-AP
products
D
TsHN
catalyst
O2 (1 atm)
O
O O O O
 
 Catalyst Yield (%) Product ratios - cis:transb 
1 Pd(OAc)2/DMSO 73 0                             :                    100 (100:0) 
2 Pd(OAc)2/py 47 89 (85:4)                :                    11 (4:7) 
3 Pd(TFA)2/py 83 84 (78:6)                :                    16 (14:2) 
4c Pd(IMes(TFA)2)/BzOH 74 54 (41:13)              :                    46 (22:24) 
5c Pd(IMes(TFA)2)/Na2CO3 34 67 (65:2)                :                    33 (32:1) 
(a) Reaction conditions: 5 mol % Pd, 33 μmol scale, 80 °C, 24 h. (b) Determined by 1H NMR spectroscopy      
(c) 32 h. 
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The Pd(OAc)2/DMSO system (Table 1.4, entry 1) which had previously given solely cis-AP 
products gave 100% trans-AP with this substrate. The two systems with exogenous pyridine 
(Table 1.4, entries 2-3) that previously gave predominantly cis-AP products now contained 
small amounts of the trans-AP products too. The NHC catalyst with BzOH (Table 1.4, entry 
4) gave 1:1 cis:trans products whereas substituting BzOH with Na2CO3 (Table 1.4, entry 5) 
favoured the cis products 2:1. They speculated that these observations could originate from 
the anion of amide 1.17 being more stable in DMSO than the corresponding Pd-N 
intermediate, thus leading to a more readily dissociated Pd-N bond and resulting ultimately in 
an increase in trans-AP (Figure 1.2). 
 
Tol
S
O
N
O O
1.17  
Figure 1.2 
 
In the case of the Pd(OAc)2/DMSO system Stahl suggested that the anionic acetate is a strong 
enough base to deprotonate the sulfonimide 1.16 and in the polar solvent DMSO, stabilisation 
of the anion does not require a metal centre. Essentially acetate deprotonates, DMSO 
stabilises the anion and palladium does not interact with the nitrogen at all, thus favouring 
trans-AP exclusively. This study by Stahl is perhaps the most important carried out in the 
field as it emphasises the fine balance between the nature of the catalyst, substrate identity 
and the influence of external additives, and how altering one factor can drastically change the 
stereochemical course of the reaction. 
Stahl and co-workers also reported an intermolecular oxidative amination, reacting 
phthalimide, as the nucleophile, with a Z-alkene.16 A product Z-1.19 that indicated a cis-AP 
pathway was obtained (Scheme 1.9). 
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Scheme 1.9 
 
The product E-1.19 that would arise from a trans-AP was not observed. This is unexpected 
given that the previous findings suggest that more acidic nucleophiles favoured trans-AP.16 
Stahl later hypothesised that in fact trans-AP could occur and E-1.19 is formed but 
reinsertion of Pd-H, followed by σ-bond rotation ultimately yields Z-1.19 (Scheme 1.10). 
This process would have to be thermodynamically more favourable.14 
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Scheme 1.10 
 
Whilst this alternate hypothesis is viable, it could simply be that cis-AP is dominant due to 
the lack of a polar solvent. The stabilisation that a polar solvent, such as DMSO, would 
provide to the phthalimide anion would mean that coordination to Pd is not necessary. This 
would lead to a decrease in Pd-N species formed, and as a result lead to an increase in trans-
AP. 
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The Hartwig group published a report on intermolecular insertion of alkenes into a Pd-amide 
species.17 Using a variety of preformed Pd-N complexes exposed to ethylene or octene, an 
aminopalladation/β-hydride elimination sequence took place. It was discovered that 
complexes with electron-rich amides reacted faster than those with electron-poor amides. 
Evidence for a cis-AP pathway was provided with deuterium studies on Z-ethylene-d2 
(Scheme 1.11), however it was only carried out for electron-rich amides, more electron-
deficient amides could proceed via a different mechanism. 
 
D
D
PdL(THF)(NPh2)
D
D
D
D
[Pd]
NPh2
[Pd]
NPh2 β-hydride elimination
D
NPh2
D
D
NPh2
D
NPh2
D
D
NPh2
β-hydride 
elimination
PdL(THF)(NPh2)
Observed
Not observed
PdL(THF)(NPh2) = Pd
P
t-But-Bu
NPh2
O
 
Scheme 1.11 
 
In 2012, Bӓckvall reported a PdII catalysed oxidative cyclisation of allylic tosyl carbamates 
(Scheme 1.12).18 
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Scheme 1.12 
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Bӓckvall proposed that the reaction could proceed via 3 different pathways; cis- or trans-AP 
or a C-H activation pathway. Only the product arising from trans-AP was observed in the 
deuterium labelling studies carried out (Scheme 1.13). 
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Scheme 1.13 
 
This key observation provides support to the initial hypothesis by Stahl. Trans-AP is 
dominant when an acidic nucleophile, in this case a carbamate, is in the presence of anionic 
acetate and DMSO, allowing easy deprotonation of the nucleophile. Stabilisation of the 
resulting anion comes from the polar solvent and does not require coordination to a metal 
centre. 
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1.2.3. Aminoarylation 
Alkene difunctionalisation is the sequence by where aminopalladation and C-X insertion are 
taking place to yield a di-substituted product. A range of different functional groups can be 
introduced depending on the reactants. However, with this comes a new problem in 
determining the stereochemical course of the aminopalladation step, as the Pd-alkyl species 
then can be further functionalised either with retention or inversion of stereochemistry with 
respects to the Pd-C bond (Scheme 1.14). 
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NR NRPd X
NR Pd NR X
cis-AP
trans-AP
Difunctionalisation
with inversion
Difunctionalisation
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Difunctionalisation
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Scheme 1.14 
 
Perhaps the most documented of the amination/functionalisation reactions is aminoarylation, 
where a Pd-aryl species is formed by oxidative addition of an aryl halide to Pd0 followed by 
aminopalladation and C-C reductive elimination of the resultant alkyl-Pd-aryl species. 
Wolfe and co-workers reported that pyrrolidines could be synthesised from γ-(N-
arylamino)alkenes and aryl halides (Scheme 1.15).19 They observed that 4 different products 
were formed in the reaction and proposed a cis-AP mechanism that accounts for all 3 cyclised 
products 1.20-1.22 and, in part, for the observed N-Ar product 1.23 (Scheme 1.16). Oxidative 
addition of ArBr to Pd gives the ArPdBr species which forms a Pd-N bond to give 1.24. This 
undergoes cis-AP to yield 1.25, now two pathways arise; i) where C-C reductive elimination 
yields 1.20, ii) where β-hydride elimination occurs to give 1.22. 1.21 is formed by the 
reinsertion of Pd-H into the C-C double bond, followed by C-C reductive elimination. 
17 
 
NH
PMP
N N N
N
PMP
Ar
PMP PMP PMP
Ar
Ar
H H H H
ArBr
Pd2(dba)3 (1 mol %)
P(o-tol)3 (4 mol %)
NaOt-Bu (1.4 eq)
PhMe, 110 °C
Ar = 4-PhC6H4
PMP = 4-Methoxyphenyl 1
.20 32% 1.21 12% 1.22 5% 1.23 19%
Scheme 1.15 
 
The formation of 1.23 is what gives the most support to the claim of a cis-AP mechanism. 
The aryl group has undergone C-N reductive elimination to furnish this product, the only way 
this could occur is if an Ar-Pd-N species 1.24 existed before the aminopalladation step took 
place. A trans-AP mechanism would most likely not see this compound being formed. 
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Scheme 1.16 
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Wolfe and co-workers obtained additional evidence to support the theory that aminoarylation 
proceeds via cis-AP when they studied the intramolecular bicyclisation of a tethered aryl 
bromide and amine across a Z-alkene 1.26 (Scheme 1.17).20 
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Scheme 1.17 
 
Using PCy3·HBF4 as the ligand, almost entirely cis-AP was observed, however changing the 
ligand to (±)-BINAP gave a 1:1 mixture of cis- and trans-AP products. The authors suggest 
that in the case of (±)-BINAP, the amine is more readily deprotonated and less likely to 
coordinate to Pd. It is possible that this bulky bidentate ligand may not allow room for Pd-N 
formation. In an analogous reaction using alcohol as the nucleophile (±)-BINAP gives a 
majority of trans-OP product 1.27 (Scheme 1.18). 
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Scheme 1.18 
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The fact that this more acidic oxygen favours trans-AP compared to the less acidic nitrogen 
supports the theory, proposed by Stahl, that the acidity of the nucleophile can alter the 
predominant aminopalladation pathway when using a set catalyst system.15 
Further studies into aminoarylation and the effects played by different external bases in the 
AP step were carried out by Wolfe.21 N-Boc amines were cyclised to yield pyrrolidines with 
high diastereoselectivity, which is indicative of a preference for one AP pathway (Scheme 
1.19). 
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Scheme 1.19 
 
Regardless of the base that was used the stereochemical outcome in both cases suggest a cis-
AP. This was also confirmed using a deuterated alkene 1.28, which gave a single 
diastereoisomer, resulting from cis-AP (Scheme 1.20). 
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Scheme 1.20 
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It is possible that Pd can form a complex 1.29 with the amine and the adjoining Boc group, 
this stabilised intermediate is formed after N-H deprotonation facilitated by the base (Figure 
1.3). 
N O
O
Pd
Ln
1.29  
Figure 1.3 
 
Wolfe and co-workers investigated intramolecular aminoarylation, in the synthesis of 
isoxazolidines22 and pyrrolidines.23 Deuterium and 13C labelling was used to prove the mode 
of aminopalladation. Once again a cis-AP pathway was shown to be dominant (Scheme 
1.2122 and 1.2223). 
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Scheme 1.21 
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Scheme 1.22 
 
Michael and co-workers reported intramolecular aminoarylation and diamination reactions 
promoted by N-fluorobenzenesulfonamide (Scheme 1.23).24 
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Scheme 1.23 
 
The stereochemical pathway was studied25 by trapping the Pd-alkyl intermediate with 
bipyridine 1.30 (Scheme 1.24). The isolated structure suggests that the mechanism proceeds 
via a trans-AP. The authors justify this preference by the type of nucleophile used, stating 
that the acidic conditions along with an N-H bond that is difficult to deprotonate promote 
trans-AP. However as previously mentioned more acidic nucleophiles, such as phthalimide 
and sulfonamide, prefer to undergo trans-AP and as acetamide is less acidic in comparison, it 
would be expected that cis-AP would be favourable in this case. This observation once again 
highlights the importance of the balance between nitrogen acidity and pH of the reaction 
mixture. 
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Scheme 1.24 
 
This observation has proved to be somewhat contradictory to the findings of other research 
groups and needs to be investigated further to determine the factors causing this preference 
for trans-AP. A mechanism was proposed, whereby the PdII-alkyl intermediate formed by 
trans-AP can undergo oxidation by FN(SO2Ph)2 to form a PdIV intermediate, PdIV may then 
be substituted by Ar or N(SO2Ph)2 in an SN2 like fashion, yielding a product whose 
stereochemistry would indicate a cis-AP pathway.  
Whilst aminoarylation is a well documented procedure, the stereochemical course of 
aminopalladation in these reactions is less so. The work by Wolfe has outlined that whilst cis-
AP seems to be dominant, it is not exclusive. These studies have also provided support to the 
mechanistic hypothesis by Stahl that were discussed earlier. 
 
1.2.4. Intermolecular Alkene Difunctionalisation 
This area has been a subject of much interest, however the mechanistic aspects have mostly 
been focused on intramolecular aminoarylation. However, following on from the previously 
discussed intramolecular vartiant, Lui and Stahl reported an intermolecular 
aminoacetoxylation of an alkene 1.31 with phthalimide (Scheme 1.25).16 
 
Ph OMe NHPhth Ph
OAc
NPhth
OMe
Pd(MeCN)2Cl2 (10 mol %)
PhI(OAc)2 (2.5 eq)
DCE, 70 °C, 52%1.31
1.32  
Scheme 1.25 
23 
 
The difunctionalised product 1.32 was obtained in an anti-configuration, however the authors 
proposed that the mechanism goes via cis-AP. The PdII-alkyl intermediate can be oxidised to 
a PdIV intermediate by PhI(OAc)2. The PdIV may then be substituted in an SN2 type 
substitution that would furnish the observed anti-configuration in 1.32.  
 
1.2.5. Aminocarbonylation 
In 1988, Tamaru and co-workers reported that alkylamines, in the presence of PdII and CO 
could undergo catalytic intramolecular aminocarbonylation.26 In this case AP takes place, 
then CO inserts into the Pd-C bond of the Pd-alkyl intermediate. Reductive elimination with 
MeOH furnishes an ester. In the case of ureas 1.33, C-N reductive elimination can also occur 
yielding a cyclic amide 1.34 (Scheme 1.26). 
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Scheme 1.26 
 
It is documented that carbonylation of a Pd-C bond usually results in retention of 
configuration,27 therefore the stereochemistry observed in this instance is evident of trans-AP 
taking place. 
Recently Malkov et al. reported on a stereoselective PdII catalysed aminocarbonylation of N-
Boc alkoxyamines 1.35, 1.36 (Scheme 1.27a).28 
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Scheme 1.27 
In order to gain an insight into the mechanistic pathways occurring in these reactions a 
substrate with an internal double bond was employed, which upon aminocarbonylation 
would, through stereochemistry of the product, cast light on the pathway involved (Scheme 
1.27b). Analysis of the product by X-ray crystallography indicated formation of syn, anti-
isoxazolidine 1.37. To rationalise the observed stereochemistry, it was suggested that the 
carbamate group would coordinate the PdII catalyst, followed by syn- addition across the 
alkene (Scheme 1.28). 
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Scheme 1.28 
 
The Pd-alkyl species can attack either face of the alkene, where formation of the syn-isomer 
takes preference over the anti-isomer, due to the increased allylic strain in the latter. The 
product that would arise from trans-AP is not observed, therefore this manifold can be ruled 
out. 
 
These studies into the aminopalladation step have provided a basis of understanding as to 
why one pathway may be dominant over another. The acidity and coordination ability of the 
nucleophile, along with the types of additives, play the most important roles in determining 
which pathway prevails. 
 
 
 
 
1.2.6. Enantioselective Intramolecular Amination 
Whilst intramolecular amination reactions are quite well documented, enantioselective 
variants have not been explored to the same extent. The ambiguity of the AP step and the lack 
of known ligands for this type of transformation are the barriers that hold back progress in 
this area. However, some research groups have shown that these reactions can indeed be 
achieved with simple ligands and under mild conditions. 
Yang and co-workers reported that in the presence of Pd(TFA)2 and (−)-sparteine, amines 
1.38 undergo carboamination to yield tricyclic products 1.39 (Scheme 1.29).29 
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Scheme 1.29 
 
 
As only one enantiomer of sparteine exists in nature, the researchers sought more efficient 
ligands that could be synthesised in both enantiomeric forms. In 2009, a similar 
carboamination reaction was reported, employing a chiral quinolineoxazoline 1.40 (Scheme 
1.30).30 Formation of a single diastereoisomer by a cis-AP route was observed. The 
stereochemistry was explained by suggesting a transition state model, in which the ligand 
coordinates to Pd in a bidentate model. The other two vacant sites are filled with the alkene 
and nitrogen. The authors state that for the observed stereochemistry, the N atom of the 
acrylamide and the alkene occupy site a and b respectively (Scheme 1.31a). 
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Scheme 1.30 
 
The si-face cyclisation shown in Scheme 1.31b is the mostly likely path leading to the 
observed stereochemistry, as others are hindered by steric repulsion of bulky groups in close 
proximity. 
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Scheme 1.31 
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The cis-AP pathway plays an important role in forming a sterically congested reactive 
intermediate, whereas the chiral ligand determines the enantiofacial selectivity of the 
reaction, thus both contributing the stereochemical outcome of the newly formed bonds.  
Mai and Wolfe reported a synthesis of enantioenriched pyrrolidines via an aminoarylation 
from N-Boc alkenylamines and aryl halides.31 The chiral monodentate ligand (R)-Siphos-PE 
was found to provide moderate to excellent enantioselectivity in this reaction (Scheme 1.32). 
 
NHBoc
R1
R1
R2
NBoc
R1
R1
R2
X
Pd(dba)3 (2.5 mol %)
(R)-Siphos-PE (7.5 mol %)
NaOt-Bu, PhMe, 90 °C
O
O
P N
Ph
Ph
(R)-Siphos-PE =
yield 61-80%
ee 72-94%R1 = H, Me, OEt
R2 = aryl, alkyl
 
Scheme 1.32 
 
Based upon their previous studies into aminoarylation21 they expected a cis-AP pathway, 
which was confirmed by deuterium labelling studies (Scheme 1.33). 
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Scheme 1.33 
 
It was noticed that altering the Pd:ligand ratio to 1:1 and 1:2 had no effect on 
enantioselectivity, which suggested the formation of a monoligated Pd complex. Whilst the 
intermediate structure in the reaction is not totally clear, it is evident that monodentate 
29 
 
ligands take precedence over chelating ones in this instance. With bis-phosphine ligands a 
decline in enantioselectivity was observed, which was credited to the loss of “one arm” of the 
chelate upon coordination to substrate (Figure 1.4). 
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Figure 1.4 
 
Sasai and colleagues reported an enantioselective amination/carbonylation using a chiral 
spiro bis(isoxazoline) ligand 1.41 (Scheme 1.34).32 The reactions yielded bicyclic products 
1.42 in practical ee’s (up to 89%). 
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Scheme 1.34 
 
The reaction was thought to proceed via trans-AP, enforced by the steric bulk of the i-Pr 
groups of ligands that led to a re-facial attack (Scheme 1.35). In this case it appears that the 
chelated Pd complex 1.43 with CO takes preference over forming a Pd-N species. 
Interestingly this shows that cis-AP is not exclusive for enantioselective reactions, and that 
30 
 
both pathways are still viable. In this case trans-AP is favoured due to the steric bulk of the 
ligand. 
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Scheme 1.35 
 
In 2011, Stahl reported a mild enantioselective oxidative amidation of alkenes, employing a 
Pd(TFA)2/pyrox catalyst system (Scheme 1.36).33 
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It was observed that when using Pd(OAc)2 as the PdII source the ee observed was severely 
diminished, for reasons not fully understood at this stage. Based on earlier results with the 
Pd(OAc)2/py, Pd(TFA)2/py and Pd(TFA)2/(−)-sparteine catalyst systems,15 the reaction was 
expected to proceed via a cis-AP mechanism. Transition state energies were calculated under 
the assumption of the cis-AP pathway being dominant (Scheme 1.37). However, further 
investigation was required to unravel the mechanistic pathways of this reaction. 
A year later, Weinstein and Stahl attempted to establish a direct correlation between the 
stereochemistry of nucleopalladation and enantioselectivity of the reaction.34 
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Scheme 1.37 
 
They used the previously mentioned deuterated substrate 1.09 (See Scheme 1.8) to probe the 
avenue of AP. Under the new reaction conditions with the pyrox ligand, an unexpected 
mixture of products 1.10-1.13 were observed, where the trans-AP pathway was dominant, 
however a significant amount of cis-AP products were also isolated (Scheme 1.38). 
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Scheme 1.38 
The 3:1 ratio of trans/cis-AP products was surprising as a cis-AP mechanism was expected to 
be the main pathway, if not exclusive. To imitate the conditions that gave the high 
enantioselectivity, they used an acyclic substrate 1.45 that would resemble the substrates used 
in the original reaction (Scheme 1.39). When 1.45 was submitted to the enantioselective 
amination conditions, trans-AP was again found to be favoured, this time 91:9, and the yield 
and ee were consistent with that previously observed, 90% and 96% respectively (Table 1.5, 
entry 1). It was noted that the difference in the enantioselectivities of the two substrates could 
be attributed directly to the AP step. In the cyclic example, trans-AP:cis-AP is 3:1 and the ee 
is poor, where as in the acylic substrate trans-AP:cis-AP is 9:1 and the ee is excellent. This 
proved that the ambiguity of the AP step is the biggest drawback in developing this type of 
reaction. 
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Scheme 1.39 
 
Table 1.5 
 PdII Ligand Yield (%) ee (%) Ratio of productsa 
trans-AP(a+b):cis-AP(c+d) 
1 Pd(TFA)2 (S)-144 90 96 91:9 (91+0):(7+2) 
2 Pd(OAc)2 (S)-144 48 20 10:90 (9+1):(51+39) 
3 Pd(TFA)2 none 55 0 1:6 
4 Pd(OAc)2 none 15 0 <1:9 
(a) Products outlined in Scheme 1.39. 
 
When the PdII source was changed to Pd(OAc)2, which in their original paper gave poor 
enantioselectivity, cis-AP was the main pathway in a ratio of 9:1 (Table 1.5, entry 2). The 
breakdown of products shows that the trans-AP still maintains high enantioselectivity (9:1), 
where as the cis-AP products are more even mixture (51:39). The main conclusion drawn 
from this observation is that trans-AP is required for any significant enantioselectivity to 
occur, at least for this catalyst, ligand and substrate combination. When the ligand was 
removed from the system, rather unexpectedly both PdII sources exhibited preference for cis-
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AP (Table 1.5, entries 3-4). This means that the ligand plays a crucial role in enforcing the 
trans-AP pathway with Pd(TFA)2 as the PdII source. However this is contrary to the previous 
hypothesis where anionic carboxylate ligands acting as a weak base would mediate cis-AP, 
instead it appears that the combination of anionic trifluoroacetate and neutral-donor pyrox 
ligands results in trans-AP. The substitution of TFA by the substrate alkene is more favoured 
than Pd-N formation (Figure 1.5). 
 
Pd TFAN
N
NH
>>
N
Pd
N
N
 
Figure 1.5 
 
It is clear from these studies that both aminopalladation pathways can give good 
stereoselectivity, however to obtain a high ee a single pathway must be dominant. It has been 
shown that in some cases cis-AP gives little or no stereoselectivity and trans-AP is required 
for the high ee observed, however this trans-AP is only obtained by the presence of the chiral 
ligand. Without the ligand, cis-AP is dominant again. This area has a lot left to be explored 
but the difficulty in predicting and controlling the AP pathways, coupled with only a small 
library of ligands available make this a difficult subject to approach. The studies carried out 
by Stahl have laid the groundwork for understanding the factors dictating the 
aminopalladation pathway. 
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1.3. Synthetic Examples of Intramolecular Amination 
There has been little, albeit important, exploration into the mechanistic aspects of this field; 
however the reactions in this area are diverse and well documented. There have been many 
examples of intramolecular amination reactions furnishing a range of heterocycles. 
 
1.3.1. Synthesis of Pyrrolidines and Related Derivatives 
Several groups have reported the synthesis of functionalised pyrrolidines from the cyclisation 
of simple cyclic and acyclic aminoalkenes (Scheme 1.40). Larock35 used a Pd(OAc)2/DMSO 
system in the presence of O2 over 72 h, however, Stahl36 reported that the same 
transformations could be furnished in just 2 h with Pd(OAc)2/pyridine in an atmosphere of 
O2. Stahl’s mechanistic studies revealed that the reoxidation of Pd by O2 was the limiting 
factor in the Pd/DMSO system.37 He reported that pyridine and other imine donor ligands 
could improve efficiency compared to neat DMSO and are required for direct oxidation of Pd 
by O2.38 
 
NHTs
a) Pd(OAc)2 (5 mol %)
NaOAc (2 eq)
DMSO, O2, rt
72 h, 93%
b) Pd(OAc)2 (5 mol %)
pyridine (10 mol %)
xylene, 80 °C
2 h, 87%
Ts
N
NHTs
N
Ts
a) Pd(OAc)2 (5 mol %)
NaOAc (2 eq)
DMSO, O2, rt
72 h, 86%
b) Pd(OAc)2 (5 mol %)
pyridine (10 mol %)
xylene, 80 °C
2 h, 91%
a) = Larock conditions
b) = Stahl conditions
 
Scheme 1.40 
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Various aryl amines with tethered alkenes were cyclised giving indoles, with little difference 
in reactivity between the two catalyst systems. Interestingly the use of an aryl amine 
containing a tethered terminal alkene 1.46 seems to prefer forming a six-membered ring 1.47 
under Larock’s conditions (Scheme 1.41a). Stahl reported that the same substrate cyclised to 
yield 2-methylindole 1.48. It would appear that the product observed by Larock could arise 
from π-allyl complex formation rather than aminopalladation. Larock’s findings contrast, 
whereas Stahl’s work compliment the results by Hegedus, where indoles 1.49 were formed 
exclusively when catalytic PdCl2(MeCN)2 was used (Scheme 1.41b).39 
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THF, 82%
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Scheme 1.41 
 
Indoles 1.48 and 1.49 most likely arise from the re-insertion of Pd-H followed by another β-
hydride elimination. 
 
Later, Stahl and co-workers reported that pyrrolidines can be synthesised using a 
Pd(TFA)2/NHC catalyst system under an atmosphere of O2 or air (Scheme 1.42).40 
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Scheme 1.42 
 
Various substituted amines were cyclised giving pyrrolidines in excellent yields. Terminal 
alkenes gave aminopalladation products similar to 1.48 and 1.49. The addition of a carboxylic 
acid additive increases the stability of the catalyst and enables the use of air as the source of 
O2. 
Pugin and Venanzi reported that aminoalkenes and their salts underwent intramolecular 
cyclisations when subjected to conditions similar to those in the original Wacker reaction, 
with catalytic PdCl2 and a CuCl2/O2 reoxidation system.41 1-Pyrroline products most likely 
arose from an aminopalladation pathway followed by β-hydride elimination, alkene 
reinsertion and another β-hydride elimation to yield the presumably more stable cyclic imine 
products over forming vinylpyrrolidines (Scheme 1.43a). 
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N R1
PdCl2 (5 mol %)
CuCl2 (10 mol %)
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Scheme 1.43 
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When tertiary nitrogen nucleophile 1.50 was used, no cyclisation took place and 
aminoketones were isolated instead (Scheme 1.43b). The tertiary nitrogen will neither form a 
Pd-N species for cis-AP or act as a nucleophile for trans-AP, the traditional Wacker 
oxidation observed is hardly surprising. 
Tamaru and co-workers42 demonstrated that pyrrolines 1.51 and pyrroles 1.52 can be 
synthesised from homoallylic amines, by the means of two different aminopalladation 
pathways operating in tandem (Scheme 1.44a). If aminopalladation forms the new Pd-C bond 
syn to the alcohol group then Pd-hydroxide elimination leads to the formation of pyrrolines 
1.53 (Scheme 1.44b, pathway A). However pyrroles are formed when aminopalladation 
leaves the new Pd-C bond anti with respects to the position of the OH group, in this case β-
hydride elimination occurs, followed by aromatisation with the loss of water (Scheme 1.44b, 
pathway B). Unfortunately the reaction conditions do not differentiate very well between the 
two pathways and the two products are formed in varying ratios, from 2:1 to 15:1 
(pyrroline:pyrrole) depending on substituents. 
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Scheme 1.44 
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Bicyclic lactones can be synthesised from the Pd-alkyl intermediate formed after 
intramolecular aminopalladation forms a new nitrogen containing heterocycle. Yoshida,43,44 
Takahata45 and Gracza46,47 have all reported syntheses of lactones in this manner. Yoshida 
initially reported the development of the conditions and reported an extensive substrate scope 
which led to Takahata applying this methodology to the synthesis of the optically active 
Geissman-Waiss lactone 1.54 (Scheme 1.45). Gracza attempted to apply the methodology to 
pyrrolidine containing natural products, such as 1-deoxynojirimycin 1.55 (Scheme 1.46). 
However, the desired lactone could not be synthesised exclusively and varying amounts of 
diastereoisomer 1.56 were found along with a small quantity of chloro derivative 1.57. 
Assuming that 1.57 was formed from the excess of CuCl2 present in the reaction, they 
discovered that 1.57 could be synthesised exclusively if CO was omitted from the reaction. 
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Scheme 1.45 
 
The methodology reported by these groups is a great example of how this type of palladium 
transformation can be used to form multiple bonds in one step and essentially streamline a 
synthesis towards a synthetically valuable intermediate or target. 
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Wolfe and co-workers reported a stereoselective synthesis of N-aryl pyrrolidines from γ-(N-
arylamino)alkenes with aryl and vinyl bromides (Scheme 1.47).19,48 The major product 1.58 
from the reaction is as expected, the minor is yet another example of side products being 
formed from β-hydride elimination and Pd-H reinsertion into the alkene. However this time 
instead of β-hydride elimination, C-C reductive elimination furnished the pyrrolidine with the 
vinyl 1.59 or aryl 1.60 in the alternated position. The diastereoselectivities obtained were 
excellent which is an indication that only one AP pathway is operating. 
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Scheme 1.47 
 
Wolfe found that whilst aryl bromides could be coupled with ease, the cheaper alternative of 
aryl chlorides could not. Aryl chlorides are generally deemed less reactive than their bromide 
counterparts and remain unactivated by the Pd/ligand system outlined in Scheme 1.47. Wolfe 
strived to develop a system that could provide the same efficient coupling with inexpensive 
aryl chlorides. When they used their previous conditions with the ligand P(t-Bu)2Me·HBF4 
the desired product was obtained but with a significant amount of regioisomers in a 11:1:1:3 
(1.61:1.62:1.63:1.64) mixture (Scheme 1.48).49 
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Scheme 1.48 
 
The problem was that an electron-rich ligand was required for Pd, however the use of such 
ligands are known to slow the rate of C-C reductive elimination.50 They found that using S-
Phos was optimal, leading to acceptable yields of the desired products and maintaining the 
high level of diastereoselectivity observed with the aryl bromide system (Scheme 1.49). 
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Scheme 1.49 
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2,5-Disubstituted pyrrolidines 1.65 and 1.66 were formed in a cis-configuration, where as 
those with a 2,3-motif 1.67 were formed trans, which is mostly likely due to steric repulsion 
between the substituent and the PdAr species in the Pd-alkyl intermediate. 
Muñiz and colleagues synthesised bicyclic nitrogen heterocycles in a single step diamination 
reaction (Scheme 1.50a).51 Utilising alkene tethered ureas, they demonstrated the scope of 
this reaction, varying the substituents bound to the alkene chain. They also varied the length 
of the alkene chain resulting in different sizes of the ring formed from the initial 
aminopalladation; 5-, 6- and 7-membered rings were formed. 
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Scheme 1.50 
 
They also demonstrated that tricyclic heterocycles could be synthesised in the same manner 
(Scheme 1.50b). Omitting the base from the reaction led to a diminishment in yield as well as 
leading to the production of an almost equal amount of the acetyl substituted compound 1.68, 
which the authors attribute to a Pd-catalysed oxidation of the arene ring.52 
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Pyrrolidine fused lactams can also be synthesised from alkene chain containing lactams and 
aryl bromides, chlorides and triflates using a Pd/X-Phos catalyst (Scheme 1.51).53 
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Scheme 1.51 
 
Michael and co-workers reported an unconventional aminoarylation reaction, whereby 5-, 6- 
and 7-membered nitrogen heterocycles were formed and coupled with aromatic solvents in 
one step (Scheme 1.52).54 
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Scheme 1.52 
 
The authors claimed that this reaction proceeds through a PdII/PdIV cycle with trans-AP, as 
opposed to conventional aminoarylation which proceeds through a Pd0/PdII cycle with ArX 
electrophiles and often cis-AP.55 They reported that first trans-AP occurs, followed by 
oxidation of PdII to PdIV, which is facilitated by NFBS. The PdIV-alkyl species can then 
undergo arene C-H activation, followed by C-C reductive elimination to relinquish the 
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product (Scheme 1.53). The inclusion of BHT in the reaction mixture is to prevent 
isomerisation reactions. 
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Scheme 1.53 
 
Pyrrolidines are possibly the most reported of all the products obtained by these Wacker-type 
palladium transformations and whilst they are synthetically valuable, the scope of these 
transformations is by no means limited to synthesising pyrrolidines. 
 
1.3.2. Synthesis of Indoles and Related Derivatives 
Alkene containing aniline derivatives have been shown to be capable of undergoing oxidative 
Wacker-type conditions to yield functionalised indoles. Hegedus and co-workers showed that 
2-methylindoles56 and indoloquinones57 could be synthesised using stoichiometric 
PdCl2(MeCN)2. With the correct substituents the Pd-alkyl intermediate could be trapped with 
no β-hydrogen present, and coupled with CO/MeOH or an alkene in a Heck-type coupling.  
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They reported catalytic reactions, using 1-10 mol % Pd to synthesise functionalised indoles.58 
However, if an internal E-alkene is reacted, the observed product is a quinoline 1.69 or the 
corresponding derivative 1.70 (scheme 1.54). 
NHR1
R3
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X
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Scheme 1.54 
 
Izumi et al. demonstrated a similar transformation (Scheme 1.55).59 
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Scheme 1.55 
 
Lau reported the synthesis of indoles60 (Scheme 1.56a) and azaindoles61 (Scheme 1.56b) 
using catalytic PdCl2(MeCN)2. The catalytic transformations took place in near identical 
yields when compared to the same reaction using stoichiometric Pd. 
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Scheme 1.56 
 
 
1.3.3. Synthesis of Oxazolidinones, Isoxazolidines and Related Derivatives 
Oxazolidinones are interesting and synthetically valuable heterocycles, furthermore they can 
be rapidly transformed into valuable 1,2-amino alcohols, a motif that is present in a range of 
biologically important compounds. 
Allylic N-tosyl carbamates can be cyclised under carbonylative conditions to yield 
oxazolidinones. Tamaru and colleagues62 synthesised oxazolidinones using standard 
conditions, they found that N-Ts carbamates gave the best results and that bulky R groups 
gave poor yields which were slightly improved by the inclusion of methyl orthoacetate 
(Scheme 1.57). Moderate d.r.’s were obtained for the secondary carbamates; R = Me 7:1, R = 
CH2i-Pr 10:1, R = CH2CH2Ph 3:1*. When R = t-Bu, the diastereoselectivity was greatly 
increased to 50:1*. (* with the inclusion of methyl orthoacetate). 
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Scheme 1.57 
 
Five years later Tamaru reported another aminocarbonylation, this time with an alkene 
containing two tethered amines.63,64 Each amine could be cyclised independently depending 
on the conditions used (Scheme 1.58). 
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Scheme 1.58 
 
This is a good example of how different additives (mainly acid and base) and the type of 
nitrogen nucleophile are linked and play an important role in this type of reaction. In this 
instance, the acidic conditions favoured the cyclisation of the ‘exo’-nitrogen, whereas the 
conditions that are buffered with methyl orthoacetate (MOA) and NaOAc lead exclusively to 
the formation of the oxazolidone 1.71. It is unclear what aminopalladation pathway is 
operating in each of these cases, but the change in reaction conditions could be an indication 
that the operating pathway has changed. 
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Allenes can be employed in carbonylation reactions leading to 5- and 6-membered cyclic 
carbamates. Tamaru65 reported the stereoselective synthesis of 1.72 and 1.73 derivatives 
(Scheme 1.59). Interestingly these reactions proceeded without the need for any MOA that 
previously played a vital role in the reactions that were outlined in scheme 1.58. 
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Scheme 1.59 
 
Overman and Remarchuk demonstrated an enantioselective synthesis of oxazolidinones using 
chiral Pd catalysts (Scheme 1.60).66 
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Utilising a substrate with an acetate leaving group, allows for an efficient catalytic cycle 
where by upon formation of the Pd-alkyl, an equivalent of HOAc is released, the acetate 
anion coming from the catalyst (Scheme 1.61). The active catalyst is then regenerated by β-
acetate elimination with Pd, yielding the product in excellent yield and enantiomeric excess. 
It was not discussed in the report, but a more traditional allylic substitution mechanism 
cannot be completely ruled out. 
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Scheme 1.61 
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In 2012, Bäckvall reported the synthesis of oxazolidinones from allylic tosylcarbamates.18 
Initially, they observed a mixture of three different products from the reaction (Scheme 1.62).  
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Scheme 1.62 
 
Products 1.76, 1.77 and 1.78 were obtained initially in a ratio of 45:5:50 respectively using 
0.5 eq HOAc, the ratio changed to 40:20:40 by replacing HOAc with NaOAc. Using a 2:1 
ratio of HOAc:NaOAc gave a 75:20:5 mixture. A 7:0.5 mixture of HOAc:NaOAc proved 
optimal, giving a product ratio of 85:10:5 (1.76:1.77:1.78). The allylic rearrangement product 
was not unexpected as Overman has reported such rearrangements in the past.67 However, it 
was noticed that it could be suppressed to just trace amounts using Z-alkenes instead of the E-
isomers. They rationalised this observation looking at the 6-membered transition states, 
stating that the rearrangement is disfavoured in Z-alkenes because of steric interactions 
between Pd and the pseudo-axial R group (Scheme 1.63).  
 
O
O NTs
H
LnPd
H
R
O
O NTs
H
LnPd
R
H>>
E-carbamate
[3,3]-sigmatropic rearrangement 
favoured
Z-carbamate
[3,3]-sigmatropic rearrangement 
disfavoured  
Scheme 1.63 
 
Their optimal conditions tolerated a range of substituents on both the alkene and at the carbon 
containing the carbamate group (Scheme 1.64). Secondary carbamates cyclised with excellent 
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diastereoselectivities (>20:1), however these required 5 mol % of Pd(OAc)2 in order to obtain 
practical yields. In the case of cyclohexene substituted carbamate the d.r. was >25:1, however 
this required 10 mol % Pd(OAc)2 and 48 h. 
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Scheme 1.64 
 
They synthesised a six-membered ring in this manner from a homoallylic carbamate. 
However this required a 10 mol % catalyst loading and 48 h reaction time, and yielded just 
46% of the product, which was isolated as the N-tosylamino alcohol derivative due to 
difficulties in purification. 
Isoxazolidines are often used as precursors to 1,3-amino alcohols, which are a motif that is 
present in a range of biologically active compounds.68 Bates and Sa-Ei published an 
aminocarbonylation using novel O-homoallylic hydroxylamines (Scheme 1.65).69 They found 
that an electron withdrawing group on the nitrogen atom was necessary for a successful 
cyclisation to occur. C-1 trisubstituted substrates formed the isoxazolidines in a 
diastereomerically pure syn-configuration. 
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Scheme 1.65 
Wolfe and co-workers recently reported that N-Boc-O-homoallylic hydroxylamines can be 
cyclised and functionalised with aryl bromides under aminoarylation conditions (Scheme 
1.66a).22 
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Scheme 1.66 
 
Their transition states suggest that high diastereoselectivities observed with the 3,5-
disubstituted rings arise from a cis-AP, with the carbamate group and alkene methyl group 
pointing away from each other (Scheme 1.66b). Trans-4,5-disubstituted rings 1.79 can also 
be synthesised, from C-2 functionalised starting hydroxylamines. The trans-configuration 
observed most likely arises from steric interaction with Pd as the cis-AP step occurs. 
As previously mentioned, Malkov and Kočovský reported a stereoselective carbonylative 
amidation of N-Boc homoallylic hydroxylamines.28 Using methodology developed in the 
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Malkov group for obtaining chiral homoallylic alcohols,70  they synthesised enantioenriched 
hydroxylamines similar to the those used by Bates69 and Wolfe22 (Scheme 1.67). 
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Scheme 1.67 
 
These cyclised without problems and tolerated a range of functionalities without much 
change in diastereoselectivity. The exception is when R2 = Me, for these substrates the d.r. is 
quite low at around 5:1, as opposed to the >50:1 observed for some substrates that have R2 = 
H. It is possible this methyl group causes some steric interactions in the transition state that 
are unfavoured, leading to the mixture of isomers (Scheme 1.68). 
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Scheme 1.68 
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1.3.4. Synthesis of Imidazolidines, Pyrazolidines and Related Derivatives 
Heterocycles containing two nitrogen atoms are useful intermediate building blocks, and as 
with oxazolidinones and isoxazolidines, they can be easily converted into vicinal 1,2- or 1,3-
diamines. 
Cyclisation of cyclic and acyclic aminals with PdII was demonstrated by Hiemstra and 
colleagues.71 Cyclic aminals were cyclised with ease, yielding syn-imidazolidines (Scheme 
1.69a). Acyclic aminals cyclised more efficiently. However, the downside of using these 
substrates is the lack of diastereoselectivity (≈ 1:1) in the aminopalladation step, which is 
unusual for this type of cyclisation (Scheme 1.69b). 
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Scheme 1.69 
 
They also found that acid/base hydrolysis would not convert the imidazolidines to the desired 
diamines. In order to cleave the aminal and obtain the diamine they had to employ a 3-step 
process of first removing protecting group R, electrochemical oxidation to an amidine and 
then finally hydrolysis could take place yielding the diamine. 
Sulfamides have been shown to cyclise under Wacker-type conditions, Stahl showed that 
cyclic sulfamides could be obtained with excellent diastereoselectivity and easily converted 
to vicinal diamines (Scheme 1.70).72 
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Scheme 1.70 
 
The catalyst system was developed from previously reported reactions using a PdII/DMSO/O2 
mixture. The presence of base NaOBz was necessary for efficient conversion, however only a 
catalytic amount was required (20 mol %). It was found that by changing the solvent to THF 
enabled the synthesis to be carried out at room temperature rather than the 80°C required by 
toluene and 1,4-dioxane. Most importantly however is the PdII/DMSO ratio, and if DMSO is 
used as the solvent the reaction yield is diminished by 50%. The optimal ratio was found to 
be 1:2 PdII/DMSO. Stahl has recently established that DMSO can act as a ligand to Pd and 
can in fact be coordinated by both oxygen and sulfur.73 Excellent diastereoselectivities can be 
obtained using secondary substrates 1.80 which cyclise giving a trans-motif 1.81 (Scheme 
72b), and using the cyclic sulfamides 1.82 which yields cis-diamines 1.83 (Scheme 1.70c). 
The sulfone bridge between nitrogen atoms can easily be removed using a straightforward 
LiAlH4 reduction. 
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Wolfe once again reported an aminoarylation, though this time using homoallylic hydrazines 
that were cyclised to pyrazolidines.74 Secondary homoallylic diamines were cyclised in 
decent yields, however interesting results were obtained when the functionality on the N-
homoallyl nitrogen atom was changed. Wolfe observed that when N-2 was not functionalised, 
the resulting pyrazolidines were obtained with a cis-3,5-motif, however functionalisation at 
N-2 with Boc or an aryl group led to trans-3,5-disubstuted pyrazolidines being formed. 
Wolfe rationalised these observations with transition state models, outlined in scheme 1.71. 
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Scheme 1.71 
 
When R1 = H there is little steric interaction with the adjoining R2 group, which is situated 
equatorially, in this favoured position the two substituents at 3- and 5- positions sit cis to each 
other. When R1 = Boc or aryl, then there is a large steric interaction with R2, therefore R2 is 
forced into an axial position with the hydrogen near the Boc/Ar group to minimise steric 
interaction. This lower energy conformation leads to the 3,5-trans product 1.84. A range of 
trans-3,5-disubstituted pyrazolidines were synthesised with excellent diastereoselectivities 
(Table 1.6). 
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Table 1.6 
R1
N
HN PG
Boc
+ R2-Br
N N
Boc PG
R1
R2
Pd(OAc)2 (2 mol %)
dppe or (±)-BINAP
(2 mol %)
NaOt-Bu, PhMe
90-110 °C
a)
 
 PG R1 R2 Yield (%) d.r. (crude) 
1 Ph Ph 4-BzC6H4 74 20:1 (11:1) 
2 PMP Pr 4-NCC6H4 63 >20:1 (>20:1) 
3 Boc Ph 2-naphthyl 55 >20:1 (>20:1) 
4 Boc Pr 3-F3CC6H4 81 >20:1 (>20:1) 
 
RL
N
HN H
Boc
+ R-Br
N NH
Boc
Rs
R
Pd(OAc)2 (2 mol %)
DPE-Phos (2 mol %)
NaOt-Bu, PhMe
70 °C
Rs R
L
b)
 
 RS RL R Yield (%) d.r. (crude) 
5 H Pr 4-ClC6H4 70 >20:1 (7:1) 
6 H Ph 3-MeC6H4 66 13:1 (10:1) 
7 Me Ph 4-PhC6H4 83 6:1 (6:1) 
 
Switching RS to a methyl group resulted in a diminished diastereoselectivity (Table 1.6, entry 
7), this is probably due to the two groups RS and RL flipping between the equatorial and axial 
positions, thus leading to a greater mixture of the two stereoisomers. 
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1.3.5. Synthesis of Other Nitrogen Heterocycles 
Hayashi, Yorimitsu and Oshima reported that functionalised aziridines could be synthesised 
with high stereoselectivity from allylic amines under aminoarylation conditions (Scheme 
1.72a).75 The reaction proceeded surprisingly efficiently and with no Heck-type coupling by-
products, that were observed in the analogous synthesis of epoxides.76 
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Scheme 1.72 
 
They carried out deuteration studies to establish that cis-AP was the operating pathway; from 
this they suggested an intermediate that justified the excellent stereoselectivity observed 
(Scheme 1.72b). The larger RL group sits axially, whilst the smaller RS sits equatorially 
nearer the aryl group, ultimately the strain is minimalised in this conformation as the steric 
repulsion is less between Ph and RS. 
Morpholines are found in a range of biologically active molecules, and new synthetic routes 
to these building blocks are always welcome. Wolfe reported the stereoselective 
aminoarylation of amines containing allyl ethers 1.85 (Scheme 1.73a).77 Using aryl bromides 
and a phosphine ligand, morpholines were synthesised with >20:1 diastereoselectivity. Wolfe 
assumed a cis-AP based on his previous studies with pyrrolidines, piperazines and other 
nitrogen heterocycles. He proposed a boat like transition state to account for the observed 
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stereochemistry (Scheme 1.73b). In this conformation, the steric repulsion between Ar and R1 
is minimalised. 
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Scheme 1.73 
 
Broggini and co-workers reported that from aniline derivatives containing tethered allylic 
amides 1.86, quinazolin-4-ones 1.87 and 1,4-benzodiazepin-5-ones 1.88 can be formed.78 
1.87 is formed when Pd(OAc)2 in DMSO with NaOAc is used, whereas Pd(OAc)2 with 20 
mol % pyridine gives 1.88 exclusively (Scheme 1.74). 
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Scheme 1.74 
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The authors proposed that 1.87 is most likely formed by 1.86 forming a π-allyl complex with 
Pd, then N-nucleophilic attack and Pd-dissociation. Formation of 1.88 is likely to follow an 
aminopalladation and β-hydride elimination mechanism (Scheme 1.75). 
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Scheme 1.75 
 
The π-allyl mechanism that forms 1.87, with the Pd/DMSO catalyst, is unexpected, however 
not unusual. White has used Pd/sulfoxide catalysts to facilitate a range of reactions involving 
the attack of a nucleophile to a π-allyl intermediate.79,80 She has shown that oxazolidinones81 
and oxazinanones82 can be synthesised efficiently via this π-allyl/C-H activation 
methodology. 
Wolfe also applied his aminoarylation methodology to the synthesis of 1,4-benzodiazepines, 
using PdII and a phosphine ligand (Scheme 1.76).83 Once again his methodology proved 
straightforward, reliable and able to tolerate varying substituents. 
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Scheme 1.76 
 
As with his work on morpholines, Wolfe assumed a cis-AP mechanism is in operation and 
accounted for the high level of stereoselectivity by proposing a transition state 1.89 (Figure 
1.6). A boat-like transition state was proposed, where R sits equatorial in the position of least 
steric interaction. The methyl of the alkene is positioned away from the bulky Ar group 
attached to the nitrogen atom.  
 
N
LnPd N
Ar1
Ar2
H
H
R
Bn
1.89  
Figure 1.6 
 
These examples show the range of substrates that are available for use in aza-Wacker type 
transformations. Different ring sizes can be synthesised with varying functionalities and the 
reactive Pd-alkyl intermediate can further couple with more reagents, expanding the scope for 
functionalisation. 
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1.4. Concluding Remarks 
There has been a great deal of advances in the past five decades, since the initial report of the 
Wacker process in 1959. Amongst the vast library of examples are those that are 
stereoselective, the key to which lie in the aminopalladation step. The studies into the 
mechanistic aspects of these Wacker-type oxidative amination reactions have proved 
invaluable in understanding the difference between the two modes of aminopalladation. The 
work carried out by Stahl is by far the most important as it not only highlights the difference 
in pathways, but how the additives and even the nature of the substrate nucleophile play a 
crucial role in determining which aminopalladation pathway operates primarily. The studies 
by Stahl show how unpredictable and how complex controlling aminopalladation can be, for 
example cis-AP is observed under neutral conditions, whereas trans-AP appears to favour 
acidic conditions. Increasing acidity increases the trans:cis-AP ratio. However, what seems to 
play a more important role is the acidity of the nucleophile; using a more acidic nucleophile 
can lead to a complete preference for cis-AP, even under acidic reaction conditions. Matters 
are further complicated when the nucleophile acidity is increased again leading to mixtures of 
cis and trans-AP products, and in the case of Pd(OAc)2/DMSO (which had shown 
exclusively cis-AP products for the previous two substrates) trans-AP was observed 
exclusively. These observations are explained in full in chapter 1.2, but this brief highlight 
shows how complex planning a stereoselective aza-Wacker transformation can be. That being 
said, many research groups have found compatible conditions and substrates, obtaining some 
excellent diastereoselectivities. Enantioselective Wacker-type reactions, which are known to 
be troublesome, are possible and only a handful of examples exist in the literature. 
The vast range of heterocycles that can be synthesised shows how versatile this type of Pd 
catalysis can be, especially when coupled with the ability to harness the reactivity of the Pd-
alkyl intermediate formed from aminopalladation. Formation of multiple bonds under 
catalytic conditions in a single step is an attractive prospect and with correct reaction 
planning, these transformations can be employed to streamline routes to functionalised 
heterocyclic compounds. 
The future of this chemistry has three avenues; the first being the development of more 
economical conditions. Ultimately being able to carry out this chemistry with lower loadings 
of Pd without a loss in reactivity or a significant increase in reaction time is desirable. Using 
air as the reoxidant would be extremely ideal, negating the need for expensive oxidants or 
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highly reactive and explosive pure oxygen. The second avenue is the development of simple 
and readily accessible ligands for enantioselective amination reactions. The third avenue is 
controlling the aminopalladation step. Ideally, to assist the design of new reactions of this 
kind, a set of rules could be set out that help predict the outcome of aminopalladation, 
depending on catalyst, substrate and conditions. This may seem quite distant, but we are now 
some way towards understanding the aminopalladation step, however there are still a lot more 
contributing factors to identify. 
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2. Results and Discussion 
2.1. Introduction 
Many pharmaceuticals and natural products feature C-N and C-O bonds in 1,2- and 1,3- 
relative positions. A wide range of precursors for 1,2 and 1,3-amino alcohols and diamines 
exist (Scheme 2.1). 
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Scheme 2.1 
 
PdII has been shown to catalyse allylic amination reactions, via two different pathways 
(Scheme 2.2). Pathway A, proceeds via a π-allyl intermediate and only works well with 
terminal alkenes. Internal alkenes have shown poor reactivity. Pathway B, is an 
aminopalladation and subsequent β-hydride elimination. Internal alkenes are required in this 
case. Terminal alkenes can be used in pathway B, however a coupling reagent must be used 
in this instance to release Pd from the Pd-alkyl intermediate.  
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1,2- and 1,3-amino alcohol and diamine motifs can generally exist as syn/anti isomers, 
however from a synthetic point of view, single diastereoisomers are often desired. White and 
co-workers have shown that oxazolidinones80 and isoxazolidines81 can be synthesised using 
PdII catalysed allylic C-H activation. However there are apparent drawbacks to using this 
methodology, often poor to moderate diastereoselectivity is observed in these reactions 
meaning that diastereoisomers must first be chromatographically separated. Secondly, there is 
usually a need for a stoichiometric external oxidant, whereas many reactions that proceed via 
aminopalladation can utilise molecular O2 and in some cases even air. There is a necessity for 
elevated temperatures and often long reaction times are required for substantial yields to be 
obtained. Many of the catalytic amination reactions that proceed via an aminopalladation 
mechanism often yield new heterocycles with excellent diastereoselectivities. However, 
whilst there has been a lot of work synthesising 1,2 and 1,3 motifs using 
aminopalladation/coupling reactions, at the time of starting this project there were no 
examples of these kind of heterocycles being synthesised using aminopalladation/β-hydride 
elimination methodology. Recently however, Bäckvall18 and Stahl72 have demonstrated the 
synthesis of 1,2-amino alcohols and 1,2-diamines respectively, but still there have been no 
reports on the synthesis of 1,3-derivatives in this manner. 
Our goal was to establish a robust and reliable diastereoselective method for intramolecular 
allylic C-H amination to give heterocycles serving as the precursors to 1,2 and 1,3-amino 
alcohols and diamines. 
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2.2. Isoxazolidines & Pyrazolidines; Precursors to 1,3-Amino Alcohols and 
1,3-Diamines 
2.2.1. Substrate Design and Development 
The study began by focusing on the synthesis of amino alcohols. From the start, it was 
decided that 5-membered heterocyclic rings would be our target. The reason for this choice is 
as follows: 5-membered rings are the easiest to form. In contrast 6-membered rings, despite 
being more stable, are less kinetically favourable than 5-membered rings, therefore are often 
slow to form.84 Compounds containing an internal C-C double bond were selected to avoid 
competing reactions via π-allyl complexes (as discussed in the previous section).80,81 In 
addition, internal alkenes possess hydrogen atoms in the necessary positions to facilitate β-
hydride elimination, The retrosynthetic routes outlined in Scheme 2.3 show that allylic and 
homoallylic alcohols are an ideal starting point for synthesising the desired substrates. We 
decided to centre our attention on synthesising isoxazolidines as the group already had 
methodology in place to synthesise enantioenriched secondary homoallylic alcohols.70 
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Scheme 2.3 
 
We planned to accomplish the transformation of homoallylic alcohols to hydroxylamines via 
Mitsunobu protocol using N-hydroxyphthalimide as the nucleophile (Scheme 2.4).69,85 The 
desired O-alkyl hydroxylamines can be obtained by cleaving the phthalimide group with 
hydrazine; this is usually a straight forward and relatively quick reaction. Finally the nitrogen 
atom of the hydroxylamine is protected as a carbamate. There are two reasons for using a 
protecting group; firstly to prevent further reaction of the amine, in both the hydroxylamine 
and oxazolidine form. Secondly, having a carbamate group present would promote Pd-N 
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formation by providing coordination through the carbamate to Pd and hence favour a cis-AP 
route. 
For screening reaction conditions, (E)-pent-3-en-1-ol 2.1 was chosen as a model substrate. 
Commercially available (E)-pent-3-enoic acid 2.2 was reduced to the corresponding alcohol 
using LiAlH4 (Scheme 2.4, step A).86 The alcohol was obtained in a respectable yield (95%), 
however care should be taken during isolation due to the volatility of the product. 
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A. LiAlH4 (1.2 eq), THF, rt, overnight B. N-hydroxyphthalimide (1.2 eq), PPh3 (1.2 eq), DIAD (1.2 eq), THF, 
rt, overnight C. i) N2H4·H2O (5 eq), CH2Cl2, rt, 3 h ii) Boc2O (1.2 eq), NaOH (2 eq), CH2Cl2/H2O (9:1), rt, 
overnight iii) imidazole (5 eq), CHCl3 (or CH2Cl2), rt, 30 min. 
Scheme 2.4 
 
Using the Mitsunobu protocol developed earlier in the group (Scheme 2.4, step B),87 the 
alcohol was reacted overnight and after consumption of starting material which was observed 
using TLC, hydrazine was added to cleave the phthalimide, leaving the free hydroxylamine 
2.3. Following this sequence, after chromatographic purification, the resulting hydroxylamine 
contained significant amounts of Ph3PO, which were co-eluting with the product. It was 
decided that phthalimide derivative 2.4 should be isolated before the addition of hydrazine, as 
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it is less polar than hydroxylamine 2.5 and Ph3PO (Fig 2.1), thus leading to an easier 
purification.  
 
phthalimide 2.4
PPh3O
hydroxylamine 2.3
 
Figure 2.1 
 
Due to volatility of hydroxylamine 2.3, it was decided to carry out the Boc protection step 
immediately without isolation. The cleavage of 2.4 with hydrazine was completed after 3 
hours stirring at room temperature. A white precipitate of phthalhydrazide 2.6 was removed 
by filtration and the solution of hydroxylamine containing excess hydrazine was reacted 
directly with Boc2O (Scheme 2.4). 
The Boc protection step87,88 proceeded with 100% conversion, however purification caused 
some issue. After column chromatography, the isolated 2.5 according to 1H NMR 
spectroscopy contained a considerable amount of unreacted Boc2O. Further chromatography 
proved unsuccessful in removing this impurity, so an alternate strategy was employed. 
Imidazole has been shown to readily react with Boc2O at room temperature, and the high 
polarity of the product 2.7 allows for easy separation from the target compound.89 Five 
equivalents of imidazole were added to the mixture of 2.5 and Boc2O in CH2Cl2 or CHCl3. 
After the excess Boc2O was consumed (monitored by TLC developing with vanillin dye), any 
leftover imidazole was removed by an aqueous wash. The N-Boc-hydroxylamine 2.5 was 
isolated with ease by column chromatography. Scheme 2.4 outlines the final procedure for 
generating the desired N-Boc-hydroxylamine 2.5 from a commercially available acid 2.2. 
With the optimal conditions for synthesising model compounds in place and the substrate in 
hand, focus was now be turned to screening reaction conditions. 
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2.2.2. Screening Conditions for Wacker-Type Oxidative Amination 
As outlined in chapter 1, it is evident that a range of different conditions can be used to 
facilitate Wacker-type oxidative cyclisations. A source of PdII is required, often in 
conjunction with a ligand, in order to successfully proceed via an aminopalladation 
mechanism. Often, different additives are employed taking on different roles, e.g. buffering 
pH or promoting β-hydride elimination. Most commonly, toluene and THF are used as the 
solvents for these reactions, for their elevated temperature tolerance and compatibility with 
organometallic compounds respectively. 
Table 2.1 outlines the development of the optimal conditions for Wacker-type oxidative 
cyclisation of 2.5. As a starting point, the conditions developed by the Malkov group used in 
the carbonylative cyclisation of 2.8 (Scheme 2.5) were used without the atmosphere of CO, 
MeOH and MeC(OMe)3 (Table 2.1, entry 1).28,87 
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Scheme 2.5 
 
Pd(OAc)2 (10 mol %) and Cu(OAc)2 (3 eq) were heated to 60 °C with 2.5 in MeCN under an 
inert atmosphere. The reaction was run overnight for 16 h. The 1H NMR spectrum of the 
crude mixture was surprisingly clean, indicating the presence of 2.9 in 95% conversion, the 
remaining material was the starting hydroxylamine 2.5. Column chromatography yielded 
isoxazolidine 2.9 (85%) isolated as a clear oil. It was a good start, however drawbacks such 
as the incomplete conversion had to be addressed. Furthermore, using 10 mol % of PdII and 3 
equivalents of CuII salts is not ideal should the reaction be scaled up for industrial purposes. 
Although an elevated temperature is not impractical it is often prefereable to be avoided. 
Running the reaction at room temperature (entry 2), slowed the conversion significantly (11% 
after 16 h), however no Pd black was observed and the catalyst remained active albeit slow. 
71 
 
Lowering the loading of Cu(OAc)2 oxidant to 30 mol % (entry 3) gave a better result, 
however conversion still remained slow (69% after 16 h). Oxygen (1 atm) was introduced 
into the system (entry 4), to speed up the re-oxidation process, similar to the known Wacker 
processes.3 Surprisingly, ketone 2.10 was obtained as the sole product (20% after 16 h), it 
was unclear whether the product of Wacker oxidation was formed after β-hydride elimination 
with the free alkene or before with the Pd-alkyl intermediate. Using Pd(MeCN)2Cl2 and 
QUINOX ligand 2.11 led to an increase in the amount of 2.10 formed (entry 5). Submitting 
cyclised alkene 2.9 to the conditions in entry 5 gave a very slow conversion to ketone 2.10 
(<5% after 16 h), which indicated that the active Pd species involved in forming ketone 2.10 
are formed during the cyclisation of 2.5. It was clear that the combination of CuII and O2 was 
leading to the formation of this undesired ketone, so in an attempt to avoid from this side 
reaction, molecular oxygen was used as the sole oxidant. This also addressed the high loading 
of CuII in the reaction. Reverting back to the initial conditions and exchanging Cu for O2 
(entry 6) yielded poor results. Using toluene at 80 °C (entry 7) had no great effect on the 
conversion, even when NaOAc was introduced to promote Pd-N formation.15 In DMSO and 
THF (entries 8-9) the conversion showed little change.  
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Table 2.1.(a) 
O N
Boc
O N
Boc
O
PdII, oxidant
additive, solvent
O
NHBoc
N
N
OS S
Ph Ph
OO
Pd(OAc)2
2.12 2.11
2.5 2.9 2.10
 
 PdII (mol %) Oxidant (eq)(b) Solvent Additive (eq) 
Temp. 
(°C) 
Conv. 
(%)(c) 
1 Pd(OAc)2 (10) Cu(OAc)2 (3) MeCN None 60 2.9 95(d) 
2 Pd(OAc)2 (10) Cu(OAc)2 (3) MeCN None rt 2.9 11 
3 Pd(OAc)2 (10) Cu(OAc)2 (0.3) MeCN None 60 2.9 69 
4 Pd(OAc)2 (10) 
Cu(OAc)2 
(0.3)/O2 
MeCN None 60 2.10 20 
5 
Pd(MeCN)2Cl2 
(5) 
Cu(OAc)2 
(0.3)/O2 
MeCN 2.11 (0.4) 60 2.10 50 
6 Pd(OAc)2 (10) O2 MeCN None 60 2.9 29 
7 Pd(OAc)2 (10) O2 PhMe NaOAc (0.2) 80 2.9 34 
8 Pd(OAc)2 (10) O2 DMSO NaOAc (0.2) 60 2.9 37 
9 Pd(OAc)2 (10) O2 THF NaOAc (0.2) 60 2.9 36 
10 Pd(OAc)2 (5) O2 THF 
NaOAc (0.2)/ 
DMSO (0.1) 
rt 
2.9 
100(e) 
11 2.12 (10) O2 THF NaOAc (0.2) rt 2.9 39 
12 Pd(OAc)2 (5) O2 THF 
NaOAc (0.2)/ 
DMF (0.1) 
rt 2.9 52 
13 Pd(OAc)2 (5) O2 MeCN 
NaOAc(0.2)/ 
DMSO (0.1) 
rt 2.9 35 
(a) Conditions: 2.5 (0.25 mmol), solvent 3 mL, 16 h. (b) The flask was flushed with O2, before a balloon (1 atm) 
of O2 was applied. (c) Conversion was estimated using 1H NMR and the ratio of SM 2.5: product 2.9(2.10). (d) 
Isolated yield 85%. (e) Isolated yield 98%. 
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The best results were obtained with the introduction of DMSO (10 mol %) as an additive 
(entry 10), resulting in a clean, complete conversion and an isolated yield of 98%. The 
complex Pd(DMSO)2(OAc)2 has been studied by Stahl.90 DMSO, as a ligand to Pd, in this 
catalyst system has been shown to promote the oxidation of Pd0 to PdII by molecular O2. 
Interestingly when DMSO was used as a solvent, the reactivity dropped considerably. Hence, 
the excess DMSO deactivates the catalytic system to some extent, creating the necessity for 
correct stoichiometry. Use of the bis-sulfoxide catalyst 2.11 introducted by White gave an 
inferior conversion (entry 11). Replacing DMSO with DMF (entry 12) and THF with MeCN 
(entry 13) also proved detremental.  
The conditions outlined in entry 10 were taken as the optimal, fitting the desired criteria of a 
low Pd loading, use of molecular O2 as an oxidant, with the reaction proceeding cleanly 
overnight at room temperature. With these conditions in hand, we set to establish the scope 
and the limitations of the intramolecular cyclisation of N-Boc homoallylic hydroxylamines. 
 
2.2.3. Investigating Longer and Functionalised Alkyl Chains 
Our model substrate contained an internal alkene that produced a terminal alkene once the 
substrate had cyclised and undergone β-hydride elimination. As a further extension of the 
method, substrates that would yield internal alkenes after β-hydride elimination were 
investigated next where the formation of different isomers can be envisioned (Scheme 2.6). 
 
O NBoc
R
Pd
H
H
O NBoc
R
O NBoc R
PdH
Pd
a)
b)
PdH
O NBoc
H
Pd
H
R
2.12
Scheme 2.6 
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First, there is the possibility of reforming the C=C double bond in either E or Z configuration 
(Scheme 2.6a). In the intermediate 2.12, C-C bond rotation is fast, so there is the chance for 
β-hydride elimination to yield one of two isomers. The E-isomer is likely favoured as it does 
not suffer the steric interactions that Z-isomer does. Secondly, re-addition/elimination of Pd-
H can lead to a shift of the double bond. The combination of these two isomerisation 
pathways could potentially give rise to a large amount of undesired side products.  
First, substrate E-2.16 was tested. It was synthesised from commercially available (E)-hex-3-
enoic acid 2.13 as shown in Scheme 2.7 following the protocol developed earlier for the 
model substrate. 
 
OH O
NPhth
O
NHBoc
NHP, PPh3
DIAD, THF
rt, overnight
i) N2H4·H2O
CH2Cl2, rt, 3 h
ii) Boc2O, NaOH
CH2Cl2, rt
overnightE-2.14 E-2.15 62% E-2.16 73%
OHOH
O
LiAlH4, THF
rt, overnight
2.14 91%2.13
OH O
NPhth
O
NHBoc
NHP, PPh3
DIAD, THF
rt, overnight
i) N2H4·H2O
CH2Cl2, rt, 3 h
ii) Boc2O, NaOH
CH2Cl2, rt
overnight
Z-2.14 Z-2.15 60% Z-2.16 64%
 
Scheme 2.7 
 
E-2.13 was submitted to the optimal reaction conditions and a mixture of isomers 2.17-2.19 
was isolated as a single fraction by column chromatography in 81% overall yield. Initial 
analysis of the 1H NMR showed both major and minor signals in both the alkane and alkene 
regions, the major signals were indicative of an internal alkene, whereas the minor signals 
suggested the presence of a terminal alkene and another internal alkene (Scheme 2.8). 
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O
NHBoc
O NBoc O NBoc O NBoc
Pd(OAc)2 (5 mol %)
DMSO (10 mol %)
NaOAc (20 mol %)
THF, O2, rt, 16 h
81%
+ +
E-2.16 2.17 2.18 2.19
Scheme 2.8 
 
Using TOCSY (Total Correlation Spectroscopy) NMR spectroscopy the major and minor 
signals were separated into separate spectra, which were used to confirm the structures of the 
3 isomers (Figure 2.2). 
 
* The t-Boc peaks are not shown, as the resonance effect between the irradiated proton and the C(CH3)3 part of 
the t-Boc group is diluted. 
Figure 2.2 
 
The major isomer corresponds to the isoxazolidine 2.17, the minor components were 
confirmed as the isoxazolidines 2.18 and a terminal alkene 2.19. Using integrations of the 
peaks corresponding to C-4/5 in each of the isomers, an approximation of the ratio of 
products was determined as 22:1.7:1 (E:Z:terminal) (Figure 2.3). 
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Figure 2.3 
 
The isomer ratios depending on the Pd sources used in the reaction are shown in Table 2.2. 
 
Table 2.2 
 PdII source 
(5 mol %) 
Isolated 
yield (%) 
Ratio of isomers 
(E:Z:terminal) 
1 Pd(OAc)2 81 13:1:trace 
2 PdCl2 54 3:trace:2 
3 Pd(TFA)2 79 13:1:trace 
 
 
Changing to Pd(TFA)2 (entry 3), gave similar results to the initial observation, however 
changing the Pd source to PdCl2 (entry 2) produced a 3:2 ratio of the E-isomer and the 
terminal alkene, in 54% yield. It may suggest that Pd-H in this instance does not dissociate 
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from the newly formed alkene as quickly as it does when Pd(OAc)2 or Pd(TFA)2 are used, 
hence reinsertion and subsequent β-hydride elimination yields the shifted alkene. The reason 
PdCl2 facilitates this transformation is unclear, however potentially the problem could be that 
Pd0 species formed from PdCl2 is not oxidised as fast as that from Pd(OAc)2, hence the 
lifetime of PdH is longer, leading to an increased probability of it being reinserted into the 
alkene. This hypothesis is supported by the fact that the overall conversion was poor, 
assuming the Pd oxidation step is the limiting factor. 
The next step was to test whether Z-alkenes yielded the same major products. The 
corresponding Z-homoallylic hydroxylamine Z-2.16 was synthesised in the usual manner 
from commercially available (Z)-hex-3-en-1-ol Z-2.14 (See Scheme 2.7). When this substrate 
was submitted to the oxidative amination conditions, the conversion was complete overnight. 
Analysis by 1H NMR spectroscopy revealed that the ratio of products 2.17-2.19 was exactly 
the same as that obtained for the E-substrate (22:1.7:1, E:Z:terminal) (Scheme 2.9).  
 
O
NHBoc
O NBoc O NBoc O NBoc
Pd(OAc)2 (5 mol %)
DMSO (10 mol %)
NaOAc (20 mol %)
THF, O2, rt, 16 h
77%
+ +
Z-2.16
2.17 2.18 2.19
Scheme 2.9 
 
The reaction conditions tolerate both E and Z alkenes without any major deterioration in 
yield, unlike allylic tosylcarbamates 2.20 reported by Bäckvall that only show practical 
reactivity with Z-alkenes (Scheme 2.10).18 
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R1
O NHTs
O
Pd(OAc)2 (1 mol %)
benzoquinone (1.5 eq)
AcOH (7 eq)
NaOAc (0.5 eq)
THF/DMSO (9:1)
50 °C, 12 h
O NTs
R1
O
R2
R2
R1 = H, alkyl, aryl
R2 = H, alkyl, cyclic
40-65%
d.r. up to >25:1
2.20
 
Scheme 2.10 
 
The preference for forming the trans-alkene 2.17 can be rationalised by observing the 
positions of the hydrogen atoms relative to Pd in each case (Scheme 2.11). As is well known, 
Pd and H must be on the same face for β-hydride elimination to occur. When E-2.16 and Z-
2.16 are cyclised both E- and Z-isoxazolidines can be formed regardless of aminopalladation 
pathway. The preference for the formation of 2.17 is likely from the increased stability of the 
E-isomer over the Z. Secondly the conformation for β-hydride elimination that gives 2.17 is 
less sterically congested than that of 2.18, which suffers from interactions between the Boc 
and Me groups. 
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2.17 2.18
 
Scheme 2.11 
 
After investigating the effect of β-hydride elimination on E and Z alkenes, it was decided to 
examine substrates that are sterically encumbered around the β-hydrogen to determine how it 
would affect the β-hydride elimination step. Using a modified Knoevenagel condensation, 
(E)-3-alkenoic acids could be synthesised from malonic acid and the desired aldehyde 
(Scheme 2.12).91 
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HO
O
OH
O
O
R
OH
R
O
piperidine (1 mol %)
HOAc (1 mol %)
DMSO, 120 °C
overnight
+
2.21 R= CH2Ph 80%
2.22 R = i-Pr 52%  
Scheme 2.12 
 
The Knoevenagel condensation proceeded without any problems and no by-products were 
observed. Ragoussis proposed a mechanism to explain why β,γ-acid 2.23 is formed in 
preference over α,β-acid 2.24 (Scheme 2.13).91b Piperidine and acetic acid form piperidinium 
acetate which facilitates the reversible dehydration of 2.25, leading to the formation of 2.26 
and 2.27. The α,β-malonic acid 2.26 cannot in this case undergo decarboxylation, but is 
instead isomerised to 2.27 through rehydration. At an elevated temperature (>100 °C) β,γ-
malonic acid 2.27 can undergo irreversible decarboxylation yielding the desired β,γ-acid 
2.23. 
 
HO OH
O O
R
O
HO OH
O O
R
HO
H
H
HO OH
O O
R
H
HO OH
O O
R
H
HO
O
R
H
HO
O
R
+
- H2O
- H2O
+ H2O
+ H2O
- CO2
α
β γ
2.23
2.242.25 2.26
2.27
 
Scheme 2.13 
 
The desired acids, which were isolated in modest to excellent yields, were then subjected to 
the usual transformations that yielded the substrates required for oxidative amination 
(Scheme 2.14). 
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The phenyl substrate 2.32 was chosen due to its position relative to the β-hydrogens. Having 
the aromatic ring in conjugation with this position could affect the β-hydride elimination step. 
 
R
O
NPhth
R
O
NHBoc
NHP, PPh3
DIAD, THF
rt, overnight
i) N2H4·H2O
CH2Cl2, rt, 3 h
ii) Boc2O, NaOH
CH2Cl2, rt
overnight2.30 79%
2.31 49%
2.32 81%
2.33 52%
R
OH
R
OH
O
LiAlH4, THF
rt, overnight
2.28 60%
2.29 73%
2.21 R = CH2Ph
2.22 R = i-Pr
 
Scheme 2.14 
 
Submitting 2.32 to the amination conditions for 16 h yielded the expected product 2.34, 
isolated in a moderate yield (61%) (Scheme 2.15). The remaining material may have suffered 
from decomposition as no remaining starting material or by-products were observed in the 1H 
NMR spectrum of the reaction mixture. This slower conversion is perhaps the result of steric 
interactions between Pd and the nearby Ph group. 
 
O
NHBoc
Ph
O NBoc
Ph
Pd(OAc)2 (5 mol %)
DMSO (10 mol %)
NaOAc (20 mol %)
THF, O2, rt, 16 h 2.34 61%2.32  
Scheme 2.15 
 
The second of these bulkier substrates investigated contains an iso-propyl group, the 
hydrogen atom of which is in the β-position with respect to where Pd addition will occur. 
This substrate was exposed to the amination conditions, and after 16 h the expected product 
2.35 was obtained (isolated yield 51%) (Scheme 2.16). Once again, the reaction suffered 
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deterioration in conversion, no left over starting material or by-products were observed in the 
1H NMR spectrum of the crude reaction mixture. 
 
O
NHBoc
O NBoc
Pd(OAc)2 (5 mol %)
DMSO (10 mol %)
NaOAc (20 mol %)
THF, O2, rt, 16 h 2.35 51%2.33  
Scheme 2.16 
 
The Pd-alkyl intermediate that arises from 2.33 contains a significant amount of steric bulk 
around the Pd atom, and it does only contain only one β-hydrogen (Scheme 2.16). The 
increased steric bulk around the β-hydrogen can suffer interactions with the Boc group. 
 
In the final modification to the alkyl chain, the position of the double bond within the chain 
was altered. Moving the alkene further along the chain could potentially open up a route to 
larger ring sizes, and in turn give amino alcohols with greater distance between OH and NH2. 
Using commercially available (E)-hex-4-en-1-ol 2.36, the relevant hydroxylamine 2.38 was 
synthesised via the usual methodology (Scheme 2.17a) and submitted to the oxidative 
amination conditions for 16 h (Scheme 2.17b). 
 
OH O
NPhth
O
NHBoc
NHP, PPh3
DIAD, THF
rt, overnight
i) N2H4·H2O
CH2Cl2, rt, 3 h
ii) Boc2O, NaOH
CH2Cl2, rt
overnight2.37 82% 2.38 87%
O
NHBoc Pd(OAc)2 (5 mol %)
DMSO (10 mol %)
NaOAc (20 mol %)
THF, O2, rt, 16 h
2.39 95%
NBoc
O
a)
b)
2.36
 
Scheme 2.17 
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Analysis of the crude reaction mixture after 16 h revealed a complete and clean conversion to 
the expected tetrahydro-1,2-oxazine 2.39, which after chromatography was isolated in 95% 
yield. This outstanding result opened up the possibility of synthesising 1,4-amino alcohol 
precursors. This reaction, with its excellent conversion, highlighted the preference for the 
formation of terminal alkenes in this type of substrate. Interestingly only a few examples of 
similar type cyclisations yielding 1,4-substrates exist in the literature,92 however none of 
these methods use a Pd catalysed Wacker-type cyclisation. Overall, this result means there is 
the possibility that rings larger than 6 can be synthesised in this manner, however 7, 8 and 9 
membered rings are harder to form. Also, when forming larger rings, reactive intermediates 
run the risk of reacting with another molecule of substrate before the intramolecular 
cyclisation can be completed. Problems aside, there is a great deal of future work that could 
be explored here. 
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2.2.4. Investigating Diastereoselectivity and Mechanistic Aspects 
It is well documented that these types of Pd transformations can yield high 
diastereoselectivities. This is often the result of a single aminopalladation pathway operating 
within the reaction system. In order to investigate this further, enantioenriched secondary 
substrates 2.40 (Scheme 2.18) were selected. The cyclisation of these substrates can in theory 
produce two isomers; syn 2.41 and anti 2.42. 
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O
N
Ot-BuO
PdX
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Ph ∗ ∗
PdX
O N
Boc
Me H
∗
O N
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O N
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O
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R
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NBoc
R
β-hydride
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O
∗ ∗
NBoc
R
2.40
2.41 2.42
2.43
 
Scheme 2.18 
 
Looking at transition state models of the two possible configurations of 2.40 reveals that the 
formation of syn 2.41 is favoured and cyclisation on the opposite face 2.43 generates a 1,3-
strain in the molecule (Scheme 2.18). 
In order to synthesise the desired chiral N-Boc homoallylic hydroxylamines 2.40, a route to 
chiral homoallylic alcohols was required. The Malkov group has also developed a route to 
(E)-homoallylic alcohols, utilising a combination of asymmetric crotylation followed by a 
Lewis acid catalysed allyl transfer (Scheme 2.19).70b Pyridine N-oxide catalysts developed by 
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Malkov and Kočovský have proved successful in asymmetric allylation reactions.93 This 
method was initially chosen for synthesising chiral (E)-homoallylic alcohols, however it did 
prove troublesome in several areas. 
 
SiCl3
R1CHO
METHOX
(i-Pr)2NEt
MeCN, -40 °C
R1
OH R
2CHO
Sn(OTf)2
CHCl3, rt R2
OH
up to 98% ee
up to 96% ee
N
OMe
OMeMeO
O
METHOX 2.44 =
 
Scheme 2.19 
 
The requisite chiral pyridine N-oxide catalyst METHOX 2.44 for the asymmetric allylation 
step had to be synthesised from commercially available (+)-α-pinene 2.45 employing a 5 step 
protocol. In the first step (+)-α-pinene 2.45 was converted to pinacarvone 2.46 using a singlet 
oxygen reaction (Scheme 2.20). 
 
O
Ac2O, pyridine
DMAP, TPP
CH2Cl2, hν , 16 h
2.46 87%2.45  
Scheme 2.20 
 
Initially this reaction was carried out in a custom glass reaction vessel, which had a cold 
water jacket to cool the reaction mixture. However this method proved tiresome as the 
reaction required constant monitoring, due to rapid evaporation of dichloromethane from the 
vessel caused by the intense heat given off by the 400W lamp. Reaction conversion was 
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monitored by 1H NMR spectroscopy, and starting material was no longer present after 12 h. 
The isolated yield of 2.46 was a disappointing 21%. A vast improvement to this method was 
achieved by using a custom continuous flow system. The reaction mixture saturated by a 
gentle stream of oxygen was pumped around the system in a loop passing through a ‘cold’ 
lamp, which provided irradiation. This method did not require any attention once it was 
running and proved to be a lot safer, as the lamps did not generate any significant heat, and 
the volume of material passing through the light was kept to a minimum. The isolated yield 
of 2.46 was greatly increased when using this method (87%). 
 
OOMe
OMeMeO
OOMe
OMeMeO
N
I
I2, pyridine
∆, 4 h
2.47 99%  
Scheme 2.21 
 
The second step was the preparation of Kröhnke salt 2.47. This step proceeded without any 
trouble and the salt was prepared in quantitative yield after 4 h (Scheme 2.21). With 2.46 and 
2.47 in hand, they were combined to form the desired pyridine using Kröhnke conditions 
(Scheme 2.22). Purification of the reaction mixture proved to be a lengthy process, due to the 
presence of several complex by-products formed by the harsh reaction conditions. The 
pyridine 2.48 was eventually isolated in 47% yield. 
 
HOAc, 110 °C
overnight
N
OMe
OMeMeO
OOMe
OMeMeO
N
I
O
NH4·OAc
2.48 47%  
Scheme 2.22 
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Introducing a methyl group onto the pinene portion of the molecule is again a step that 
proved to be more difficult than the literature suggested. Deprotonating pyridine 2.48 with 
LDA and treating with MeI, is a relatively straight forward approach in theory, however in 
practice the reaction was suffering from an incredibly poor yield (10%). The remaining 
material contained mostly unreacted starting material and some complex by-products. It was 
suspected that the starting pyridine 2.48 contained traces of water that was neutralising LDA, 
so several measures were introduced to ensure all moisture was removed from the reaction. 
Pyridine 2.48 was placed in toluene and evaporated to dryness 3 times to azeotropically 
remove water. MeI was stirred in dry THF with molecular sieves for 3 h before use. 
Diisopropylamine was distilled over CaH before it was used to form LDA in situ. However 
even with these measures, no increase in yield was observed. Using commercially obtained 
LDA gave no improvement in yield. It was noted that LDA formed in situ was made by a 
mixture of diisopropylamine and n-BuLi (1:1.1), the leftover 0.1 eq of n-BuLi may be 
responsible for deprotonating the pyridine leading to the constantly observed 10% yield. 
When straight n-BuLi (1.1 eq) was used in the reaction, then the desired methylated pyridine 
2.49 was obtained as the major product (isolated yield 81%) (Scheme 2.23). 
 
n-BuLi, MeI
THF,   40 °C
N
OMe
OMeMeO
2.49 81%
N
OMe
OMeMeO
-
 
Scheme 2.23 
 
The final step was to oxidise the pyridine 2.49 to a pyridine N-oxide with m-CPBA, this 
proceeded as expected with a moderate yield of 46% (Scheme 2.24). 
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m-CPBA
CH2Cl2 N
OMe
OMeMeO
O
N
OMe
OMeMeO
2.49 2.44  
Scheme 2.24 
 
After the synthesis of METHOX 2.44, crotyl trichlorosilane 2.50 was synthesised from crotyl 
chloride (Scheme 2.25). Once again this synthesis was not straight forward as the silane 2.50 
is extremely moisture sensitive. HSiCl3 was added to a dried flask of crotyl chloride, Hünig’s 
base, CuCl and 4Å MS, the reaction was left overnight. 
 
SiCl3Cl
HSiCl3
(i-Pr)2NEt
CuCl, Et2O
4Å MS, rt
overnight
2.50
 
Scheme 2.25 
 
Once the staring material had been consumed (monitored by 1H NMR spectroscopy), the 
reaction mixture was transferred to a separate dry flask via cannula to remove any solids. The 
reaction mixture was placed under a gentle vacuum to remove the excess Et2O, and then 
heated lightly to separate the crotyl silane 2.50 from the excess HSiCl3 and base (isolated 
yield was not recorded, instead the distilled silane was used in slight excess immediately). 
With METHOX and crotyl trichlorosilane in hand, the asymmetric allylation reaction could 
take place. Using p-tolualdehyde, the allylation took place with little problem and the desired 
alcohol 2.51 was isolated in 79% (Scheme 2.26). 
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SiCl3
p-tolualdehyde
METHOX
(i-Pr)2NEt
MeCN,   40 °C
OH
2.51
79%, 84% ee
-
 
Scheme 2.26 
 
However, when 2.51 was submitted for chiral GC the observed ee was moderate and poorer 
than expected, compared to the literature (98% ee). The recovered METHOX had also been 
reduced back to the pyridine by the presence of trace amounts of HSiCl3. This disappointing 
result prompted a change in route, as synthesising METHOX was a lengthy process, and the 
allylation suffered a deteriorated ee. 
An alternate route was found in the literature where the synthesis of enantioenriched 
secondary (E)-homoallylic alcohols was carried out by allyl transfer from an allyl menthol 
derivative 2.52 (Scheme 2.27).94 
 
HO
O
MgCl
THF, rt
2.52 75%  
Scheme 2.27 
 
This route only takes one step to form the chiral transfer reagent 2.52 and uses relatively 
cheap starting materials; crotyl chloride and (−)-methone. However, the drawback of this 
method is that it requires a 2:1 stoichiometry of allyl transfer reagent to aldehyde, compared 
to the method reported by Malkov which takes place catalytically. The chiral transfer reagent 
was synthesised with ease, after forming crotyl magnesium chloride in situ and treating with 
(-)-menthone. The major diastereoisomer 2.52 was separated from any minor isomers and 
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impurities with column chromatography, and was isolated in 75% yield. With 2.52 in hand, 
the desired (E)-homoallylic alcohols could be synthesised. A range of aliphatic and aromatic 
aldehydes were converted into the corresponding homoallylic alcohols via a p-TsOH 
catalysed allyl transfer (Table 2.3). Aromatic aldehydes containing electron donating groups 
were avoided as they are known to cause racemisation during the Mitsunobu step.28 
 
Table 2.3 
HO RCHO, p-TsOH
CH2Cl2, rt
overnight
R
OH
2.52
2.53a-f
 
Entry 2.53 R = Yield (%) ee(a) 
1 a Ph 64 96 
2 b Bn 80 92 
3 c CH2CH2Ph 86 94 
4 d Cy 63 97 
5 e CH(Et)2 77 94 
6 f n-C6H13 27 92 
(a) Enantiomeric excess was determined by chiral HPLC (entry 1-                                      
2), chiral GC (entry 3-6) and by comparison to literature.70b, 94 
 
The allyl transfer reactions proceeded with good yields and gave excellent ee’s. The 
exception was 2.53f which gave an unusually poor yield, however as the ee was sufficient 
and the amount of obtained material was enough to carry out subsequent transformations, it 
was decided that no further optimisation was necessary. The alcohol derivatives were then 
successfully converted into the corresponding hydroxylamines using the established 
methodology (Table 2.4). 
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Table 2.4 
OH O
NPhth
O
NHBoc
NHP, PPh3
DIAD, THF
rt, overnight
i) N2H4·H2O
CH2Cl2, rt, 3 h
ii) Boc2O, NaOH
CH2Cl2, rt
overnight
R R R
2.53a-f 2.54a-f 2.55a-f  
Entry R = Phthalimide 
derivatives (2.54) 
Yield 
(%) 
Hydroxylamine 
derivatives (2.55) 
Yield 
(%) 
1 Ph 2.54a 51 2.55a 59 
2 Bn 2.54b 57 2.55b 44 
3 CH2CH2Ph 2.54c 40 2.55c 56 
4 Cy 2.54d 29 2.55d 39 
5 CH(Et)2 2.54e 19 2.55e 63 
6 nC6H13 2.54f 45 2.55f 43 
 
Phthalimide derivatives 2.54a-f were synthesised in moderate yields, with some of the alkyl 
derivatives (2.54d-e) suffering poor yields. The Mitsunobu reaction proceeds via an SN2 
mechanism, meaning that hydroxyphthalimide substitutes the hydroxyl group with inversion 
of stereochemistry. Malkov reported that the inversion of stereochemistry proceeds with 
extremely little or no loss in ee.28,87 The preservation of optical activity in compounds 2.54a-f 
seemed to confirm that. Finally, the phthalimides 2.54a-f were converted into the 
corresponding N-Boc hydroxylamines 2.55a-f, which were obtained in moderate yields 
(Table 2.4). With these substrates finally available, the diastereoselectivity of the amination 
was tested. 
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Table 2.5 
O
NHBoc
O NBocPd(OAc)2 (5 mol %)
DMSO (10 mol %)
NaOAc (20 mol %)
THF, O2, rt, 16 h 2.56a-f
R R
2.55a-f  
Entry  Isoxazolidine 
2.56 
R = Yield 
(%) 
d.r.a,b 
1 a Ph 98 >30:1 
2 b Bn 96 ≈18:1 
3 c CH2CH2Ph 96 >30:1 
4 d Cy 96 >30:1 
5 e CH(Et)2 93 >30:1 
6 f nC6H13 95 >30:1 
(a) Ratio of syn and anti diastereoisomers was determined by 1H NMR spectroscopy                     
(b) Ratios of  >30:1 refer to instances in which the minor diastereoisomer could not                    
be distinguished from the baseline of the 1H NMR spectra. 
 
The cyclisation of N-Boc hydroxylamines 2.55a-f proceeded smoothly and with excellent 
yields (Table 2.5); as outlined previously the formation of terminal alkenes appears favoured 
over the formation of the internal ones. Analysis of 1H NMR spectrum of the crude reaction 
mixture revealed the presence of only one diastereoisomer for the majority of the examples 
(the minor diastereoisomer could not be detected amongst the baseline noise) (Figure 2.4a). 
However, benzyl substituted isoxazolidine 2.56b (Table 2.5, entry 2) showed a reduced but 
still credible 18:1 ratio of diastereoisomers (Figure 2.4b). 
The formation of syn-isoxazolidines was confirmed by nOe (see appendix 5.3) and can be 
rationalised by looking at all possible modes of aminopalladation and the transition states 
involved with each. Each diastereoisomer can be formed by both cis- and trans-AP pathways, 
however based on the earlier results in the group and by others, cis-AP is most likely to be in 
operation (Scheme 2.28).21,22,28,31 It is speculated that the carbonyl adjacent to nitrogen is 
involved in the coordination of Pd to nitrogen, thus disfavouring the trans-AP approach. 
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Additionally, Stahl has provided evidence that suggests trans-AP is favoured in acidic 
reaction conditions, in which nitrogen deprotonation and Pd-N formation are not favoured.  
 
Figure 2.4. a) 1H NMR showing single isomer, b) 1H NMR showing 18:1 mixture 
 
O NBoc
Ph
O NBoc
Ph
O NBoc
Ph
O NBoc
Ph
O NBoc
Ph
O NBoc
Ph
Pd Pd
PdPd
cis-AP trans-AP
syn (major)
anti (minor)  
Scheme 2.28 
 
The reaction developed in this study operates under mildly basic conditions, with the 
presence of NaOAc, which facilitates the deprotonation of the nitrogen nucleophile, and in 
turn leads to the formation of the Pd-N intermediate (Scheme 2.29). DMSO serves as a ligand 
to Pd and is necessary for the oxidation of Pd0 by O2. Stahl has shown that Pd(OAc)2 and 
DMSO can form Pd(DMSO)2(OAc)2 in situ, where DMSO can be O- and/or S- bound. The 
more labile O-bound DMSO is likely to enable weakly coordinating L-type ligands access to 
the coordination sphere of Pd, i.e. in this case the carbonyl group of the Boc group. For the 
oxidation of Pd0, Stahl speculates that S-bound DMSO can coordinate to Pd0 and essentially 
stabilise it by inhibiting aggregation into Pd black, thus allowing O2 to oxidise back to PdII.90c 
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Scheme 2.29. Proposed cis-AP reaction mechanism 
 
A cis-AP pathway has been proved for carbonylative cyclisation of the same substrate S-
2.55a, trapping the intermediate with CO and forming ester 2.57 (Scheme 2.30).28 
Me
Ph
O
N
Ot-BuO
PdX
H
Ph
PdX
O N
Boc
H Me
PdII, CuII
cis-APmajor
CO, MeOH
Ph
CO2Me
O N
Boc
O
NHBoc
Ph
2.57
S-2.55a
 
Scheme 2.30 
 
In conclusion, syn-isoxazolidines have been obtained with high diastereoselectivities and 
excellent yields. 
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2.2.5. Pyrazolidines 
Building upon the success achieved with isoxazolidines, it was envisaged that dinitrogen 
analogues could be cyclised in a similar manner to yield functionalised pyrazolidines. Again 
starting from (E)-homoallylic alcohols and using the Mitsunobu protocol, the desired diamine 
substrates could synthesised in one step (Scheme 2.31). 
 
OH N
NH
DIAD (2.5 eq)
PPh3, THF
rt, overnight
E-2.14 E-2.58 28%
O
O
O O
OH N
NH
DIAD (2.5 eq)
PPh3, THF
rt, overnight
Z-2.14 Z-2.58 25%
O
O
O O
 
Scheme 2.31 
 
Using an excess of DIAD in place of a nucleophile allowed for the addition of the hydrazine 
moiety to the alkyl chain. The E and Z alkenes explored previously were chosen once again 
so that the isomerisation effect could be observed with this new substrate. The yields 
obtained were relatively low, but the isolated material was sufficient to proceed with. The 1H 
NMR spectra of each suffered from some peak broadening due to rotamers. Both diamines 
were subjected to the reaction conditions for 16 h, however after this time a significant 
amount of starting material remained (≈50%). To improve the conversion, a second batch of 
Pd(OAc)2 (5 mol %) was added to the reaction mixture, which was left to stir for a further 16 
h (Scheme 2.32). After this time, the conversion was sufficient enough (SM < 5%) and the 
pyrazolidines were purified and analysed with NMR spectroscopy. Interestingly the 
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pyrazolidines isomers 2.59-2.61 were obtained in similar ratios to analogous isoxazolidines 
(2.17-2.19); E:Z:terminal 12:1:1. 
 
RN
NHR Pd(OAc)2 (2 × 5mol %)
DMSO
NaOAc, THF
O2, rt, 32 h
76% from E-2.58
RN NR
E:Z:terminal 12:1:1
E-2.58
R = COOi-Pr
2.59
RN NRRN NR
+ +
2.60
2.61
RN
NHR Pd(OAc)2 (2 × 5mol %)
DMSO
NaOAc, THF
O2, rt, 32 h
72% from Z-2.58
RN NR
E:Z:terminal 12:1:1
Z-2.58
R = COOi-Pr
2.59
RN NRRN NR
+ +
2.60
2.61
 
Scheme 2.32 
 
It is difficult to identify the primary cause for the loss of reactivity is in this reaction, when 
compared to the analogous hydroxylamine. The increased steric bulk of having a second 
carbamate group, the lower acidity of NH and the coordinating nature of the second 
carbamate group (Scheme 2.33) may all contribute in the drop in reactivity. 
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Scheme 2.33 
 
After the initial 16 h, adding a second portion of Pd(OAc)2 (5 mol %) and reacting for a 
further 16 h enabled a more efficient conversion of the product 2.59 (Scheme 2.32).  
A secondary hydrazine substrate was synthesised to see if these substrates maintained similar 
diastereoselectivity to that observed with oxyamines (Scheme 2.34).  
 
OH
N
NHDIAD (2.5 eq)
PPh3, THF
rt, overnight
2.62 38%
O
O
O O
Ph
Ph2.53a (96% ee)
 
Scheme 2.34 
 
2.62 Was synthesised in the same manner as the previous two hydrazine substrates and was 
obtained in 38% yield. A broad 1H NMR spectra was obtained at room temperature (Figure 
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2.5a), at 115 °C in DMSO-d6 sharper peaks were obtained (Figure 2.5b). Slow bond rotation 
at room temperature causes the appearance of broad peaks which is the result of the same 
atoms or groups of atoms being observed in multiple positions at one time, throughout 
different molecules in the mixture. The elevated temperature causes an increase in bond 
rotation, which has the effect of ‘averaging out’ these poorly defined peaks, meaning that 
atoms are observed in the same position throughout the molecules in the mixture. Hence 
sharper peaks are obtained. 
 
Figure 2.5 
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Substrate 2.62 was cyclised using the modified oxidative amination conditions that were used 
for the previous hydrazine compounds (Scheme 2.35). 2.63 was isolated in 78% yield and 
showed a d.r. of >30:1, however it could not be assumed that the syn-pyrazolidine was 
formed. 
 
N
NH
Pd(OAc)2 (2 × 5mol %)
DMSO
NaOAc, THF
O2, rt, 32 h
2.63 78% d.r. >30:1
O
O
O O
N N
O
O
O
O
Ph
Ph
2.62
 
Scheme 2.35 
 
As outlined by Wolfe in his synthesis of pyrazolidines via an oxidative aminoarylation, the 
substituent on N-2 plays a crucial role in determining the stereochemical outcome of the 
newly formed C-N bond (Scheme 2.36).74 
 
R2
N
HN R1
Boc
N N
ArPd
Boc
R2
H
H
N N
R2
H
ArPd
H
Boc
R1 = H
R1 = Ph
ArBr
[Pd]
base
N N
Boc H
R2
Ar
3,5-cis
N N
Boc Ph
R2
Ar
3,5-trans
equatorial R2
axial R2
1
2
1 2
2
1
 
Scheme 2.36 
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Bulkier substituents at N-2 cause a degree of steric repulsion between the bulky group and 
the substituents of the neighbouring carbon atom, as a consequence R2 sits axially forcing the 
molecule to adopt a conformation that favours anti-pyrazolidine formation. With small 
groups at N-2, there is little steric interaction with the neighbouring substituents, therefore R2 
can sit equatorially and the molecule adopts a conformation favouring syn-pyrazolidine 
formation. With the bulky carbamate group it could be assumed that 2.63 was in the anti-
conformation. This was confirmed by nOe studies (see appendix 5.2) and by single crystal X-
ray. The single crystal was grown by vapour diffusion using diethyl ether/hexane over several 
days. The ring structure was shown to be in a twisted anti-conformation that positioned the 
carbamate groups on opposing faces with respect to each other and to the neighbouring 
substituents at C-3 and C-5 (Figure 2.6, see also appendix 5.1). 
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Figure 2.6 
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2.2.6. Applications of Isoxazolidines and Pyrazolidines 
Amino acids and their derivatives often show useful pharmacological properties,96 such as 
allosedridine.97 Amino acids can be accessed directly from 1,3-amino alcohols. Transforming 
isoxazolidines into amino alcohols was an essential step in the applications of the chemistry 
developed in this study. Using MoCO6, isoxazolidine 2.56a was transformed into 
corresponding amino alcohol 2.64, in 61% yield, as outlined in scheme 2.37. 
 
OHO NBoc Mo(CO)6 (5 eq)
MeCN:H2O (9:1), ∆ PhPh
NHBoc
2.56a 2.64 (61%)  
Scheme 2.37 
 
Unnatural sugar derivatives in the form of 3-amino-tetrahydrofurans were synthesised by a 
colleague at Glasgow University, and can be obtained in 2 steps from the amino alcohol 2.64. 
The amino alcohol was submitted to oxidation conditions using m-CPBA, which formed 
epoxide 2.65 in 68% yield and 7:1 d.r. (Scheme 2.38). Amino sugar derivative 2.66 was 
obtained in 68% yield after cyclisation with BF3·OEt2.87 
 
OHm-CPBA
(1.2 eq)
CH2Cl2, rt
overnight
Ph
NHBoc
2.65
O
OH
Ph
NHBoc
2.64
BF3·OEt2 
(10 mol %)
CH2Cl2, rt
30 min
OPh
NHBoc
OH
2.66
 
Scheme 2.38 
 
Attempts to isolate a single crystal of 2.56a failed, so the next logical step was to remove the 
Boc protecting group and attempt to grow a crystal from the amine or corresponding amine 
salt. Deprotection of 2.56a was carried out with trifluoroacetic acid,88 yielding the free amine 
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2.67 (Scheme 2.39), however attempts to isolate a single crystal of the amine or the 
corresponding salt failed. 
 
OO NBoc
TFA (5 eq)
CH2Cl2, 1 h PhPh
NH
2.56a 2.67 (89%)  
Scheme 2.39 
 
1,3-Diamines 2.68 are also valuable targets so the ability to cleave the N-N bond of 
pyrazolidines was required. Wolfe has reported the successful cleavage of N-N bonds in 
pyrazolidines using SmI2.19 However, attempts to repeat this procedure and cleave the N-N 
bond of 2.63 proved unsuccessful. A few other methods were carried out in an attempt to 
cleave the N-N bond, however were still unsuccessful (Table 2.6); SmI2 returned unreacted 
starting material, both when made in situ and when used as a commercial reagent. Li/NH3 
completely cleaved the hydrazine component and yielded internal alkene 2.69, whereas 
LiAlH4 yielded methyl amine 2.70. 
 
Table 2.6 
NH HN
O
O
O
O
Ph
N N
O
O
O
O
Ph
N N
Ph
2.63
2.70
Ph
2.69
2.68
 
Entry Conditions Product 
1 SmI2 (Prepared in situ) SM 
2 SmI2 (Commercial) SM 
3 Li/NH3 2.69 
4 LiAlH4 2.70 
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It may be a case of altering the protecting groups to allow SmI2 to react with the N-N bond,75 
however due to time constraints this could not be explored further. 
 
2.2.7. Attempted Enantioselective Variant 
Attempts were made to develop an enantioselective version of the Wacker-type amination 
process. The idea was to take the achiral model substrate 2.5 and induce enantioselectivity in 
the newly formed bond using a chiral ligand for PdII. Several different ligands (Figure 2.7), 
PdII sources and conditions were tested (Table 2.7). 
 
N
N
O
R
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S
O
O
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S O
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O O
O
P
OAg
O
N
Pd
N
Pd
OO
OO
PP
O
O O
O
2.75
2.76
2.77
2.78 2.79
2.80 =
–
 
Figure 2.7  
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Table 2.7a 
O
NHBoc
O
∗
NBoc
2.5 2.71  
Entry PdII  
(mol %) 
Ligand  
(mol %) 
Additivesb  
(mol %) 
Time Yieldc 
(%) 
eed 
(%) 
1 Pd(OAc)2 (5) (-)-Sparteine  
2.72 (15) 
DMSO (10), 
NaOAc (20), O2 
5 days 50 0 
2 Pd(OAc)2 (5) Bn-QUINOX  
2.73 (15) 
DMSO (10), 
NaOAc (20), O2 
3 days 47 0 
3 Pd(OAc)2 (5) i-Pr–QUINOX  
2.74 (15) 
DMSO (10), 
NaOAc (20), O2 
5 days 65 0 
4 PdCl2 (5) i-Pr –QUINOX 
2.74 (15) 
DMSO (10), 
NaOAc (20), O2 
5 days 78 0 
5 Pd(TFA)2 (5) i-Pr –QUINOX 
2.74 (15) 
DMSO (10), 
NaOAc (20), O2 
16 h 66 0 
6 Pd(OAc)2 (5) 2.75 (10) NaOAc (20), O2 16 h 42 0 
7 Pd(OAc)2 (5) 2.76 (10) NaOAc (20), O2 16 h 55 0 
8 Pd(OAc)2 (5) 2.77 (20) DMSO (10), 
NaOAc (20), O2 
16 h 51 0 
9 Pd(OAc)2 (5) (R)-BNPPA 
2.78 (5) 
DMSO (10), 
NaOAc (20), O2 
16 h 21 0 
10 Pd(OAc)2 (5) (R)-BNPPA-Ag 
salt 
2.79 (5) 
DMSO (10), 
NaOAc (20), O2 
16 h 36 0 
11 2.80 (5) None DMSO (10), 
NaOAc (20), O2 
16 h 10 5 
(a) Conditions: 2.5 (0.25 mmol), solvent 3 mL, rt. (b) The flask was flushed with O2, before a balloon (1 atm) of 
O2 was applied. (c) Yields are of isolated 2.71. (d) ee’s were determined by HPLC; Chiracel IB column, 98:2 
hexane: propan-2-ol, 0.75mL min-1, 220nm detector, retention time = 12.02 min, 13.87 min. 
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Initially the conditions were kept the same but with the addition of a chiral ligand. Using (-)-
sparteine 2.72 and QUINOX ligands 2.73 and 2.74 (Table 2.7, entries 1-3) gave sluggish 
reactivity, and took 3-5 days to obtain a respectable yield. However, no enantiomeric excess 
was observed. Changing the PdII source to PdCl2 (Table 2.7, entry 4), gave a slight 
improvement in yield but still no ee. Changing to Pd(TFA)2 (Table 2.7, entry 5) sped up the 
reaction dramatically, resulting in a 66% yield after 16 h, though the isoxazolidine 2.71 was 
still racemic. As DMSO is acting as a ligand to Pd, the sluggish reactivity and lack of ee 
could be attributed to a competition effect between the two ligands. Chiral sulfoxides 2.75 
and 2.76 were used in place of DMSO (Table 2.7, entries 6-7), however once again no ee was 
observed. A similar result was obtained for phosphoramidite 2.77 (Table 2.7, entry 8). To 
understand the lack of enantioselectivity, the mechanism of the reaction was analysed 
(Scheme 2.40).   
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Scheme 2.40 
 
Because of the coordination from the carbonyl and the alkene that is required for cis-AP, 
there is simply no room in the Pd coordination sphere for a donating ligand. The sluggish 
reactivity could potentially come from slow exchange between the carbonyl/alkene and the 
chiral bidentate ligand. The lack of ee also provides further evidence for a cis-AP 
mechanism; if trans-AP was in operation, then some of the Pd coordination sphere would be 
accessible for ligands and some ee should be observed. In the key intermediate for cis-AP 
there is only the one counter-ion remaining bound to Pd. A strategy to make a chiral counter-
ion for Pd was attempted, using phosphoric acid 2.78 and its silver salt 2.79 (Table 2.7, 
entries 9-10). Once again, no ee was observed. Using a premade Pd complex 2.80 (Table 2.7, 
entry 11) gave a poor yield of 10%, but showed a small amount of enantiomeric induction 
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(5%). In light of Stahl’s report,34 outlining the effects of the different aminopalladation 
modes on enantioselectivity, this study was abandoned as it was evident that cis-AP does not 
favour chiral induction through a ligand. 
Briefly, an attempt was made to induce enantioselectivity by substituting the t-Boc of the 
substrate for a chiral sulfoxide alternative (Scheme 2.41).  
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Scheme 2.41 
 
(S)-(−)-menthyl p-toluene-sulfinate was synthesised from L-menthol and p-TsCl in moderate 
yield (Scheme 2.42).98 
 
O
S
O
tol
p-TsCl
P(OMe)3, NEt3
CH2Cl2, 3 days
∆, 43%
HO
 
Scheme 2.42 
 
It was planned to substitute menthol with hydroxylamine 2.3. However, this could not be 
achieved with either the free hydroxylamine or its corresponding lithium salt 2.81 (Scheme 
2.43). 
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Scheme 2.43 
 
 
2.2.8. Optimisation of Tandem Cyclisation/Wacker Oxidation Conditions 
It was decided to examine further the competition between formation of alkene 2.9 and 
ketone 2.10 during the oxidative Wacker-type amination that was mentioned earlier (Section 
2.2.2., Table 2.1, entries 4-5). We aimed to investigate whether the reaction conditions 
leading to the formation of ketone 2.10 could be optimised further (Table 2.8).  
Using 2,2’-bipyridine as a ligand gave a reduction in ketone 2.10 (Table 2.8, entry 3). 
QUINOX 2.11 was used as the ligand again and after 72 h a 62% conversion (Table 2.8, 
entry 4) was obtained. Carrying out the reaction in the presence of water (Table 2.8, entry 5) 
or under anhydrous conditions (Table 2.8, entry 6) gave similar yields. Changing oxidant to 
p-benzoquinone (Table 2.8, entry 7) gave no change in conversion. Removal of the co-
oxidant gave the best result (Table 2.8, entry 8), 85% conversion and 81% yield. 
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Table 2.8.a 
O
NHBoc O NBoc
O
O NBoc
+
2.5 2.9 2.10N
N
O
2.11 =
 
Entry PdII (mol %) Oxidantb (mol %) Ligand 
(mol %) 
Solvent Conv.c,d 
2.10 (%) 
Conv.c 
2.9 (%) 
1 Pd(OAc)2 (10) Cu(OAc)2 (30)/ O2 None MeCN 20 0 
2 Pd(MeCN)2Cl2 
(5) 
Cu(OAc)2 (30)/ O2 2.11 (40) MeCN 50 0 
3 Pd(MeCN)2Cl2 
(5) 
Cu(OAc)2 (30)/ O2 bipy (40) MeCN 25 0 
4e Pd(MeCN)2Cl2 
(5) 
Cu(OAc)2 (30)/ O2 2.11 (40) MeCN 62 22 
5 Pd(MeCN)2Cl2 
(5) 
Cu(OAc)2 (30)/ O2 2.11 (40) MeCN/ 
5% H2O 
65 17 
6 Pd(MeCN)2Cl2 
(5) 
CuCl (30)/ O2 2.11 (40) MeCN 56 0 
7 Pd(MeCN)2Cl2 
(5) 
BQ (30)/ O2 2.11 (40) MeCN 56 0 
8 Pd(MeCN)2Cl2 
(5) 
O2 2.11 (40) MeCN 85 (81) 15c 
9 Pd(MeCN)2Cl2 
(5) 
O2 2.11 (40) DMPU 44 13 
(a) Conditions: 2.5 (0.25 mmol), solvent 3 mL, 60 °C, 16 h. (b) The flask was flushed with O2, before a balloon 
(1 atm) of O2 was applied. (c) Conversion was determined using 1H NMR and the ratio of SM:product(s). (d) 
Isolated yields are in parenthesis. (e) This reaction was run for 72 h. BQ = p-benzoquinone, BIPY = 2,2ʹ-
bipyridine.  
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2.3. Oxazolidinones; an Attempted Synthesis of 1,2-Amino Alcohol 
Precursors 
 
Oxazolidinones are ideal precursors to 1,2-amino alcohols as the carbonyl can easily be 
hydrolysed to yield the amine and hydroxyl groups. Alongside the synthesis of 
isoxazolidines, a PdII catalysed oxidative cyclisation strategy was envisioned. A brief 
retrosynthetic analysis revealed that the desired oxazolidinones could be accessed from 
allylic carbamates, which in turn could be synthesised from allylic alcohols (Scheme 2.44). 
 
O N EWG
O
O N
H
EWG
O
OH
 
Scheme 2.44 
 
Using a similar design to that used for 1,3-amino alcohols, the nitrogen nucleophile would 
contain an electron-withdrawing group that would hopefully enable a cis-AP pathway. 
Several substrates bearing different electron withdrawing groups were synthesised,100,101 
which were used in the optimisation of conditions (Scheme 2.45). 
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Scheme 2.45 
 
As a starting point, conditions similar to those developed in the group for the synthesis of 
isoxazolidines via an oxidative cyclisation/carbonylation were chosen.29 From this starting 
point, several conditions and substrates were screened as outlined in table 2.9. 
A mixture of compounds was obtained in the reaction of 2.83a (Table 2.9, entry 1), the 
desired oxazolidinone 2.84a was obtained along with the product of an allylic rearrangement 
2.85a. This type of rearrangement is not uncommon.67 The remainder of the material with the 
near 1:1 mixture of 2.84a and 2.85a obtained with starting material. Switching the reaction 
solvent to toluene and DMSO (Table 2.9, entry 2-3) gave complex mixtures. Going back to 
MeCN, but using the substrate 2.83b gave a similar result to that obtained with 2.83a (Table 
2.9, entry 4). In an attempt to suppress the allylic rearrangement the substrate was switched to 
one containing a more electron withdrawing Ts group 2.83c. However the cyclisation with 
these conditions led to the decomposition of the compound and the isolated material was 
mainly TsNH2. It was speculated that the double bond could be shifted by Pd, leading to CO2 
and TsNH2 evolution. Adding ground pH 7.0 buffer tablet to the reaction suppressed this 
decomposition somewhat, however trace amounts of TsNH2 were still observed (Table 2.9, 
entry 6). Switching to N,N-diisopropylethylamine (Table 2.9, entry 7) in an attempt to 
promote nitrogen deprotonation and Pd-N formation led to slight increase of both 2.84c and 
2.85c. The introduction of an oxygen atmosphere into the system (Table 2.9, entry 8) 
provided the best result, obtaining 65% conversion of 2.84c, however a greater amount of 
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TsNH2 was obtained in this reaction. Submitting 2.83c to the amination conditions used for 
the synthesis of 1,3-substrates returned unreacted starting material (Table 2.9, entry 9). 
Table 2.9.a 
O N
H
O
R
2.83a R = OBn
2.83b R = OMe
2.83c R = Ts
O N
O
R HN
R
+
2.84a-c 2.85a-c
 
Entry Substrate 
2.83 (R =) 
PdII (mol 
%) 
Oxidant (eq) Additive 
(eq) 
Solvent Yield 
2.84 (2.85)d 
1 a (OBn) PdCl2 (10) Cu(OAc)2 (3) MOA (1) MeCN 20 (18) 
2 a (OBn) PdCl2 (10) Cu(OAc)2 (3) MOA (1) Toluene 0e 
3 a (OBn) PdCl2 (10) Cu(OAc)2 (3) MOA (1) DMSO 0e 
4 b (OMe) PdCl2 (10) Cu(OAc)2 (3) MOA (1) MeCN 14 (15) 
5 c (Ts) PdCl2 (10) Cu(OAc)2 (3) MOA (1) MeCN 0f 
6 c (Ts) PdCl2 (10) Cu(OAc)2 (3) MOA (1) c MeCN 22 (15)g 
7 c (Ts) PdCl2 (10) Cu(OAc)2 (3) DIPEA (1)c MeCN 37 (25)g 
8 c (Ts) Pd(OAc)2 
(10) 
Cu(OAc)2 
(3)/O2b 
DIPEA (1)c MeCN 65 (17)h 
9 c (Ts) Pd(OAc)2 
(5) 
DMSO/O2b NaOAc THF SM 
(a) Conditions: substrate 2.83a-c (0.38 mmol), solvent 3 mL, 60 °C, 3 days (b) The flask was flushed with O2, 
before a balloon (1 atm) of O2 was applied. (c) 0.1g ground pH 7.0 buffer tablet was added. (d) Remaining 
material is starting carbamate unless stated otherwise. (e) A complex mixture was obtained. (f) Isolated material 
was predominatly TsNH2. (g) Trace amounts of TsNH2 were observed. (h) ≈15% TsNH2 was isolated. MOA = 
methyl orthoacetate, DIPEA = N,N-diisopropylethylamine. 
 
Ultimately, efforts to optimise these conditions were halted in favour of the more successful 
isoxazolidines that do not suffer from a competing rearrangement reaction. Bӓckvall and co-
workers18 (see page 49) later provided an insight into this reaction and found that in fact the 
cyclisation is operating via a trans-AP pathway (see page 13-14).  
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2.4. Conclusion 
During this study, conditions have been identified for the successful transformations of 
hydroxylamines and hydrazines to isoxazolidines and pyrazolidines respectively. The role of 
each component of the reaction conditions have been outlined in the proposed cis-AP 
reaction mechanism. DMSO is essential for the enabling the re-oxidation of Pd0 by molecular 
O2 and preventing Pd-black formation. NaOAc in the reaction mixture and the presence N-
Boc group on the substrate are required for the successful formation of the Pd-N species for 
cis-AP. The range of substrates can be extended to substituted alkene, secondary substrates 
and even those leading to the formation of larger rings. Substrates that are functionlised on 
the alkyl chain can be cyclised efficiently, however substrates with steric bulk around the the 
β-hydrogen give a slower conversion. syn-Isoxazolidines can be formed with excellent 
diastereoselectivities (up to >30:1), whilst maintaining the efficient and mild reaction 
conditions. Side products have been observed in the form of keto-isoxazolidine 2.10, the 
conditions leading to this by-product have been optimised. Hydrazine substrates have shown 
similar reactivity to that observed for hydroxylamines. Attempts into developing an 
enantioselective variant proved unsuccessful with chiral ligands as, in line with recent 
literature,34 Pd in a cis-AP intermediate cannot support donating type ligands and a trans-AP 
pathway or a chiral counter ion is required for enantioselective induction to take place. 
Studies into optimising conditions leading to oxazolidinones was less successful due to a 
competing 3,3ʹ-allylic rearrangement, that could not be productively suppressed. 
Isoxazolidines were successfully transformed into the corresponding 1,3-amino alcohols, 
proving the validity of this chemistry as a gateway for synthetically valuable amino alcohols 
building blocks. Ultimately, this study is a valuable addition to the ever growing field of 
Wacker-type palladium transformations. 
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2.5. Future Work 
Ideally, for industrial purposes, the catalysis conditions would contain as little Pd as possible. 
Efforts into lowering the Pd loading to 1% or lower whilst maintaining a decent reactivity are 
highly desirable. Additionally utilising air instead of O2 would be beneficial, cutting costs of 
obtaining the pure gas and removing the risks associated with pure oxygen. With regards to 
the substrates, the example leading to 1,4-amino alcohol precursor oxazine 2.39 could be 
further expanded, opening up a whole new substrate scope, with diastereoselectivity being 
chief amongst them. Attempts can be made to synthesise larger ring sizes, however there is 
the possibility that these may suffer a loss in reactivity as forming larger rings becomes 
unfavourable. Expanding the scope of the hydrazine substrates is another avenue to be further 
explored. By removing or replacing the carbamate (with something non-coordinating) on the 
alkyl tethered amine, perhaps the reactivity can be bought into line with that observed for 
hydroxlamines. The coordination effect that appears to be inhibiting Pd would be removed 
and the cyclisation could take place faster and without the need for additional Pd. Also, in 
line with the reports by Wolfe,75 perhaps the syn- or anti-ring configuration can be tuned by 
the size of this group. Removing one, or both of the protecting groups from the pyrazolidines, 
may be the key to cleaving the N-N bond yielding the desired 1,3-diamines. Further studies 
into tuning the enantioselective conditions should be carried out. Employing more acidic 
conditions and altering the substrate so that a trans-AP is favoured would be the key to 
successfully inducing enantioselectivity with a donating ligand. Additionally, further studies 
into finding a suitable chiral counter-ion could enable some stereochemical induction whilst 
maintaining the cis-AP pathway. Finally, applications of this chemistry could be explored, 
first by coupling the cyclisation with different substrates, such as those seen in 
aminoarylation, aminocarbonylation, etc. Secondly applying the chemistry to natural product 
or a target orientated synthesis.   
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3. Experimental 
3.1. General Considerations 
All infrared spectra were obtained using a Perkin-Elmer, spectrum 65 FT-IR 
spectrophotometer; spectra for liquids were acquired as a thin film using sodium chloride 
plates or in the case of solids, as a KBr disc. 
 
All 1H and 13C NMR spectra were measured at 400 and 100 MHz respectively using a Bruker 
DPX 400 MHz spectrometer.  The solvent used for NMR spectroscopy was chloroform-d1 (δ 
7.26, 1H; δ 77.0, 13C) using TMS (tetramethylsilane) as the internal reference, unless stated 
otherwise.  Chemical shifts are given in parts per million (ppm) and J values are given in 
Hertz (Hz). Various 2D-techniques and DEPT experiments were used to establish the 
structures and to assign the signals. 
The mass spectra were recorded using a Thermoscientific exactive (Orbi) ESI (Ethanol) via 
nanomate (Advion) and by the EPSRC national mass spectrometry service at the University 
of Wales, Swansea, utilising electrospray (ES). 
 
All chromatographic manipulations used silica gel as the adsorbent.  Reactions were 
monitored using thin layer chromatography (TLC) on aluminium backed plates with Merck 
TLC 60 F254 silica gel.  TLC visualised by UV radiation at a wavelength of 254 nm, or 
stained by exposure to an ethanolic solution of vanillin (acidified with concentrated sulphuric 
acid) or an ethanolic solution of Phosphomolybdic acid, followed by charring where 
appropriate. Purification by column chromatography using Apollo ZEOprep 60/ 40-63 
micron silica gel. 
 
The reactions requiring anhydrous conditions were carried out using flame dried glassware, 
under a nitrogen atmosphere unless otherwise stated.  Reaction solvents were used as 
obtained commercially. Tetrahydrofuran (THF) was distilled under an argon atmosphere 
from the sodium/benzophenone ketyl radical. 
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3.2. Experimental Data 
3.2.1. General Procedure for Knoevenagel Condensation91 
Acetic acid (0.017g, 0.29 mmol) was added dropwise to a solution of piperidine (0.025 g, 
0.29 mmol) in DMSO (2 mL) and stirred at room temperature for 5 minutes. Malonic acid 
(3.1 g, 29.8 mmol) and the desired aldehyde (1 g, 14.9 mmol) in DMSO (15 mL) was added 
and stirred at room temperature for 15 minutes. The mixture was then heated to 120 °C and 
stirred at this temperature overnight. CO2 evolution was observed upon heating. Once the 
reaction was complete, the mixture was cooled and extracted with diethyl ether (2 × 10 mL). 
The combined fractions were washed with water (15 mL) and dried over anhydrous Na2SO4 
and evaporated under reduced pressure. The crude oil was purified using column 
chromatography (light petroleum: EtOAc, 10:1) to yield the pure carboxylic acid. 
 
2
3
1HO
4
5
O
Ph
 
(E)-5-Phenylpent-3-enoic acid (2.21).101 Clear oil, (80%): 1H NMR (400 MHz; CDCl3) δ 
3.09 (d, J = 6.8 Hz, 2H, H-2), 3.37 (d, J = 6.8 Hz, 2H, H-5), 5.56 – 5.64 (m, 1H, H-3), 5.69 – 
5.77 (m, 1H, H-4), 7.15 – 7.20 (m, 3H), 7.25 – 7.29 (m, 2H), 11.93 (br s, OH); 13C NMR 
(100 MHz, CDCl3) δ 37.8 (CH2, C-2), 39.0 (CH2, C-5), 122.4 (CH, C-3), 126.2 (CH, Ph), 
128.5 (CH × 2, Ph), 128.6 (CH × 2, Ph), 133.9 (CH, C-4), 140.0 (C), 178.8 (CO); IR (NaCl) ν 
3028, 2671, 1710, 1494, 1416, 1289, 1223, 970, 699, 489 cm-1; HRMS (ESI) 199.0729 
(C11H12O2Na requires 199.0730). 
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(E)-5-Methylhex-3-enoic acid (2.22).102 Clear oil, (52%): 1H NMR (400 MHz; CDCl3) δ 
0.99 (d, J = 6.8 Hz, 6H, H-6), 2.30 (oct, J = 6.8 Hz, 1H, H-5), 3.06 (d, J = 7.6 Hz, 2H, H-2), 
5.43 – 5.59 (m, 2H, H-3/4), 11.97 (br s, OH); 13C NMR (100 MHz, CDCl3) δ 22.1 (CH3 × 2, 
C-6), 31.0 (CH, C-5), 37.8 (CH2, C-2), 118.0 (CH, C-3/4), 142.2 (CH, C-3/4), 179.0 (CO); IR 
(NaCl) ν 2961, 2668, 1713, 1416, 1288, 1223, 970, 625, 472 cm-1; HRMS (ESI) 151.0730 
(C7H12O2Na requires 151.0730). 
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3.2.2. General Procedure for LiAlH4 Reduction of Acids to Alcohols86 
THF (20 mL) was added to a 250 mL round bottom flask charged with LiAlH4 (0.13 g, 3.41 
mmol) under an atmosphere of nitrogen. The mixture was cooled to 0 °C and the acid (0.5 g, 
2.84 mmol) in THF (10 mL) was added dropwise and the mixture was allowed to warm to 
room temperature and left to stir overnight. Sodium sulphate decahydrate was added portion 
wise at 0 °C, until any excess LiAlH4 was quenched. The resultant mixture was filtered 
through a thin pad of celite to remove the magnesium salts. The solvent was removed from 
the filtrate in vacuo, to yield the crude alcohol. Purification with column chromatography 
(light petroleum: EtOAc 10:1) yielded the pure alcohol. 
 
2
31
HO
4
5
 
(E)-Pent-3-en-1-ol (2.1).86 Clear oil, was used without purification (95%): 1H NMR (400 
MHz; CDCl3) δ 1.67 (d, J = 6.4 Hz, 3H, H-5), 1.80 (br s, OH), 2.25 (q, J = 6.4 Hz, 2H, H-2), 
3.62 (t, J = 6.4 Hz, 2H, H-1), 5.37 – 5.45 (m, 1H, H-3), 5.52 – 5.61 (m, 1H, H-4); 13C NMR 
(100 MHz, CDCl3) δ 18.0 (CH3, C-5), 35.9 (CH2 C-2), 62.0 (CH2, C-1), 127.1 (CH, C-3), 
128.4 (CH, C-4); IR (NaCl) ν 3340, 2936, 2920, 1449, 1378, 1045, 966 cm-1; HRMS (ESI) 
87.0804 (C5H11O requires 87.0808). 
 
2
31
HO
4
5
6  
(E)-Hex-3-en-1-ol (E-2.14).103 Clear oil, was used without purification (91%): 1H NMR (400 
MHz; CDCl3) δ 0.99 (t, J = 6.7 Hz, 3H, H-6), 2.04 (quin, J = 6.7 Hz, 2H, H-5), 2.27 (q, J = 
6.7 Hz, 2H, H-2), 3.63 (t, J = 6.7 Hz, 2H, H-1), 5.38 (dt, J = 15.2, 6.7 Hz, 1H, H-3), 5.60 (dt, 
J = 15.2, 6.7 Hz, 1H, H-4); 13C NMR (100 MHz, CDCl3) δ 13.7 (CH3, C-6), 25.6 (CH2, C-5), 
35.9 (CH2, C-2), 62.0 (CH2, C-1), 124.8 (CH, C-3), 135.6 (CH, C-4); IR (NaCl) ν 3341, 
2962, 2932, 1459, 1048, 968 cm-1; HRMS (ESI) 101.0962 (C6H13O requires 101.0961). 
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(E)-5-Phenylpent-3-en-1-ol (2.28).104 Clear oil, (60%): 1H NMR (500 MHz; CDCl3) δ 2.06 
(br s, OH), 2.27 (q, J = 6.5 Hz, 2H, H-2), 3.34 (d, J = 7.0 Hz, 2H, H-5), 3.61 (t, J = 6.5 Hz, 
2H, H-1), 5.44 – 5.51 (m, 1H, H-3), 5.69 (dtt, J = 15.5, 7.0, 1.5 Hz, 1H, H-4), 7.16 – 7.20 (m, 
3H), 7.26 – 7.29 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 36.0 (CH2, C-2), 39.2 (CH2, C-5), 
62.1 (CH2, C-1), 126.1 (CH, Ph), 127.6 (CH, C-3), 128.4 (CH × 2, Ph), 128.5 (CH × 2, Ph), 
132.3 (CH, C-4), 140.6 (C); IR (NaCl) ν 3342, 3027, 2928, 1494, 1453, 1046, 969, 746, 698 
cm-1; HRMS (ESI) 185.0937 (C11H14ONa requires 185.0937). 
 
2
31
HO
4
5
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(E)-5-Methylhex-3-en-1-ol (2.29).105 Clear oil, (73%): 1H NMR (500 MHz; CDCl3) δ 0.98 
(d, J = 7.0 Hz, 6H, H-6), 2.05 (br s, OH), 2.23 – 2.31 (m, 3H, CH & CH2, H-2/5), 3.62 (t, J = 
6.5 Hz, 2H, H-1), 5.31 – 5.37 (dtd, J = 15.2, 6.5, 1.2 Hz, 1H, H-3), 5.50 – 5.55 (ddt, J = 15.2, 
6.5, 1.2 Hz, 1H, H-4); 13C NMR (125 MHz, CDCl3) δ 22.5 (CH3 × 2, C-6), 31.1 (CH, C-5), 
35.9 (CH2, C-2), 62.1 (CH2, C-1), 122.7 (CH, C-3), 141.2 (CH, C-4); IR (NaCl) ν 3342, 
2958, 2929, 2870, 1466, 1048, 970 cm-1; HRMS (ESI) 137.0936 (C7H14ONa requires 
137.0937). 
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3.2.3. Preparation of Chiral Allyl Donor 2.52 from (−)-menthone94b 
A flame dried flask was charged with magnesium turnings (0.71 g, 30 mmol) and THF (40 
mL). The mixture was cooled to 0 °C and crotyl chloride (2.65 g, 30 mmol) in THF (10 mL) 
was added dropwise via syringe. The mixture was stirred at 0 °C for 30 minutes or until the 
exothermic reaction had subsided, before being warmed to room temperature to be stirred for 
24 hours or until all of the magnesium had dissolved. The Grignard solution was transferred 
to a new sealed flask via cannula to remove any excess magnesium. The solution was cooled 
to 0 °C and a solution of (−)-menthone (3 g, 19.5 mmol) in THF (20 mL) was added 
dropwise via syringe. The reaction mixture was maintained at 0 °C stirring for a further 2 
hours. Upon completion, the reaction mixture was partitioned between brine (30 mL) and 
EtOAc (40 mL), the organic layer was washed with 1M HCl (30 mL), dried with MgSO4 and 
the solvent removed in vacuo. A crude yellow oil was obtained which was purified using 
column chromatography (light petroleum: EtOAc 30:1). 
 
1
2 OH
5
3
4  
(1R,2S,5R)-1-((R)-But-3-en-2-yl)-2-isopropyl-5-methylcyclohexanol (2.52).94b Clear oil, 
(75%): [α]D +9.8 (c 1.3, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.75 – 1.02 (m, 2H), 0.85 (d, 
J = 6.4 Hz, 3H), 0.91 (d, J = 7.2 Hz, 3H), 0.92 (d, J = 7.2 Hz, 3H), 0.96 (d, J = 7.2 Hz, 3H), 
1.32 – 1.34 (m, 1H), 1.33 – 1.35 (m, 1H), 1.46 – 1.53 (m, 2H), 1.57 (br s, OH), 1.67 – 1.79 
(m, 2H), 2.09 (sep, J = 6.8 Hz, 1H), 2.60 (quin, J = 7.2 Hz, 1H), 5.10 – 5.15 (m, 2H, H-4), 
5.88 (ddd, J = 16.8, 10.4, 8.0 Hz, 1H, H-3); 13C NMR (100 MHz, CDCl3) δ 14.7, 18.0, 20.6, 
22.6, 23.4, 25.0, 27.6, 35.2, 41.5, 45.2, 45.9, 76.2, 116.7, 140.8; IR (NaCl) ν 3574, 2952, 
2917, 2848, 1457, 1378, 1007, 942, 913, 742 cm-1; HRMS (ESI) 233.1896 (C14H26ONa 
requires 233.1896). 
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3.2.4. General Procedure for p-TsOH Catalysed Allyl Transfer94b 
To a mixture of (1R,2S,5R)-1-((R)-but-3-en-2-yl)-2-isopropyl-5-methylcyclohexanol 2.52 
(0.5 g, 2.4 mmol) and the desired aldehyde (0.13 g, 1.2 mmol) in dichloromethane (5 mL) 
was added p-toluenesulfonic acid monohydrate (23 mg, 0.12 mmol). The reaction mixture 
was stirred overnight and a yellow colour change was observed. Once the reaction was 
complete, saturated NaHCO3 solution (10 mL) was added. The organic layer was separated 
and dried over MgSO4, filtered and the solvent removed in vacuo. The resultant crude yellow 
oil was purified using column chromatography (light peteroluem: EtOAc 20:1). 
 
2
3
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4
5
OH
 
(S,E)-1-Phenylpent-3-en-1-ol (2.53a).94a Clear liquid (64%): [α]D −59.0 (c 1.0, CHCl3); 
literature gives [α]D -66.4 (c 1.0 CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.67 (dd, J = 6.4, 1.2 
Hz, 3H, H-5), 2.23 (br s, OH), 2.36 – 2.47 (m, 2H, H-2), 4.65 (dd, J = 8.0, 5.2 Hz, 1H, H-1), 
5.37 – 5.45 (m, 1H, H-3), 5.53 – 5.62 (m, 1H, H-4), 7.23 – 7.29 (m, 1H), 7.30 – 7.35 (m, 4H); 
13C NMR (100 MHz, CDCl3) δ 18.1 (CH3, C-5), 42.8 (CH2, C-2), 73.5 (CH, C-1), 125.9 (CH 
× 2, Ph), 126.9 (CH, C-3), 127.4 (CH, Ph), 128.4 (CH × 2, Ph), 129.4 (CH, C-4), 144.1 (C); 
IR (NaCl) ν 3383, 3028, 2916, 1494, 1453, 1041, 967, 758, 699, 551 cm-1; HRMS (ESI) 
185.0936 (C11H14ONa requires 185.0937); chiral HPLC (Chiralcel IB column, hexane: 2-
propanol = 98:2, 0.75 mL min-1) showed 96% ee (tR = 13.68 min, tS = 17.59 min). 
 
 
 
 
 
 
 
122 
 
3
4
2
1 5
6
OH
Ph
 
(S,E)-1-Phenylhex-4-en-2-ol (2.53b).70b Clear liquid (80%): [α]D +11.0 (c 1.0, CHCl3); 1H 
NMR (400 MHz; CDCl3) δ 1.60 (dd, J = 6.4, 1.2 Hz, 3H, H-6), 1.80 (br s, OH), 1.99 – 2.07 
(m, 1H, H-3), 2.11 – 2.17 (m, 1H, H-3), 2.60 (dd, J = 13.6, 7.8 Hz, 1H, H-1), 2.69 (dd, J = 
13.6, 4.8 Hz, 1H, H-1), 3.70 (dddd, J = 7.8, 4.8 Hz, 1H, H-2), 5.32 – 5.40 (m, 1H, H-4), 5.42 
– 5.51 (m, 1H, H-5), 7.10 – 7.15 (m, 3H), 7.18 – 7.22 (m, 2H); 13C NMR (100 MHz, CDCl3) 
δ 18.2 (CH3, C-6), 40.0 (CH2, C-3), 43.3 (CH2, C-1), 72.1 (CH, C-2), 126.4 (CH, Ph), 127.1 
(CH, C-4), 128.5 (CH × 2, Ph), 128.9 (CH, C-5), 129.5 (CH × 2, Ph), 138.7 (C); IR (NaCl) ν 
3401, 3027, 2917, 1601, 1496, 1453, 1080, 1031, 742, 700, 602, 555, 505 cm-1; HRMS (ESI) 
199.1092 (C12H16ONa requires 199.1093); chiral HPLC (Chiralcel IB column, hexane: 2-
propanol = 98:2 0.75 mL min-1) showed 92% ee (tR = 13.6 min, tS = 11.5 min). 
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(R,E)-1-Phenylhept-5-en-3-ol (2.53c).94b Clear liquid (86%): [α]D +23.0 (c 1.0, CHCl3); 1H 
NMR (400 MHz; CDCl3) δ 1.68 (dd, J = 6.0, 0.8 Hz, 3H, H-7), 1.73 – 1.78 (m, 2H, H-2), 
1.85 (br s, OH), 2.06 – 2.13 (m, 1H, H-4), 2.20 – 2.27 (m, 1H, H-4), 2.67 (dt, J = 13.6, 8.4 
Hz, 1H, H-1), 2.80 (dt, J = 13.6, 8.4 Hz, 1H, H-1), 3.57 – 3.63 (m, 1H, H-3), 5.39 – 5.45 (m, 
1H, H-5), 5.51 – 5.59 (m, 1H, H-6), 7.15 – 7.22 (m, 3H), 7.25 – 7.29 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 18.1 (CH3, C-7), 32.1 (CH2, C-1), 38.4 (CH2, C-2), 40.9 (CH2, C-4), 70.3 
(CH, C-3), 125.8 (CH, Ph), 127.0 (CH, C-5), 128.4 (CH × 2, Ph), 128.5 (CH × 2, Ph), 129.1 
(CH, C-6), 142.2 (C); IR (NaCl) ν 3368, 3026, 2930, 2856, 1603, 1496, 1454, 1046, 968, 
746, 699 cm-1; HRMS (ESI) 213.1247 (C13H18ONa requires 213.1250); chiral GC (Supelco γ-
DEX column, oven for 2 min at 120 °C, then 0.5 °C min-1) showed 94% ee (tR = 44.8 min, tS 
= 47.9 min). 
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(S,E)-1-Cyclohexylpent-3-en-1-ol (2.53d).106 Clear liquid (63%): [α]D −1.18 (c 4.0, CHCl3); 
1H NMR (400 MHz; CDCl3) δ 0.84 – 1.41 (m, 7H, Cy), 1.65 – 1.81 (m, 7H, 2 × CH2, Cy & 
CH3, H-5), 2.05 (dt, J = 14.0, 8.0 Hz, 1H, H-2), 2.22 – 2.28 (m, 1H, H-2), 3.30 – 3.34 (m, 
1H, H-1), 5.40 – 5.48 (m, 1H, H-3), 5.51 – 5.58 (m, 1H, H-4); 13C NMR (100 MHz, CDCl3) δ 
18.0 (CH3, C-5), 26.2 (CH2, Cy), 26.3 (CH2, Cy), 26.4 (CH2, Cy), 28.2 (CH2, Cy), 29.1 (CH2, 
29.1), 37.5 (CH2, C-2), 43.0 (CH, Cy), 75.0 (CH, C-1), 127.7 (CH, C-3), 128.6 (CH, C-4); IR 
(NaCl) ν 3390, 2925, 2853, 1449, 1031, 969, 892 cm-1; HRMS (ESI) 191.1404 (C11H20ONa 
requires 191.1406); chiral GC (Supelco α-DEX column, oven for 30 min at 105 °C, then 0.5 
°C min-1) showed 97% ee (tR = 30.1 min, tS = 31.0 min). 
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(S,E)-3-Ethyloct-6-en-4-ol (2.53e).94a Clear liquid (77%): [α]D −0.73 (c 3.0, CHCl3); 1H 
NMR (400 MHz; CDCl3) δ 0.91 (t, J = 7.6 Hz, 6H, H-1), 1.21 – 1.50 (m, 5H, H-2/3), 1.52 (br 
s, OH), 1.70 (d, J = 6.4 Hz, 3H, H-8), 2.06 (dt, J = 14.0, 8.8 Hz, 1H, H-5), 2.19 – 2.24 (m, 
1H, H-5), 3.55 – 3.62 (m, 1H, H-4), 5.40 – 5.48 (m, 1H, H-6), 5.52 – 5.59 (m, 1H, H-7); 13C 
NMR (100 MHz, CDCl3) δ 11.6 (2 × CH3, C-1), 18.1 (CH3, C-8), 21.3 (CH2, C-2), 21.9 
(CH2, C-2), 37.5 (CH2, C-5), 46.0 (CH, C-3), 72.1 (CH, C-4), 127.9 (CH, C-6), 128.8 (CH, 
C-7); IR (NaCl) ν 3391, 2962, 2934, 2875, 1461, 1378, 968 cm-1; HRMS (ESI) 179.1404 
(C10H20ONa requires 179.1406); chiral GC (Supelco α-DEX column, oven for 2 min at 65 
°C, then 0.5 °C min-1) showed 94% ee (tR = 36.0 min, tS = 36.6 min). 
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(R,E)-Undec-2-en-5-ol (2.53f).70b Clear liquid (27%): [α]D +1.7 (c 1.0, CHCl3); 1H NMR 
(400 MHz; CDCl3) δ 0.89 (t, J = 6.4 Hz, 3H, H-11), 1.26 – 1.36 (m, 8H, 4 × CH2, H-
7/8/9/10), 1.41 – 1.47 (m, 3H, OH & CH2, H-6), 1.69 (dd, J = 6.0, 0.8 Hz, 3H, H-1), 2.05 (dt, 
J = 14.8, 8.0 Hz, 1H, H-4), 2.19 – 2.25 (m, 1H, H-4), 3.55 – 3.59 (m, 1H, H-5), 5.39 – 5.47 
(m, 1H, H-3), 5.51 – 5.60 (m, 1H, H-2); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3, C-11), 
18.0 (CH3, C-1), 22.6 (CH2, C-7/8/9/10), 25.7 (CH2, C-7/8/9/10), 29.4 (CH2, C-7/8/9/10), 
31.8 (CH2, C-7/8/9/10), 36.8 (CH2, C-6), 40.7 (CH2, C-4), 71.0 (CH, C-5), 127.2 (CH, C-3), 
128.8 (CH, C-2); IR (NaCl) ν 3360, 2957, 2929, 2857, 1455, 967 cm-1; HRMS (ESI) 
169.1587 (C11H21O requires 169.1587); chiral GC (Supelco γ-DEX column, oven for 2 min at 
120 °C, then 0.5 °C min-1) showed 92% ee (tR = 28.2 min, tS = 31.0 min). 
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3.2.5. General Procedure for the Synthesis of Phthalimide Protected Hydroxylamines  
 
To a flame dried flask with an inert atmosphere, was added PPh3 (3.4 g, 1.3 mmol) and N-
hydroxyphthalimide (2.2 g, 1.3 mmol). THF (30 mL) was added and the mixture stirred until 
all the solids had dissolved. The desired alcohol (1.2 g, 1.2 mmol) was added via syringe and 
the mixture cooled to 0 °C. DIAD (2.6 mL, 1.3 mmol) was added dropwise via syringe. The 
reaction was stirred overnight at room temperature. Upon completion the THF was 
evaporated and the mixture was partitioned between saturated NaHCO3 solution (30 mL) and 
light petroleum: EtOAc (1:1, 30 mL), the organic layer separated and washed further with sat. 
NaHCO3 solution (2 × 30 mL) and with brine (30 mL). The mixture was dried with MgSO4, 
filtered and the solvent removed in vacuo. The resultant yellow oil (sometimes solidifies on 
standing) was purified using column chromatography (light petroleum: EtOAc 10:1) to the 
yield the pure phthalimide derivative. 
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(E)-2-(Pent-3-enyloxy)isoindoline-1,3-dione (2.4). Colourless oil, (51%): 1H NMR (400 
MHz; CDCl3) δ 1.66 (dd, J = 6.2, 1.4 Hz, 3H, H-5), 2.47 – 2.53 (m, 2H, H-2), 4.22 (t, J = 7.0 
Hz, 2H, H-1), 5.44 – 5.52 (m, 1H, H-3), 5.57 – 5.64 (m, 1H, H-4), 7.73 – 7.78 (m, 2H), 7.80 
– 7.86 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH3, C-5), 31.5 (CH2, C-2), 77.8 (CH2, 
C-1), 123.5 (CH × 2, Phth), 125.4 (CH, C-3), 128.3 (CH, C-4), 129.0 (C), 134.5 (CH × 2, 
Phth), 163.6 (CO); IR (NaCl) ν 2942, 1789, 1733, 1467, 1374, 1245, 1187, 1127, 877, 700 
cm-1; HRMS (ESI) 254.0784 (C13H12NO3 requires 254.0788). 
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(E)-2-(Hex-3-enyloxy)isoindoline-1,3-dione (E-2.15). Colourless oil, (62%): 1H NMR (400 
MHz; CDCl3) δ 0.96 (t, J = 7.6 Hz, 3H, H-6), 2.01 (quin, J = 7.6 Hz, 2H, H-5), 2.49 – 2.54 
(m, 2H, H-2), 4.22 (t, J = 8.0 Hz, 2H, H-1), 5.41 – 5.49 (m, 1H, H-3), 5.60 – 5.67 (m, 1H, H-
4), 7.74 – 7.77 (m, 2H), 7.82 – 7.85 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 13.6 (CH3, C-6), 
25.6 (CH2, C-5), 31.5 (CH2, C-2), 77.9 (CH2, C-1), 123.1 (CH, C-3), 123.5 (CH × 2, Phth), 
129.0 (C), 134.5 (CH × 2, Phth), 135.4 (CH, C-4), 163.6 (CO); IR (NaCl) ν 2962, 1790, 
1733, 1467, 1373, 1187, 877, 700 cm-1; HRMS (ESI) 268.0944 (C14H15NO3Na requires 
268.0940). 
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(Z)-2-(Hex-3-enyloxy)isoindoline-1,3-dione (Z-2.15). Colourless oil, (60%): 1H NMR (400 
MHz; CDCl3) δ 0.98 (t, J = 7.5 Hz, 3H, H-6), 2.09 (quin, J = 7.5 Hz, 2H, H-5), 2.55 – 2.60 
(m, 2H, H-2), 4.20 (t, J = 7.2 Hz, 2H, H-1), 5.38 – 5.44 (m, 1H, H-3), 5.50 – 5.56 (m, 1H, H-
4), 7.73 – 7.78 (m, 2H), 7.82 – 7.87 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 14.2 (CH3, C-6), 
20.7 (CH2, C-5), 26.4 (CH2, C-2), 77.7 (CH2, C-1), 122.7 (CH, C-3), 123.5 (CH × 2, Phth), 
129.0 (C), 134.5 (CH × 2, Phth), 134.9 (CH, C-4), 163.6 (CO); IR (NaCl) ν 2963, 1783, 
1727, 1465, 1377, 1187, 987, 699 cm-1; HRMS (ESI) 268.0943 (C14H15NO3Na requires 
268.0944). 
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(E)-2-(Hex-4-enyloxy)isoindoline-1,3-dione (2.37). White solid (82%): mp 44 - 46°C; 1H 
NMR (400 MHz; CDCl3) δ 1.65 (dd, J = 6.0, 1.2 Hz, 3H, H-6), 1.85 (quin, J = 6.9 Hz, 2H, 
H-2), 2.16 – 2.22 (m, 2H, H-3), 4.21 (t, J = 6.9 Hz, 2H, H-1), 5.43 – 5.51 (m, 2H, H-4/5), 
7.74 – 7.77 (m, 2H), 7.82 – 7.85 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 17.9 (CH3, C-6), 
28.0 (CH2, C-2), 28.5 (CH2, C-3), 78.0 (CH2, C-1), 123.5 (CH × 2, Phth), 126.2 (CH, C-4/5), 
129.0 (C), 129.8 (CH, C-4/5), 134.4 (CH × 2, Phth), 163.7 (CO); IR (NaCl) ν 2940, 1789, 
1732, 1372, 1186, 1127, 1016, 877, 700 cm-1; HRMS (ESI) 268.0940 (C14H15NO3Na requires 
268.0944). 
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(E)-2-(5-Phenylpent-3-enyloxy)isoindoline-1,3-dione (2.30). Colourless oil, (79%): 1H 
NMR (400 MHz; CDCl3) δ 2.54 (q, J = 6.9 Hz, 2H, H-2), 3.33 (d, J = 6.8 Hz, 2H, H-5), 4.23 
(t, J = 6.9 Hz, 2H, H-1), 5.53 – 5.61 (m, 1H, H-3), 5.72 – 5.79 (m, 1H, H-4), 7.15 – 7.18 (m, 
3H), 7.24 – 7.28 (m, 2H), 7.70 – 7.73 (m, 2H), 7.79 – 7.82 (m, 2H); 13C NMR (100 MHz, 
CDCl3) δ 31.1 (CH2, C-2), 39.2 (CH2, C-5), 77.7 (CH2, C-1), 123.8 (CH × 2, Phth), 125.9 
(CH, Ph), 126.0 (CH, C-3), 128.4 (CH × 2, Ph), 128.5 (CH × 2, Ph), 129.0 (C), 132.3 (CH, C-
4), 134.5 (CH × 2, Phth), 140.4 (C), 163.6 (CO); IR (NaCl) ν 3027, 2950, 2896, 1788, 1738, 
1603, 1372, 1187, 1128, 991, 706, 518 cm-1; HRMS (ESI) 330.1092 (C19H17NO3Na requires 
330.1101). 
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(E)-2-(5-Methylhex-3-enyloxy)isoindoline-1,3-dione (2.31). Clear colourless oil, (49%): 1H 
NMR (400 MHz; CDCl3) δ 0.85 (d, J = 6.4 Hz, 6H, H-6), 2.12 – 2,17 (m, 1H, H-5), 2.41 (q, 
J = 7.0 Hz, 2H, H-2), 4.12 (t, J = 7.0 Hz, 2H, H-1), 5.28 – 5.35 (m, 1H, H-3), 5.44 – 5.49 (m, 
1H, H-4), 7.66 – 7.69 (m, 2H), 7.72 – 7.76 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 22.4 
(CH3, C-6), 31.0 (CH, C-5), 31.4 (CH2, C-2), 77.9 (CH2, C-1), 121.1 (CH, C-3), 123.4 (CH × 
2, Phth), 128.9 (C), 131.4 (CH × 2, Phth), 140.8 (CH, C-4), 163.5 (CO); IR (NaCl) ν 2958, 
1790, 1735, 1467, 1373, 1187, 1128, 977, 878, 701 cm-1; HRMS (ESI) 282.1095 
(C15H17NO3Na requires 282.1101). 
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(R,E)-2-(1-Phenylpent-3-enyloxy)isoindoline-1,3-dione (2.54a). Colourless oil (51%): [α]D 
+120.0 (c 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.59 – 1.61 (dd, J = 6.4, 1.2 Hz, 3H, 
H-5), 2.62 – 2.70 (m, 1H, H-2), 2.84 – 2.94 (m, 1H, H-2), 5.33 – 5.36 (t, J = 7.0 Hz, 1H, H-
1), 5.34 – 5.41 (m, 1H, H-3), 5.51 – 5.59 (m, 1H, H-4), 7.23 – 7.35 (m, 3H), 7.45 – 7.47 (m, 
2H), 7.74 – 7.76 (m, 2H), 7.83 – 7.85 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH3, C-
5), 38.0 (CH2, C-2), 88.8 (CH, C-1), 123.3 (CH × 2, Phth), 123.5 (CH × 2, Phth), 125.3 (CH, 
C-3), 128.2 (CH × 2, Ph), 128.2 (CH × 2, Ph), 128.7 (CH, C-4), 128.8 (C), 129.0 (CH, Ph), 
137.7 (C), 163.7 (CO); IR (NaCl) ν 2981, 2935, 1789, 1733, 1467, 1379, 1188, 1015, 878, 
700 cm-1; HRMS (ESI) 330.1095 (C19H17NO3Na requires 330.1101). 
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(R,E)-2-(1-Phenylhex-4-en-2-yloxy)isoindoline-1,3-dione (2.54b). Colourless oil (57%): 
[α]D −12.0 (c 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.54 (d, J = 5.2 Hz, 3H, H-6), 2.30 
– 2.32 (m, 2H, H-3), 2.01 (qd, J = 14.4, 6.2 Hz, 2H, H-1), 4.55 (quin, J = 6.2 Hz, 1H, H-2), 
5.39 – 5.52 (m, 2H, H-4/5), 7.04 – 7.08 (m, 1H), 7.13 – 7.18 (m, 4H), 7.61 – 7.64 (m, 2H), 
7.67 – 7.71 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH3, C-6), 35.6 (CH2, C-3), 38.9 
(CH2, C-1), 87.6 (CH, C-2), 123.4 (CH × 2, Phth), 125.7 (CH, C-4/5), 126.4 (CH, Ph), 128.3 
(CH × 2, Ph), 128.7 (CH, C-4/5), 129.0 (C), 129.3 (CH × 2, Ph), 134.4 (CH × 2, Phth), 137.3 
(C), 164.1 (CO); IR (NaCl) ν 3028, 2934, 1789, 1736, 1454, 1375, 1188, 1127, 975, 878, 700 
cm-1; HRMS (ESI) 344.1257 (C20H19NO3Na requires 344.1255). 
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(S,E)-2-(1-Phenylhept-5-en-3-yloxy)isoindoline-1,3-dione (2.54c). Colourless oil (40%): 
[α]D −52.0 (c 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.62 (d, J = 5.2 Hz, 3H, H-7), 1.93 
– 2.07 (m, 2H, H-2), 2.40 – 2.48 (m, 2H, H-4), 2.85 – 2.96 (m, 2H, H-1), 4.32 (quin, J = 5.9 
Hz, 1H, H-3), 5.44 – 5.58 (m, 2H, H-5/6), 7.16 – 7.20 (m, 1H), 7.25 – 7.31 (m , 4H), 7.72 – 
7.77 (m, 2H), 7.81 – 7.86 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH3, C-7), 31.3 
(CH2, C-1), 34.3 (CH2, C-2), 36.1 (CH2, C-4), 87.0 (CH, C-3), 123.5 (CH × 2, Phth), 125.5 
(CH, C-5/6), 125.9 (CH, Ph), 128.4 (CH × 2, Ph), 128.5 (CH × 2, Phth), 128.6 (CH, C-5/6), 
129.0 (C), 134.4 (CH × 2, Phth), 142.0 (C), 164.3 (CO); IR (NaCl) ν 2934, 1789, 1734, 1374, 
1188, 1124, 976, 878, 700 cm-1; HRMS (ESI) 358.1414 (C21H21NO3Na requires 358.1412). 
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(R,E)-2-(1-Cyclohexylpent-3-enyloxy)isoindoline-1,3-dione (2.54d). Colourless oil (29%): 
[α]D −29.3 (c 1.5, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.13 – 1.29 (m, 8H, Cy), 1.58 (d, J 
= 5.6 Hz, 3H, H-5), 1.64 – 1.74 (m, 1H), 1.76 – 1.83 (m, 1H), 1.85 – 1.97 (m, 1H), 2.33 – 
2.43 (m, 2H, H-2), 4.11 (q, J = 4.0 Hz, 1H, H-1), 5.46 – 5.60 (m, 2H, H-3/4), 7.72 – 7.76 (m, 
2H), 7.80 – 7.84 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH3, C-5), 26.2 (CH2 × 2, 
Cy), 26.5 (CH2, Cy), 28.1 (CH2, Cy), 28.2 (CH2, Cy), 32.9 (CH2, C-2), 39.8 (CH, Cy), 91.2 
(CH, C-1), 123.3 (CH × 2, Phth), 126.6 (CH, C-3/4), 127.5 (CH, C-3/4), 129.1 (C), 134.3 
(CH × 2, Phth), 164.3 (CO); IR (NaCl) ν 2928, 2853, 1790, 1734, 1450, 1374, 1188, 1122, 
977, 878, 702 cm-1; HRMS (ESI) 336.1570 (C19H23NO3Na requires 336.1568). 
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(R,E)-2-(3-Ethyloct-6-en-4-yloxy)isoindoline-1,3-dione (2.54e). Colourless oil (19%): [α]D 
−26.9 (c 10.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.94 (t, J = 6.3 Hz, 3H, H-1), 1.00 (t, J 
= 6.3 Hz, 3H, H-1), 1.21 – 1.28 (m, 2H, H-2), 1.46 – 1.58 (m, 5H, H-2/3/8), 1.74 – 1.83 (m, 
1H, H-2), 2.36 – 2.40 (m, 2H, H-5), 4.36 (dt, J = 8.9, 3.0 Hz, 1H, H-4), 5.48 – 5.53 (m, 2H, 
H-6/7), 7.72 – 7.76 (m, 2H), 7.80 – 7.84 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 11.8 (CH3, 
C-1), 12.0 (CH3, C-1), 17.9 (CH3, C-8), 21.5 (CH2, C-2), 21.8 (CH2, C-2), 32.9 (CH2, C-5), 
43.3 (CH, C-3), 88.8 (CH, C-4), 123.3 (CH × 2, Phth), 126.9 (CH, C-6/7), 127.4 (CH, C-6/7), 
129.1 (C), 134.3 (CH × 2, Phth), 164.3 (CO); IR (NaCl) ν 2963, 2935, 1790, 1735, 1374, 
1188, 976, 878, 701 cm-1; HRMS (ESI) 324.1565 (C18H23NO3Na requires 324.1570). 
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(S,E)-2-(Undec-2-en-5-yloxy)isoindoline-1,3-dione (2.54f). Colourless oil (45%): [α]D 
−16.5 (c 2.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.89 (t, J = 6.6 Hz, 3H, H-11), 1.26 – 
1.36 (m, 6H, H-8/9/10), 1.52 (quin, J = 7.4 Hz, 2H, H-7), 1.62 (d, J = 4.8 Hz, 3H, H-1), 1.64 
– 1.71 (m, 2H, H-6), 2.40 (t, J = 5.6 Hz, 2H, H-4), 4.27 (quin, J = 5.6 Hz, 1H, H-5), 5.45 – 
5.57 (m, 2H, H-2/3), 7.72 – 7.76 (m, 2H), 7.80 – 7.85 (m, 2H); 13C NMR (100 MHz, CDCl3) 
δ 14.1 (CH3, C-11), 18.0 (CH3, C-1), 22.6 (CH2, C-8/9/10), 25.0 (CH2, C-7), 29.3 (CH2, C-
8/9/10), 31.7 (CH2, C-8/9/10), 32.3 (CH2, C-6), 36.0 (CH2, C-4), 87.6 (CH, C-5), 123.4 (CH 
× 2, Phth), 125.8 (CH, C-2/3), 128.2 (CH, C-2/3), 129.1 (C), 134.4 (CH × 2, Phth), 164.3 
(CO); IR (NaCl) ν 2929, 2856, 1790, 1734, 1374, 1188, 976, 701 cm-1; HRMS (ESI) 
338.1727 (C19H25NO3Na requires 338.1724). 
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3.2.6. General Procedure for the Synthesis of Homoallylic Hydrazines 
To a flame dried flask with an inert atmosphere was added PPh3 (0.58 g, 2.2 mmol) and THF 
(40 mL), the mixture was stirred until all the solids had dissolved. The alcohol (0.2 g. 2.0 
mmol) was added via syringe and the mixture cooled to 0 °C. DIAD (0.8 mL, 5 mmol) was 
added dropwise via syringe. The reaction was stirred overnight at room temperature. Upon 
completion saturated NaHCO3 solution (20 mL) was added and the mixture extracted with 
light petroleum: EtOAc (1:1, 50 mL), the organic layer separated and washed further with sat. 
NaHCO3 solution (2 × 30 mL) and brine (20 mL). The mixture was dried with MgSO4, 
filtered and the solvent removed in vacuo. The resultant yellow oil (sometimes solidifies on 
standing) was purified using column chromatography (light petroleum: EtOAc 10:1) to the 
yield the pure diamine derivative. 
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(E)-Diisopropyl 1-(hex-3-enyl)hydrazine-1,2-dicarboxylate (E-2.58). Colourless oil (28%): 
1H NMR (400 MHz; CDCl3) δ 0.94 (t, J = 7.2 Hz, 3H, H-6), 1.25 (d, J = 6.4 Hz, 12H, H-8), 
1.99 (quin, J = 7.2 Hz, 2H, H-5), 2.25 (q, J = 5.2 Hz, 2H, H-2), 3.45 – 2.55 (m, 2H, H-1), 
4.90 – 4.97 (m, 2H, H-7), 5.31 – 5.40 (m, 1H, H-3), 5.48 – 5.55 (m, 1H, H-4), 6.48 (s, NH); 
13C NMR (100 MHz, CDCl3) δ 13.7 (CH3, C-6), 22.0 (CH3 × 4, C-8), 25.6 (CH2, C-5), 30.8 
(CH2, C-2), 49.5 (CH2, C-1), 69.6 (CH, C-7), 70.0 (CH, C-7), 125.4 (CH, C-3), 134.4 (CH, 
C-4), 160.0 (CO), 164.5 (CO); IR (NaCl) ν 3309, 2982, 2937, 2876, 1811, 1748, 1715, 1615, 
1499, 1467, 1385, 1376, 1259, 1181, 1096, 903, 764 cm-1; HRMS (ESI) 309.1781 
(C14H26N2O4Na requires 309.1796). 
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(Z)-Diisopropyl 1-(hex-3-enyl)hydrazine-1,2-dicarboxylate (Z-2.58). Colourless oil (25%): 
1H NMR (400 MHz; CDCl3) δ 0.97 (t, J = 7.5 Hz, 3H, H-6), 1.26 (d, J = 5.6 Hz, 12H, H-8), 
2.05 (quin, J = 7.5 Hz, 2H, H-5), 2.33 (q, J = 5.3 Hz, 2H, H-2), 3.46 – 3.54 (m, 2H, H-1), 
4.88 – 5.00 (m, 2H, H-7), 5.25 – 5.35 (m, 1H, H-3), 5.42 – 5.52 (m, 1H, H-4), 6.46 (s, NH); 
13C NMR (100 MHz, CDCl3) δ 14.3 (CH3, C-6), 20.5 (CH2, C-2), 22.0 (CH3 × 4, C-8), 25.6 
(CH2, C-5), 49.6 (CH2, C-1), 69.7 (CH, C-7), 69.9 (CH, C-7), 125.0 (CH, C-3), 134.1 (CH, 
C-4), 156.1 (CO), 156.4 (CO); IR (NaCl) ν 3303, 2981, 2936, 2877, 1713, 1511, 1467, 1413, 
1302, 1256, 1203, 1109, 1049, 763 cm-1; HRMS (ESI) 309.1777 (C14H26N2O4Na requires 
309.1796). 
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(R,E)-Diisopropyl 1-(1-phenylpent-3-enyl)hydrazine-1,2-dicarboxylate (2.62). Colourless 
oil (36%): [α]D +32.8 (c 5.0, CHCl3); 1H NMR (400 MHz; CDCl3 at 25°C) δ 1.25 (d, broad, J 
= 6.0 Hz, 12H, H-7), 1.61 – 1.62 (s, broad, 3H, H-5), 2.46 – 2.64 (m, broad, 1H, H-2), 2.72 – 
2.79 (m, broad, 1H, H-2), 4.88 – 5.01 (m, broad, 2H, H-6), 5.35 – 5.47 (m, broad, 2H, H-1/3), 
5.49 – 5.60 (m, broad, 1H, H-4), 7.27 – 7.34 (m, broad, 5H); 1H NMR (400 MHz; DMSO-
d6at 115°C) δ 1.08 (d, J = 6.4 Hz, 6H, H-7), 1.14 (d, J = 6.4 Hz, 6H, H-7), 1.52 (d, J = 6.2 
Hz, 3H, H-5), 2.45 – 2.52 (m, 1H, H-2), 2.59 – 2.66 (m, 1H, H-2), 4.60 – 4.70 (m, 1H, H-6), 
4.76 (quin, J = 6.4 Hz, 1H, H-6), 5.04 (t, J = 7.2 Hz, 1H, H-1), 5.23 – 5.35 (m, 1H, H-3), 
5.40 – 5.46 (m, 1H, H-4), 7.17 – 7.31 (m, 5H), 8.40 (s, NH); 13C NMR (100 MHz, DMSO-d6) 
δ 17.7 (CH3, C-5), 21.9 (CH3 × 4, C-7), 34.0 (CH2, C-2), 61.2 (CH, C-1), 69.5 (CH, C-6), 
70.1 (CH, C-6), 127.5 (CH, C-3), 127.6 (CH, C-4), 128.1 (CH × 2, Ph), 128.2 (CH × 3, Ph), 
139.2 (C), 155.6 (CO), 156.2 (CO); IR (NaCl) ν 3293, 2980, 2936, 1709, 1403, 1385, 1300, 
1259, 1230, 1109, 1035, 968, 759, 699 cm-1; HRMS (ESI) 371.1937 (C19H28N2O4Na requires 
371.1941). 
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3.2.7. General Procedure for the Synthesis of N-Boc Hydroxylamines 
Hydrazine hydrate (62 mg, 1.95 mmol) was added to a solution of the desired phthalimide 
protected hydroxylamine (0.12 g, 0.4 mmol) in CH2Cl2 (20 mL) and stirred at room 
temperature. A white precipitate is formed throughout the reaction. More CH2Cl2 can be 
added if the precipitate begins to hinder stirring. The reaction was monitored by TLC and 
after consumption of the starting material the precipitate was filtered off. The filtrate was 
collected and Boc2O (0.1 g, 0.47 mmol) was added along with a solution of NaOH (30 mg, 
0.78 mmol) in H2O (5 mL). The mixture was vigorously stirred overnight or until complete 
consumption of the amine was observed. The reaction mixture was added to a separating 
funnel and the organic layer isolated, dried over MgSO4, filtered and the solvent was 
removed in vacuo. The resultant crude oil was purified using column chromatography (10:1, 
light petroleum: EtOAc) to yield the pure N-Boc hydroxylamine. To remove any unreacted 
Boc2O that has co-eluted with the carbamate, the mixture was dissolved in CHCl3 and stirred 
with imidazole (5 eq, 1.95 mmol) for 30 min. The mixture was washed with H2O, dried with 
MgSO4 and the solvent removed in vacuo. The pure N-Boc hydroxylamine could then be 
isolated using flash chromatography (light petroleum: EtOAc 4:1). 
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(E)-tert-Butyl pent-3-enyloxycarbamate (2.5). Colourless oil (89%): 1H NMR (400 MHz; 
CDCl3) δ 1.41 (s, 9H, H-6), 1.59 (dq, J = 6.4, 1.2 Hz, 3H, H-5), 2.26 (qt, J = 6.8, 1.2 Hz, 2H, 
H-2), 3.79 (t, J = 6.8 Hz, 2H, H-1), 5.31 – 5.39 (m, 1H, H-3), 5.43 – 5.52 (m, 1H, H-4), 7.06 
(s, NH); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH3, C-5), 28.2 (CH3 × 3, C-6), 31.4 (CH2, C-
2), 76.2 (CH2, C-1), 81.6 (C), 126.7 (CH, C-3), 127.5 (CH, C-4), 156.9 (CO); IR (NaCl) ν 
3295, 2978, 2935, 1719, 1479, 1455, 1368, 1251, 1168, 967, 774 cm-1; HRMS (ESI) 
224.1256 (C10H19NO3Na requires 224.1257). 
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(E)-tert-Butyl hex-3-enyloxycarbamate (E-2.16). Colourless oil (73%): 1H NMR (400 
MHz; CDCl3) δ 0.97 (t, J = 7.4 Hz, 3H, H-6), 1.48 (s, 9H, H-7), 1.97 – 2.05 (m, 2H, H-5), 
2.34 (qd, J = 6.5, 1.2 Hz, 2H, H-2), 3.86 (t, J = 6.5 Hz, 2H, H-1), 5.39 (dtt, J = 15.2, 6.5, 1.2 
Hz, 1H, H-3), 5.57 (dtt, J = 15.2, 6.5, 1.2Hz, 1H, H-4), 7.20 (s, NH); 13C NMR (100 MHz, 
CDCl3) δ 13.7 (CH3, C-6), 25.6 (CH2, C-5), 28.2 (CH3 × 3, C-7), 31.4 (CH2, C-2), 76.3 (CH2, 
C-1), 81.6 (C), 124.4 (CH, C-3), 134.7 (CH, C-4), 156.9 (CO); IR (NaCl) ν 3291, 2965, 2933, 
1719, 1457, 1392, 1368, 1250, 1170, 1112, 968, 773 cm-1; HRMS (ESI) 238.1414 
(C11H21NO3Na requires 238.1414). 
 
2
31
O 4
5
6
H
NO
7
7
7
O
 
(Z)-tert-Butyl hex-3-enyloxycarbamate (Z-2.16). Colourless oil (64%): 1H NMR (400 MHz; 
CDCl3) δ 0.97 (t, J = 7.6 Hz, 3H, H-6), 1.49 (s, 9H, H-7), 2.06 (quind, J = 7.2, 1.6 Hz, 2H, 
H-5), 2.41 (qd, J = 7.2, 1.6 Hz, 2H, H-2), 3.85 (t, J = 7.2 Hz, 2H, H-1), 5.35 (dtt, J = 10.8, 
7.2, 1.6 Hz, 1H, H-3), 5.49 (dtt, J =10.8, 7.2, 1.6 Hz, 1H, H-4), 7.46 (s, NH); 13C NMR (100 
MHz, CDCl3) δ 14.1 (CH3, C-6), 20.5 (CH2, C-5), 26.2 (CH2, C-2), 28.2 (CH3 × 3, C-7), 76.0 
(CH2, C-1), 81.4 (C), 124.0 (CH, C-3), 134.0 (CH, C-4), 157.0 (CO); IR (NaCl) ν 3291, 
2967, 2934, 1720, 1479, 1457, 1392, 1251, 1113, 1015, 774 cm-1; HRMS (ESI) 238.1412 
(C11H21NO3Na requires 238.1414). 
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(E)-tert-Butyl hex-4-enyloxycarbamate (2.38). Colourless oil (87%): 1H NMR (400 MHz; 
CDCl3) δ 1.48 (s, 9H, H-7), 1.64 – 1.71 (m, 5H, H-2/6), 2.04 – 2.09 (m, 2H, H-3), 3.85 (t, J = 
6.6 Hz, 2H, H-1), 5.37 – 5.49 (m, 2H, H-4/5), 7.12 (s, NH); 13C NMR (100 MHz, CDCl3) δ 
17.9 (CH3, C-6), 27.9 (CH2, C-2), 28.2 (CH3 × 3, C-7), 28.8 (CH2, C-3), 76.3 (CH2, C-1), 
81.6 (C), 125.5 (CH, C-4/5), 130.3 (CH, C-4/5), 156.9 (CO); IR (NaCl) ν 3294, 2978, 2935, 
1720, 1479, 1455, 1368, 1251, 1170, 1113, 966 cm-1; HRMS (ESI) 238.1410 (C11H21NO3Na 
requires 238.1414). 
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(E)-tert-Butyl 5-phenylpent-3-enyloxycarbamate (2.32). Colourless oil (81%): 1H NMR 
(400 MHz; CDCl3) δ 1.48 (s, 9H, H-6), 2.39 (q, J = 6.7 Hz, 2H, H-2), 3.34 (d, J = 6.7 Hz, 
2H, H-5), 3.89 (t, J = 6.7 Hz, 2H, H-1), 5.48 – 5.55 (m, 1H, H-3), 5.65 – 5.72 (m, 1H, H-4), 
7.17 – 7.21 (m, 3H), 7.26 – 7.30 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 28.2 (CH3 × 3, C-
6), 31.4 (CH2, C-2), 39.1 (CH2, C-5), 76.1 (CH2, C-1), 81.7 (C), 126.0 (CH, Ph), 127.1 (CH, 
C-3), 128.4 (CH × 2, Ph), 128.5 (CH × 2, Ph), 131.5 (CH, C-4), 140.5 (C), 156.9 (CO); IR 
(NaCl) ν 3294, 2977, 2932, 1719, 1454, 1368, 1250, 1167, 1111, 969, 699 cm-1; HRMS (ESI) 
300.1570 (C16H23NO3Na requires 300.1570). 
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(E)-tert-Butyl 5-methylhex-3-enyloxycarbamate (2.33). Colourless oil (52%): 1H NMR 
(400 MHz; CDCl3) δ 0.96 (d, J = 6.7 Hz, 6H, H-6), 1.48 (s, 9H, H-7), 2.25 (sex, J = 6.7 Hz, 
1H, H-5), 2.33 (q, J = 6.7 Hz, 2H, H-2), 3.86 (t, J = 6.7 Hz, 2H, H-1), 5.35 (dtd, J = 15.6, 
6.7, 1.2Hz, 1H, H-3), 5.49 (ddt, J = 15.2, 6.7, 1.2 Hz, 1H, H-4), 7.08 (s, NH); 13C NMR (100 
MHz, CDCl3) δ 22.5 (CH3 × 2, C-6), 28.2 (CH3 × 3, C-7), 31.0 (CH, C-5), 31.4 (CH2, C-2), 
76.4 (CH2, C-1), 81.6 (C), 122.3 (CH, C-3), 140.2 (CH, C-4), 156.9 (CO); IR (NaCl) ν 3294, 
2960, 2928, 1719, 1458, 1368, 1250, 1168, 1110, 971 cm-1; HRMS (ESI) 252.1570 
(C12H23NO3Na requires 252.1570). 
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(R,E)-tert-Butyl 1-phenylpent-3-enyloxycarbamate (2.55a). Colourless oil (59%): [α]D 
+23.3 (c 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.45 (s, 9H, H-6), 1.62 (dd, J = 6.2, 1.4 
Hz, 3H, H-5), 2.38 – 2.45 (m, 1H, H-2), 2.62 – 2.70 (m, 1H, H-2), 4.74 (t, J = 7.0 Hz, 1H, H-
1), 5.34 – 5.42 (m, 1H, H-3), 5.45 – 5.54 (m, 1H, H-4), 6.87 (s, NH), 7.29 – 7.39 (m, 5H); 13C 
NMR (100 MHz, CDCl3) δ 18.0 (CH3, C-5), 28.2 (CH3 × 3, C-6), 38.5 (CH2, C-2), 81.6 (C), 
87.6 (CH, C-1), 126.1 (CH, C-3), 127.3 (CH × 2, Ph), 128.1 (CH, C-4), 128.2 (CH, Ph), 
128.5 (CH × 2, Ph), 140.0 (C), 156.4 (CO); IR (NaCl) ν 3303, 2978, 2917, 2850, 1747, 1716, 
1699, 1454, 1368, 1247, 1167, 1104, 1009, 968, 758 cm-1; HRMS (ESI) 300.1569 
(C16H23NO3Na requires 300.1570). 
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(R,E)-tert-Butyl 1-phenylhex-4-en-2-yloxycarbamate (2.55b). Colourless oil (44%): [α]D 
−10.8 (c 5.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.47 (s, 9H, H-7), 1.66 – 1.68 (m, 3H, 
H-6), 2.25 – 2.29 (m, 2H, H-3), 2.79 (dd, J = 13.9, 7.0 Hz, 1H, H-1), 2.98 (dd, J = 13.9, 6.0 
Hz, 1H, H-1), 3.99 (quin, J = 6.0 Hz, 1H, H-2), 5.48 – 5.51 (m, 2H, H-4/5), 6.97 (s, NH), 
7.18 – 7.22 (m, 3H), 7.26 – 7.29 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 18.1 (CH3, C-6), 
28.2 (CH3 × 3, C-7), 35.2 (CH2, C-3), 38.6 (CH2, C-1), 81.6 (C), 86.3 (CH, C-2), 126.2 (CH, 
Ph), 126.6 (CH, C-4/5), 128.0 (CH, C-4/5), 128.4 (CH × 2, Ph), 129.4 (CH × 2, Ph), 138.3 
(C), 157.1 (CO); IR (NaCl) ν 3303, 2978, 2933, 1718, 1695, 1454, 1368, 1248, 1165, 1104, 
1009, 969, 744 cm-1; HRMS (ESI) 314.1727 (C17H25NO3Na requires 314.1727). 
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(S,E)-tert-Butyl 1-phenylhept-5-en-3-yloxycarbamate (2.55c). Colourless oil (56%): [α]D 
−34.0 (c 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.49 (s, 9H, H-8), 1.66 (dd, J = 5.8, 1.0 
Hz, 3H, H-7), 1.76 – 1.92 (m, 2H, H-2), 2.24 – 2.31 (m, 1H, H-4), 2.33 – 2.42 (m, 1H, H-4), 
2.66 – 2.73 (m, 1H, H-1), 2.81 – 2.88 (m, 1H, H-1), 3.79 (quin, J = 5.8 Hz, 1H, H-3), 5.43 – 
5.56 (m, 2H, H-5/6), 6.94 (s, NH), 7.16 – 7.21 (m, 3H), 7.26 – 7.29 (m, 2H); 13C NMR (100 
MHz, CDCl3) δ 18.0 (CH3, C-7), 28.3 (CH3 × 3, C-8), 31.7 (CH2, C-1), 33.9 (CH2, C-2), 35.8 
(CH2, C-4), 81.6 (C), 84.7 (CH, C-3), 125.8 (CH, Ph), 126.5 (CH, C-5/6), 128.0 (CH, C-5/6), 
128.3 (CH × 2, Ph), 128.4 (CH × 2, Ph), 142.3 (C), 157.1 (CO); IR (NaCl) ν 3300, 2925, 
1751, 1718, 1695, 1454, 1367, 1246, 1165, 1104, 968, 699 cm-1; HRMS (ESI) 328.1883 
(C18H27NO3Na requires 328.1883). 
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(R,E)-tert-Butyl 1-cyclohexylpent-3-enyloxycarbamate (2.55d). Colourless oil (39%): [α]D 
−24.5 (c 10.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.83 – 1.35 (m, 8H, Cy), 1.49 (s, 9H, 
H-6), 1.54 – 1.61 (m, 1H, Cy), 1.63 – 1.76 (m, 5H, H-5 + Cy), 2.22 – 2.34 (m, 2H, H-2), 3.52 
(q, J = 4.3 Hz, 1H, H-1), 5.45 – 5.56 (m, 2H, H-3/4), 7.01 (s, NH); 13C NMR (100 MHz, 
CDCl3) δ 18.1 (CH3, C-5), 26.3 (CH2, Cy), 26.4 (CH2, Cy), 26.6 (CH2, Cy), 28.3 (CH3 × 3, 
C-6), 28.5 (CH2, Cy), 28.6 (CH2, Cy), 32.6 (CH2, C-2), 39.3 (CH, Cy), 81.4 (C), 89.7 (CH, 
C-1), 127.2 (CH, C-3/4), 127.4 (CH, C-3/4), 157.0 (CO); IR (NaCl) ν 3300, 2978, 2927, 
2853, 1752, 1694, 1367, 1246, 1169, 1104, 1009, 968, 771 cm-1; HRMS (ESI) 306.2037 
(C16H29NO3Na requires 306.2040). 
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(R,E)-tert-Butyl 3-ethyloct-6-en-4-yloxycarbamate (2.55e). Colourless oil (63%): [α]D 
−38.7 (c 1.5, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.90 (t, J = 7.4 Hz, 6H, H-1), 1.21 – 
1.32 (m, 2H, H-2), 1.34 – 1.59 (m, 12H, H-2/3/9), 1.67 (dd, J = 3.4, 1.0 Hz, 3H, H-8), 2.24 – 
2.27 (m, 2H, H-5), 3.75 (q, J = 6.0 Hz, 1H, H-4), 5.46 – 5.56 (m, 2H, H-6/7), 6.93 (s, NH); 
13C NMR (100 MHz, CDCl3) δ 11.8 (CH3, C-1), 12.0 (CH3, C-1), 18.1 (CH3, C-8), 21.6 
(CH2, C-2), 21.7 (CH2, C-2), 28.3 (CH3 × 3, C-9), 32.5 (CH2, C-5), 42.4 (CH, C-3), 81.4 (C), 
87.3 (CH, C-4), 127.1 (CH, C-6/7), 127.8 (CH, C-6/7), 156.9 (CO); IR (NaCl) ν 3305, 2964, 
2934, 1752, 1694, 1457, 1367, 1168, 1102 cm-1; HRMS (ESI) 294.2039 (C15H29NO3 requires 
294.2040). 
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(S,E)-tert-Butyl undec-2-en-5-yloxycarbamate (2.55f). Colourless oil (43%): [α]D −40.5 (c 
2.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.88 (t, J = 6.6 Hz, 3H, H-11), 1.26 – 1.37 (m, 
8H, H-7/8/9/10), 1.40 – 1.56 (m, 11H, H-6/12), 1.67 (d, J = 5.6 Hz, 3H, H-1), 2.21 – 2.34 (m, 
2H, H-4), 3.73 (quin, J = 5.8 Hz, 1H, H-5), 5.40 – 5.55 (m, 2H, H-2/3), 6.95 (s, NH); 13C 
NMR (100 MHz, CDCl3) δ 14.1 (CH3, C-11), 18.0 (CH3, C-1), 22.6 (CH2, C-7/8/9/10), 25.3 
(CH2, C-7/8/9/10), 28.2 (CH3 × 3, C-12), 29.5 (CH2, C-7/8/9/10), 31.8 (CH2, C-6), 32.0 (CH2, 
C-7/8/9/10), 35.7 (CH2, C-4), 81.4 (C), 85.4 (CH, C-5), 126.8 (CH, C-2/3), 127.6 (CH, C-
2/3), 157.1 (CO); IR (NaCl) ν 3299, 2956, 2931, 1720, 1696, 1456, 1367, 1246, 1169, 1104, 
1010, 967 cm-1; HRMS (ESI) 308.2192 (C16H31NO3Na requires 308.2196). 
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3.2.8. General Procedure for Palladium Catalyzed Intramolecular Amination of N-Boc 
Hydroxylamines 
A flask was charged with palladium acetate (2.8 mg, 0.013 mmol) and sodium acetate (4.1 
mg, 0.05 mmol) and flushed with O2. DMSO (1.8 μL, 0.025 mmol) in THF (2 mL) was 
added and a balloon of O2 applied. The desired substrate (50 mg, 0.25 mmol) in THF (1 mL) 
was added to the flask via syringe and stirred at room temperature overnight. The mixture 
was filtered through a pad of celite, washing with ethyl acetate, and the solvent removed in 
vacuo to yield a brown oil. The crude oil was purified using column chromatography (10:1, 
light petroleum: EtOAc). 
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tert-Butyl 3-vinylisoxazolidine-2-carboxylate (2.9). Colourless oil (98%): 1H NMR (400 
MHz; CDCl3) δ 1.50 (s, 9H, H-8), 2.04 – 2.13 (m, 1H, H-4), 2.44 – 2.52 (m, 1H, H-4), 3.80 
(dt, J = 8.1, 7.2 Hz, 1H, H-5), 4.08 (td, J = 8.1, 4.3 Hz, 1H, H-5), 4.58 – 4.63 (m, 1H, H-3), 
5.14 (dt, J = 10.2, 1.2 Hz, 1H, H-7), 5.28 (dt, J = 16.8, 1.2 Hz, 1H, H-7), 5.83 (ddd, J = 16.8, 
10.2, 6.4Hz, 1H, H-6); 13C NMR (100 MHz, CDCl3) δ 28.2 (CH3 × 3, C-8), 35.2 (CH2, C-4), 
61.0 (CH, C-3), 68.6 (CH2, C-5), 81.9 (C), 116.0 (CH2, C-7), 137.5 (CH, C-6), 157.1 (CO); 
IR (NaCl) ν 2980, 1733, 1705, 1368, 1324, 1165, 1065, 990, 923 cm-1; HRMS (ESI) 
222.1101 (C10H17NO3Na requires 222.1101). 
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tert-Butyl 3-vinylmorpholine-2-carboxylate (2.39). Colourless oil (95%): 1H NMR (400 
MHz; CDCl3) δ 1.47 – 1.50 (m, 10H, H-5/9), 1.75 – 1.80 (m, 1H, H-4), 1.89 – 2.03 (m, 2H, 
H-4/5), 3.85 – 3.91 (m, 1H, H-6), 4.02 – 4.06 (m, 1H, H-6), 4.67 – 4.72 (m, 1H, H-3), 5.23 
(dt, J = 10.6, 1.6 Hz, 1H, H-8), 5.26 (dt, J = 17.5, 1.6 Hz, 1H, H-8), 6.02 (ddd, J = 17.5, 
10.6, 5.4 Hz, 1H, H-7); 13C NMR (100 MHz, CDCl3) δ 20.3 (CH2, C-5), 26.5 (CH2, C-4), 
28.3 (CH3 × 3, C-9), 56.4 (CH, C-3), 71.4 (CH2, C-6), 81.3 (C), 116.6 (CH2, C-8), 135.4 (CH, 
C-7), 155.1 (CO); IR (NaCl) ν 2977, 1727, 1697, 1391, 1367, 1309, 1171, 1094, 897, 759 cm-
1; HRMS (ESI) 236.1254 (C11H19NO3Na requires 236.1257). 
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(E)-tert-Butyl 3-(prop-1-enyl)isoxazolidine-2-carboxylate (2.17). Colourless oil, isolated as 
a mixture of 22:1.7:1 of E:Z:Terminal isomers respectively (81% from E-2.16, 77% from Z-
2.16): 1H NMR (400 MHz; CDCl3) δ E isomer: 1.49 (s, 9H, H-9), 1.70 (ddd, J = 6.6, 1.6, 1.2 
Hz, 3H, H-8), 2.00 – 2.09 (m, 1H, H-4), 2.40 – 2.48 (m, 1H, H-4), 3.77 (dt, J = 8.2, 7.2 Hz, 
1H, H-5), 4.07 (td, J = 8.2, 4.0 Hz, 1H, H-5), 4.56 (q, J = 7.6 Hz, 1H, H-3), 5.46 (ddq, J = 
15.2, 7.6, 1.6 Hz, 1H, H-6), 5.70 (dqd, J = 15.2, 6.6, 1.2 Hz, 1H, H-7); Z isomer: 1.74 (dd, J 
= 6.8, 1.6 Hz, 3H, CH3), 4.94 (dt, J = 8.8, 5.2 Hz, 1H), 5.42 – 5.49 (m, 1H), 5.53 – 5.61 (m, 
1H); Terminal isomer: 5.07 – 5.15 (m, 2H), 5.76 – 5.87 (m, 1H); 13C NMR (100 MHz, 
CDCl3) δ 17.6 (CH3, C-8), 28.2 (CH3 × 3, C-9), 35.5 (CH2, C-4), 60.7 (CH, C-3), 68.6 (CH2, 
C-5), 81.7 (C), 127.2 (CH, C-7), 130.6 (CH, C-6), 157.3 (CO); IR (NaCl) ν 2978, 1732, 1705, 
1367, 1321, 1167, 1061, 964, 851, 767 cm-1; HRMS (ESI) 236.1257 (C11H19NO3Na requires 
236.1257). 
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(E)-tert-Butyl 3-styrylisoxazolidine-2-carboxylate (2.34). Colourless oil (61%): 1H NMR 
(400 MHz; CDCl3) δ 1.50 (s, 9H, H-8), 2.13 – 2.21 (m, 1H, H-4), 2.52 – 2.60 (m, 1H, H-4), 
3.84 (dt, J = 8.4, 7.4 Hz, 1H, H-5), 4.14 (td, J = 7.4, 4.0 Hz, 1H, H-5), 4.75 – 4.80 (br q, J = 
7.4 Hz, 1H, H-3), 6.17 (dd, J = 16.0, 7.4 Hz, 1H, H-6), 6.60 (d, J = 16.0 Hz, 1H, H-7), 7.21 – 
7.39 (m, 5H, Ph); 13C NMR (100 MHz, CDCl3) δ 28.3 (CH3 × 3, C-8), 35.8 (CH2, C-4), 60.8 
(CH, C-3), 68.8 (CH2, C-5), 82.0 (C), 126.5 (CH × 2, Ph), 127.7 (CH, Ph), 128.6 (CH × 2, 
Ph), 128.8 (CH, C-6), 131.0 (CH, C-7), 136.5 (C), 157.1 (CO); IR (NaCl) ν 2979, 2930, 
1730, 1705, 1367, 1322, 1165, 1071, 965, 750, 694 cm-1; HRMS (ESI) 298.1411 
(C16H21NO3Na requires 298.1414). 
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tert-Butyl 3-(2-methylprop-1-enyl)isoxazolidine-2-carboxylate (2.35).92d Colourless oil 
(51%): 1H NMR (400 MHz; CDCl3) δ 1.49 (s, 9H, H-8), 1.73 (dd, J = 7.6, 1.2 Hz, 6H, H-7), 
1.93 – 2.01 (m, 1H, H-4), 2.43 – 2.50 (m, 1H, H-4), 3.73 – 3.79 (m, 1H, H-5), 4.09 (td, J = 
8.0, 4.0 Hz, 1H, H-5), 4.85 (dt, J = 8.6, 4.8 Hz, 1H, H-3), 5.16 – 5.22 (br dsep, J = 8.6, 1.2 
Hz, 1H, H-6); 13C NMR (100 MHz, CDCl3) δ 18.0 (CH3, C-7), 25.7 (CH3, C-7), 28.3 (CH3 × 
3, C-8), 36.1 (CH2, C-4), 57.1 (CH, C-3), 68.7 (CH2, C-5), 81.7 (C), 125.3 (CH, C-6), 134.1 
(C), 157.4 (CO); IR (NaCl) ν 2977, 2930, 1732, 1704, 1367, 1322, 1167, 1060, 853, 770 cm-
1; HRMS (ESI) 250.1413 (C12H21NO3Na requires 250.1414). 
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(3S,5R)-tert-butyl 5-phenyl-3-vinylisoxazolidine-2-carboxylate (2.56a). Colourless oil 
(98%): [α]D −3.8 (c 5.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.52 (s, 9H, H-8), 2.07 – 
2.14 (m, 1H, H-4), 2.84 – 2.91 (m, 1H, H-4), 4.78 (q, J = 7.0 Hz, 1H, H-3), 4.90 (dd, J = 
10.0, 6.5 Hz, 1H, H-5), 5.17 (dt, J = 10.0, 1.2 Hz, 1H, H-7), 5.33 (dt, J = 17.0, 1.2 Hz, 1H, 
H-7), 5.93 (ddd, J = 17.0, 10.0, 7.0 Hz, 1H, H-6), 7.30 – 7.40 (m, 5H); 13C NMR (100 MHz, 
CDCl3) δ 28.3 (CH3 × 3, C-8), 43.7 (CH2, C-4), 62.7 (CH, C-3), 82.0 (C), 82.7 (CH, C-5), 
115.6 (CH2, C-7), 126.8 (CH × 2, Ph), 128.5 (CH, Ph), 128.5 (CH × 2, Ph), 137.2 (C), 137.9 
(CH, C-6), 157.6 (CO); IR (NaCl) ν 2879, 2931, 1731, 1705, 1456, 1368, 1326, 1255, 1165, 
1091, 1034 cm-1; HRMS (ESI) 298.1411 (C16H21NO3Na requires 298.1414). 
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(3S,5S)-tert-Butyl 5-benzyl-3-vinylisoxazolidine-2-carboxylate (2.56b). Colourless oil 
(96%): [α]D −2.5 (c 0.5, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.48 (s, 9H, H-8), 1.76 – 
1.83 (m, 1H, H-4), 2.44 – 2.51 (m, 1H, H-4), 2.83 (dd, J = 14.2, 6.5 Hz, 1H, H-8), 3.14 (dd, J 
= 14.2, 6.2 Hz, 1H, H-8), 4.14 (dq, J = 10.0, 6.5 Hz, 1H, H-5), 4.55 – 4.61 (m, 1H, H-3), 
5.10 (dt, J = 10.2, 1.2 Hz, 1H, H-7), 5.24 (dt, J = 17.2, 1.2 Hz, 1H, H-7), 5.81 (ddd, J = 17.2, 
10.2, 7.2 Hz, 1H, H-6), 7.20 – 7.31 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 28.2 (CH3 × 3, 
C-9), 38.5 (CH2, C-8), 40.9 (CH2, C-4), 62.3 (CH, C-3), 81.5 (CH, C-5), 115.4 (CH2, C-7), 
126.6 (CH, Ph), 128.5 (CH × 2, Ph), 129.1 (CH × 2, Ph), 137.2 (C), 138.0 (CH, C-6), 157.6 
(CO); IR (NaCl) ν 2977, 2926, 1731, 1706, 1455, 1368, 1328, 1255, 1166, 1082, 920, 853, 
753, 700 cm-1; HRMS (ESI) 312.1568 (C17H23NO3Na requires 312.1570). 
 
146 
 
O1
5
4
3
N
2
6
7
Boc
10
8
9
Ph
 
(3S,5S)-tert-Butyl 5-phenethyl-3-vinylisoxazolidine-2-carboxylate (2.56c). Colourless oil 
(96%): [α]D −34.7 (c 3.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.50 (s, 9H, H-10), 1.71 
(ddd, J = 17.6, 12.0, 9.6 Hz, 1H, H-4), 1.84 – 1.93 (m, 1H, H-8), 1.99 – 2.08 (m, 1H, H-8), 
2.52 (ddd, J = 17.6, 14.4, 8.4 Hz, 1H, H-4), 2.68 – 2.84 (m, 2H, H-9), 3.84 – 3.91 (m, 1H, H-
5), 4.58 – 4.63 (m, 1H, H-3), 5.11 (dt, J = 10.0, 1.2Hz, 1H, H-7), 5.25 (dt, J = 17.0, 1.2 Hz, 
1H, H-7), 5.84 (ddd, J = 17.0, 10.0, 6.8 Hz, 1H, H-6), 7.18 – 7.22 (m, 3H), 7.26 – 7.30 (m, 
2H); 13C NMR (100 MHz, CDCl3) δ 28.3 (CH3 × 3, C-10), 32.3 (CH2, C-9), 34.3 (CH2, C-8), 
41.2 (CH2, C-4), 62.2 (CH, C-3), 80.2 (CH, C-5), 81.8 (C), 115.4 (CH2, C-7), 126.1 (CH, Ph), 
128.4 (CH × 2, Ph), 128.5 (CH × 2, Ph), 138.1 (CH, C-6), 141.2 (C), 157.5 (CO); IR (NaCl) ν 
2978, 2931, 1730, 1704, 1454, 1367, 1330, 1254, 1165, 1082, 988, 920, 852, 749, 700 cm-1; 
HRMS (ESI) 326.1727 (C18H25NO3Na requires 326.1727). 
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(3S,5R)-tert-Butyl 5-cyclohexyl-3-vinylisoxazolidine-2-carboxylate (2.56d). Colourless oil 
(96%): [α]D −67.4 (c 4.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.95 – 1.34 (m, 4H, Cy), 
1.48 – 1.76 (m, 16H, H-4/8/Cy), 1.97 – 2.02 (m, 1H, Cy), 2.48 (ddd, J = 12.0, 8.8, 5.8 Hz, 
1H, H-4), 3.59 (ddd, J = 10.0, 7.6, 5.8 Hz, 1H, H-5), 4.57 – 4.62 (m, 1H, H-3), 5.10 (dt, J = 
10.2, 1.2 Hz, 1H, H-7), 5.24 (dt, J = 17.0, 1.2 Hz, 1H, H-7), 5.83 (ddd, J = 17.0, 10.2, 6.8 
Hz, 1H, H-6); 13C NMR (100 MHz, CDCl3) δ 25.6 (CH2, Cy), 25.8 (CH2, Cy), 26.3 (CH2, 
Cy), 28.2 (CH3 × 3, C-8), 28.8 (CH2, Cy), 29.9 (CH2, Cy), 39.1 (CH2, C-4), 40.5 (CH, Cy), 
62.2 (CH, C-3), 81.5 (C), 85.5 (CH, C-5), 115.07 (CH2, C-7), 138.3 (CH, C-6), 157.7 (CO); 
IR (NaCl) ν 2977, 2927, 2854, 1735, 1708, 1392, 1367, 1254, 1170, 1083, 987, 918, 853, 774 
cm-1; HRMS (ESI) 304.1881 (C16H27NO3Na requires 304.1883). 
147 
 
O1
5
4
3
N
2
6
7
Boc
11
8
9
10
10
9
 
(3S,5R)-tert-Butyl 5-(pentan-3-yl)-3-vinylisoxazolidine-2-carboxylate (2.56e). Colourless 
oil (93%): [α]D +19.6 (c 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.85 – 0.93 (m, 6H, H-
10), 1.22 – 1.33 (m, 2H, H-9), 1.42 – 1.45 (m, 2H, H-9), 1.49 (s, 9H, H-11), 1.51 – 1.56 (m, 
1H, H-8), 1.74 (ddd, J = 13.7, 10.4, 6.8 Hz, 1H, H-4), 2.51 (ddd, J = 13.7, 8.8, 5.6 Hz, 1H, 
H-4), 3.74 (ddd, J = 12.4, 10.4, 5.6 Hz, 1H, H-5), 4.59 – 4.65 (m, 1H, H-3), 5.10 (dt, J = 
10.1, 1.3 Hz, 1H, H-7), 5.25 (dt, J = 16.9, 1.3 Hz, 1H, H-7), 5.83 (ddd, J = 16.9, 10.1, 6.8 
Hz, 1H, H-6); 13C NMR (100 MHz, CDCl3) δ 10.3 (CH3, C-10), 11.0 (CH3, C-10), 22.0 
(CH2, C-9), 28.2 (CH3 × 3, C-11), 29.7 (CH2, C-9), 39.4 (CH2, C-4), 42.7 (CH, C-8), 62.2 
(CH, C-3), 81.6 (C), 83.8 (CH, C-5), 115.1 (CH2, C-7), 138.3 (CH, C-6), 157.9 (CO); IR 
(NaCl) ν 2966, 2934, 2877, 1734, 1709, 1459, 1368, 1326, 1254, 1168, 1119, 1074, 919, 852, 
775 cm-1; HRMS (ESI) 292.1883 (C15H27NO3Na requires 292.1883). 
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(3S,5S)-tert-Butyl 5-hexyl-3-vinylisoxazolidine-2-carboxylate (2.56f). Colourless oil 
(95%): [α]D −5.9 (c 1.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H, H-
13), 1.26 – 1.45 (m, 8H, H-9/10/11/12), 1.49 (s, 9H, H-14), 1.53 – 1.77 (m, 3H, H-4/8), 2.54 
(ddd, J = 12.0, 8.4, 5.6 Hz 1H, H-4), 3.83 – 3.90 (m, 1H, H-5), 4.57 – 4.62 (m, 1H, H-3), 5.10 
(d, J = 10.0 Hz, 1H, H-7), 5.24 (d, J = 16.8 Hz, 1H, H-7), 5.84 (ddd, J = 16.8, 10.0, 6.8 Hz, 
1H, H-6); 13C NMR (100 MHz, CDCl3) δ 14.1 (CH3, C-13), 22.6 (CH2, C-9/10/11/12), 26.0 
(CH2, C-9/10/11/12), 28.2 (CH3 × 3, C-14), 29.2 (CH2, C-9/10/11/12), 31.7 (CH2, C-
9/10/11/12), 32.4 (CH2, C-8), 41.3 (CH2, C-4), 62.2 (CH, C-3), 81.3 (CH, C-5), 81.6 (C), 
115.2 (CH2, C-7), 138.2 (CH, C-6), 157.5 (CO); IR (NaCl) ν 2956, 2931, 2859, 1734, 1708, 
1457, 1392, 1367, 1330, 1170, 1090, 987, 919, 853 cm-1; HRMS (ESI) 306.2033 
(C16H29NO3Na requires 306.2040). 
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3.2.9. Alternate Conditions for Cyclisation of 2.5 
Conditions outlined in Table 2.1, entry 1. 
A flask was charged with Pd(OAc)2 (5.6 mg, 0.025 mmol) and Cu(OAc)2·H2O (0.15 g, 0.75 
mmol), flushed with N2 and then sealed with a balloon of N2. 2.5 (50 mg, 0.25 mmol) in 
MeCN (3 mL) was added via syringe. The mixture was heated to 60°C and stirred for 16 h. 
Upon consumption of starting material, the mixture was cooled and partitioned between 
EtOAc (10 mL) and sat. NaHCO3 solution (10 mL), the aqueous layer was extracted further 
with EtOAc (10 mL). The combined organic fractions were washed with brine (10 mL), dried 
with MgSO4 and the solvent removed in vacuo. The crude oil was purified using column 
chromatography (10:1, light petroleum : EtOAc).  
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3.2.10. General Procedure for Palladium Catalyzed Intramolecular Amination of 
Hydrazines 
A flask was charged with palladium acetate (1.5 mg, 0.007 mmol) and sodium acetate (2 mg, 
0.028 mmol) and flushed with O2. DMSO (1 mg, 0.014 mmol) in THF (2 mL) was added and 
a balloon of O2 applied. The desired substrate (50 mg, 0.14 mmol) in THF (1 mL) was added 
to the flask via syringe and stirred at room temperature overnight. Another portion of 
palladium acetate (1.5 mg, 0.007 mmol) was added to the reaction mixture and left to stir for 
a further 24 h. The mixture was filtered through a pad of celite with ethyl acetate and the 
solvent removed in vacuo to yield a brown oil. The crude oil was purified using column 
chromatography (10:1, light petroleum: EtOAc). 
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(E)-Diisopropyl 3-(prop-1-enyl)pyrazolidine-1,2-dicarboxylate (2.59). Colourless oil, 
isolated as a mixture of 12:1:1 of E:Z:Terminal isomers respectively (76% from E-2.58, 72% 
from Z-2.58): 1H NMR (400 MHz; CDCl3) δ E isomer: 1.24 – 1.29 (m, 12H, H-10), 1.68 (dt, 
J = 6.4, 1.5 Hz, 3H, H-8), 1.86 (ddt, J = 12.4, 8.0, 5.2 Hz, 1H, H-4), 2.21 (ddt, J = 12.4, 8.0, 
5.2 Hz, 1H, H-4), 3.19 – 3.25 (m, 1H, H-5), 3.92 – 3.98 (m, 1H, H-5), 4.65 – 4.69 (m, 1H, H-
3), 4.91 – 5.02 (m, 2H, H-9), 5.33 (ddq, J = 15.2, 5.8, 1.5 Hz, 1H, H-6), 5.74 (dqd, J = 15.2, 
6.4, 1.2 Hz, 1H, H-7); Z isomer: 4.94 – 5.02 (m, 1H), 5.25 – 5.34 (m, 1H), 5.54 – 5.65 (m, 
1H); Terminal isomer: 5.10 – 5.15 (m, 2H), 5.77 – 5.85 (m, 1H); 13C NMR (100 MHz, 
CDCl3) δ 17.5 (CH3, C-8), 21.8 (CH3, C-10), 22.0 (CH3 × 3, C-10), 32.3 (CH2, C-4), 46.4 
(CH2, C-5), 60.1 (CH, C-3), 69.8 (CH, C-9), 69.9 (CH, C-9), 126.8 (CH, C-7), 129.4 (CH, C-
6), 157.2 (CO); IR (NaCl) ν 2980, 2935, 1701, 1407, 1375, 1318, 1180, 1108, 964, 922, 762 
cm-1; HRMS (ESI) 307.1622 (C14H24N2O4Na requires 307.1628). 
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(3R,5S)-Diisopropyl 3-phenyl-5-vinylpyrazolidine-1,2-dicarboxylate (2.63). Colourless oil 
(78%): [α]D +8.4 (c 9.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.21 – 1.30 (m, 12H, H-9), 
2.30 – 2.37 (m, 1H, H-4), 2.41 – 2.47 (m, 1H, H-4), 4.85 (m, 1H, H-3), 4.94 – 5.06 (m, 2H, 
H-8), 5.17 (dt, J = 10.4, 1.5 Hz, 1H, H-7), 5.27 (t, J = 7.2 Hz, 1H, H-5), 5.42 (dt, J = 15.8, 
1.5 Hz, 1H, H-7), 5.78 (ddd, J = 15.8, 10.4, 4.4 Hz, 1H, H-6), 7.21 – 7.37 (m, 5H); 13C NMR 
(100 MHz, CDCl3) δ 22.0 (CH3 × 4, C-9), 40.7 (CH2, C-4), 60.7 (CH, C-3), 62.1 (CH, C-5), 
70.0 (CH, C-8), 70.1 (CH, C-8), 115.9 (CH2, C-7), 125.9 (CH × 2, Ph), 127.3 (CH, Ph), 128.5 
(CH × 2, Ph), 135.7 (CH, C-6), 140.8 (C), 156.9 (CO), 157.0 (CO); IR (NaCl) ν 2981, 2935, 
1767, 1704, 1455, 1373, 1308, 1179, 1108, 921 cm-1; HRMS (ESI) 369.1782 (C19H26N2O4Na 
requires 369.1785). 
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3.2.11. Reduction of Vinylisoxazolidine 2.56a with Mo(CO)6 
A solution of the isoxazolidine 2.56a (0.15 g, 0.55 mmol) in a 9:1 mixture of CH3CN and 
H2O (8 mL) was added to Mo(CO)6 (0.72 g, 2.73 mmol) and the resulting solution was 
heated to reflux (~90 oC) for 2 h, during which time the colour had changed from white to 
black. The mixture was then cooled to room temperature, filtered through celite, and the 
filtrate was evaporated. The residue was purified by column chromatography (gradient 9:1 to 
2:1, light petroleum: EtOAc). 
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tert-Butyl (3S,5R)-5-hydroxy-5-phenylpent-1-en-3-ylcarbamate (2.64). Colourless oil 
(61%): [α]D +24.8 (c 5.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 1.44 (s, 9H, H-8), 1.82 – 
1.93 (br. m, 1H, H-4), 2.00 (dt, J = 14.0, 8.0 Hz, 1H, H-4), 2.45 – 2.58 (m, 1H), 4.22 – 4.32 
(m, 1H, H-3), 4.66 – 4.75 (m, 1H), 4.80 (dd, J = 8.0, 4.4 Hz, 1H, H-5), 5.13 (d, J = 10.4 Hz, 
1H, H-7), 5.21 (d, J = 17.6 Hz, 1H, H-7), 5.75 – 5.83 (m, 1H, H-6), 7.28 – 7.38 (m, 5H); 
13CNMR (100 MHz, CDCl3) δ  28.4 (CH3 × 3, C-8), 31.6 (CH, C-3), 44.3 (CH2, C-4), 72.3 
(CH, C-5), 79.6 (C), 115.0 (CH2, C-7), 125.8 (CH × 2, Ph), 127.7 (CH, Ph), 128.6 (CH × 2, 
Ph), 138.6 (CH, C-6), 144.4 (C), 156.8 (CO); IR ν  3347, 2977, 2927, 1691, 1504, 1454, 
1391, 1366, 1249, 1170, 1024, 700 cm-1; HRMS (ESI) 300.1570 (C16H23NO3Na requires 
300.1570). 
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3.2.12. Removal of t-Boc Group from Vinylisoxazolidine 2.56a 
To a solution of 2.56a (150 mg, 0.85 mmol) in CH2Cl2 (2 mL), TFA (1.5 mL, 20 mmol) was 
added slowly at 0 °C. The reaction mixture was stirred for 1 h at 0 °C. Upon consumption of 
the starting material, the excess TFA was neutralised with slow additions of sat. NaHCO3 
solution. Once effervescence subsided and the solution tested basic, the mixture was 
extracted with CH2Cl2 (10 mL), dried with MgSO4 and the solvent removed in vacuo. The 
residue was purified by column chromatography (4:1, light petroleum: EtOAc). 
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(3S,5R)-5-Phenyl-3-vinylisoxazolidine (2.67). Colourless oil (89%): [α]D +24.8 (c 5.0, 
CHCl3); 1H NMR (400 MHz; CDCl3) δ 2.06 (dt, J = 12.4, 7.6 Hz, 1H, H-4), 2.90 (dt, J = 
12.4, 7.6 Hz, 1H, H-4), 4.05 – 4.16 (br m, 1H), 4.92 – 5.30 (br m, 1H), 5.20 (br d, J = 9.6 Hz, 
1H, H-7), 5.31 (br d, J = 16.8 Hz, 1H, H-7), 5.78 – 5.96 (br m, 1H, H-6), 7.27 – 7.38 (br m, 
5H); IR (NaCl) ν 3209, 3030, 2980, 2925, 1711, 1642, 1603, 1493, 1451, 1424, 1029, 989, 
920, 758, 699 cm-1; HRMS (ESI) 198.0889 (C11H13NONa requires 198.0889).  
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3.2.13. Optimal Conditions for Oxidative Cyclisation/Wacker-Oxidation 
A flask was charged with Pd(MeCN)2Cl2 (3.4 mg, 0.013 mmol), QUINOX ligand 2.11 
(20mg, 0.1 mmol) and MeCN (2 mL). O2 was bubbled through the solution for 2 mins. 2.5 
(50 mg, 0.25 mmol) in MeCN (1 mL) was added via syringe and the reaction heated to 60 °C 
and stirred for 16 h. Upon consumption of starting material the reaction mixture was cooled 
to room temperature and filtered through a pad of celite with EtOAc (5 mL). The solvent was 
removed from the filtrate in vacuo, the crude oil that remained was purified by column 
chromatography (10:1, EtOAc: light petroleum). 
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tert-Butyl 3-acetylisoxazolidine-2-carboxylate (2.10). Colourless oil (81%): 1H NMR (400 
MHz; CDCl3) δ 1.52 (s, 9H, H-8), 2.29 (s, 3H, H-7), 2.39 – 2.56 (m, 2H, H-4), 3.75 (dt, J = 
8.4, 7.6 Hz, 1H, H-5), 4.09 (tdd, J = 8.4, 4.0, 0.8 Hz, 1H, H-5), 4.61 (dd, J = 9.2, 5.2 Hz, 1H, 
H-3); 13C NMR (100 MHz, CDCl3) δ 26.3 (CH3, C-7), 28.2 (CH3 × 3, C-8), 30.7 (CH2, C-4), 
66.6 (CH, C-3), 69.1 (CH2, C-5), 83.0 (C), 157.2 (CO), 206.9 (CO); IR (NaCl) ν 3479, 3377, 
2979, 2917, 1721, 1457, 1369, 1255, 1162, 1070, 847, 732 cm-1; HRMS (ESI) 238.1051 
(C10H17NO4Na requires 238.1050).  
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3.2.14. Synthesis of METHOX 
Oxidation of (+)-α-pinene70a 
(+)-α-pinene (15 g, 110 mmol), acetic anhydride (10 mL, 110 mmol), pyridine (6 mL, 73 
mmol), DMAP (3.4 g, 28mmol) and TPP (7 mg, 0.011 mmol) were place in a custom 
reaction vessel. CH2Cl2 (80 mL) was added and the mixture was pumped through a 
continuous flow system. O2 was bubbled through the system at a steady rate (c.a. 100 bubbles 
min-1). The reaction mixture was irradiated with a 24W lamp. The reaction was monitored by 
1H NMR; CH2Cl2 was topped up as necessary. After 16 h, the starting material was 
consumed. The solution was transferred to a separating funnel, sat. NaHCO3 was added until 
the solution became basic. The organic extract was then washed with 1M HCl to yield a 
green solution. The organic layer was further washed with sat. CuSO4 solution and brine, 
dried with MgSO4, filtered and the solvent removed in vacuo to yield a red/brown oil, which 
was distilled on a kugelrohr and yielded a clear oil. 
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(1S,5S)-6,6-Dimethyl-2-methylenebicyclo[3.1.1]heptan-3-one (2.46).70a Viscous colourless 
oil (87%): [α]D −35 (c 4.0, CHCl3); 1H NMR (400 MHz; CDCl3) δ 0.82 (s, 3H, H-9), 1.31 (d, 
J = 10.4 Hz, 1H, H-7), 1.37 (s, 3H, H-9), 2.27 (sep, J = 3.0 Hz, 1H, H-5), 2.54 (dd, J = 19.2, 
3.0 Hz, 1H, H-4), 2.66 – 2.72 (m, 2H, H-4/7), 2.78 (t, J = 5.6 Hz, 1H, H-1), 5.02 (d, J = 1.6 
Hz, 1H, H-8), 5.97 (d, J = 1.6 Hz, 1H, H-8); 13C NMR (100 MHz, CDCl3) δ 21.6 (CH3, C-9), 
26.0 (CH3, C-9), 32.4 (CH2, C-7), 38.5 (CH, C-5), 40.8 (C), 42.5 (CH2, C-4), 48.2 (CH2, C-
1), 117.5 (CH2, C-8), 149.1 (C), 200.2 (CO); IR (NaCl) ν 3398, 2930, 1706, 1625, 1464, 
1397, 1370, 1329, 1284, 1263, 1101, 1060, 925 cm-1; HRMS (ESI) 173.0936 (C10H14ONa 
requires 173.0937).  
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Preparation of Kröhnke salt70a 
To a solution of iodine (11.6 g, 45.7 mmol) in pyridine (20 mL), 2,4,6-
trimethoxyacetophenone (8 g, 38 mmol) was added in one portion, and mixture heated to 
reflux. After 4 h the mixture was cooled and the resulting precipitate was filtered and washed 
with pyridine (3 × 15 mL), and dried in a desiccator. The resulting brown solid was used 
without further purification. 
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1-(2-Oxo-2-(2,4,6-trimethoxyphenyl)ethyl)pyridinium iodide (2.47).70a Brown solid 
(99%): mp 200 – 203°C; 1H NMR (400 MHz; DMSO-d6) δ 3.86 (s, 6H, H-3), 3.91 (s, 3H, H-
4), 6.02 (s, 2H, H-1), 6.37 (s, 2H, H-2), 8.23 (dd, J = 7.8, 6.2 Hz, 2H, H-6), 8.71 (t, J = 7.8 
Hz, 1H, H-7), 8.93 (d, J = 6.2 Hz, 2H, H-5); 13C NMR (100 MHz, DMSO-d6) δ 55.8 (CH3), 
56.3 (CH3 × 2), 69.4 (CH2), 91.2 (CH × 2), 107.3 (C), 127.8 (CH × 2), 146.1 (CH × 2), 146.2 
(CH), 160.5 (C × 2), 164.5 (C), 190.3 (CO); IR (KBr) ν 3398, 3120, 2947, 2839, 2793, 1708, 
1581, 1415, 1126, 759 cm-1; HRMS (ESI) 288.1226 (C16H18NO4 requires 288.1230).  
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Kröhnke Annulation of 2.46 and 2.4770a 
Ammonium acetate (70 g) was dissolved in AcOH (70 mL), heated to 110 °C and stirred until 
dissolved. Kröhnke salt 2.47 (12 g, 28.9 mmol) was added and stirred at 110 °C until 
dissolved leaving a red/orange solution. Pinacarvone 2.46 (4 g, 26.3 mmol) was added 
turning the mixture brown in colour. The mixture was left to reflux at 110 °C overnight. 
Water (20 mL) was added, the mixture was then basified with sat. NaOH solution. The 
aqueous media was then extracted with ethyl acetate (3 × 50 mL). The combined organic 
extracts were dried with MgSO4 and the solvent removed in vacuo. A crude brown solid was 
isolated. Column chromatography using 9:1 petroleum ether: EtOAc was used to purify the 
compounds. 
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(+)-5-(2’,4’,6’-Trimethoxyphenyl)-10,10-dimethyl-6-aza-tricyclo[7.1.1.02,7]undeca- 
2(7),3,5-triene (2.48).70a Brown solid (47%): [α]D +42.0 (c 1.0, CHCl3); 1H NMR (400 MHz; 
CDCl3) δ 0.71 (s, 3H, H-12), 1.39 (d, J = 9.4 Hz, 1H, H-10), 1.42 (s, 3H, H-12), 2.37 (sep, J 
= 2.8 Hz, 1H, H-8), 2.68 (dt, J = 9.4, 5.8 Hz, 1H, H-11), 2.77 (t, J = 5.8 Hz, 1H, H-11), 3.15 
(d, J = 2.8 Hz, 2H, H-7), 3.70 (s, 6H, H-14), 3.85 (s, 3H, H-15), 6.20 (s, 2H, H-13), 6.95 (d, J 
= 7.6 Hz, 1H, H-2/3), 7.22 (d, J = 7.6 Hz, 1H, H-2/3); 13C NMR (100 MHz, CDCl3) δ 21.4 
(CH3, C-12), 26.1 (CH3, C-12), 31.8 (CH2, C-10), 36.6 (CH2, C-7), 39.6 (C), 40.3 (CH, C-8), 
46.4 (CH, C-11), 55.4 (CH3, C-15), 56.0 (CH3 × 2, C-14), 91.0 (CH × 2, C-13), 113.1 (C), 
122.7 (CH, C-2/3), 132.6 (CH, C-2/3), 139.2 (C), 151.2 (C), 156.0 (C), 159.0 (C × 2), 161.0 
(C); IR (NaCl) ν 2934, 1609, 1587, 1453, 1223, 1204, 1156, 1127, 1042, 948, 810, 729 cm-1; 
HRMS (ESI) 340.1902 (C21H26NO3 requires 340.1907).  
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Methylation of Pyridine 2.4870a 
A solution of pyridine derivative 2.48 (2.3 g, 6.8 mmol) in THF (40 mL) was cooled to −40 
°C. nBuLi (2.2M in hexane, 3.4 mL, 7.45 mmol) was added dropwise turning the mixture a 
deep red colour. The solution was stirred at −40 °C for 1 h. A solution of MeI (1.06 g, 7.45 
mmol) in THF (5 mL) was added dropwise. After the addition the mixture was allowed to 
warm to room temperature and left to stir overnight. Water (30 mL) was added to quench the 
reaction. The mixture was extracted with CH2Cl2 (3 × 30 mL), the combined organic 
fractions were washed with brine (2 × 30 mL), dried with MgSO4 and the solvent removed in 
vacuo to yield a brown solid. Column chromatography was used to purify the compound (4:1, 
light petroleum: EtOAc).  
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(1S,8R,9S)-8,10,10-Trimethyl-5-(2,4,6-trimethoxyphenyl)-6-zatricyclo[7.1.1.02,7]undeca-
2,4,6-triene (2.49).70a Brown solid (81%): [α]D +1.05 (c 5.0, CHCl3); 1H NMR (400 MHz; 
CDCl3) δ 0.62 (s, 3H, H-12), 1.31 (d, J = 7.2 Hz, 3H, H-13), 1.35 (s, 3H, H-12), 2.08 (td, J = 
6.0, 2.4 Hz, 1H, H-8), 2.48 (dt, J = 10.0, 6.0 Hz, 2H, H-11), 2.69 (t, J = 6.0 Hz, 1H, H-10), 
3.17 (qd, J = 7.2, 2.4 Hz, 1H, H-7), 3.64 (s, 6H, H-15), 3.77 (s, 3H, H-16), 6.14 (s, 2H, H-
14), 6.89 (d, J = 7.4 Hz, 1H, H-2/3), 7.12 (d, J = 7.4 Hz, 1H, H-2/3); 13C NMR (100 MHz, 
CDCl3) δ 18.6 (CH3, C-12), 21.4 (CH3, C-13), 26.4 (CH3, C-12), 28.6 (CH2, C-11), 39.6 (CH, 
C-7), 41.5 (C), 47.0 (CH, C-8), 47.1 (CH, C-10), 55.4 (CH3, C-16), 56.2 (CH3 × 2, C-15), 
91.5 (CH × 2, C-14), 113.4 (C), 122.8 (CH, C-2/3), 132.5 (CH, C-2/3), 138.9 (C), 151.0 (C), 
159.1 (C × 2), 159.8 (C), 161.0 (C); IR (NaCl) ν 2931, 1609, 1587, 1465, 1334, 1223, 1204, 
1156, 1128, 1037, 811, 730 cm-1; HRMS (ESI) 354.2056 (C22H28NO3Na requires 354.2064).  
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Oxidation of 2.4970a 
To a solution of the methylated pyridine derivative 2.49 (0.3 g, 0.81 mmol) in CH2Cl2 (10 
mL), m-CPBA (0.3 g, 0.89 mmol) in CH2Cl2 (10 mL) was added in four portions via syringe. 
The reaction was stirred for 2 h. Et2O (10 mL) was added and washed with sat. NaHCO3 
solution (10 mL) and with brine (10 mL). The organic phase was dried with MgSO4, filtered 
and the solvent removed in vacuo to yield a pale yellow solid. The pure pyridine N-oxide was 
purified using column chromatography (light petroleum: EtOAc, 10:1). 
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(+)-5-(2’,4’,6’-Trimethoxyphenyl)-8,10,10-trimethyl-6-azatricyclo[7.1.1.02,7]undeca-
2,4,6-triene 6-Oxide (2.44).70a Pale yellow solid (46%): 1H NMR (400 MHz; CDCl3) δ 0.59 
(s, 3H), 1.34 (s, 3H), 1.42 (d, J = 6.8 Hz, 3H), 2.01 – 2.04 (m, 1H), 2.03 – 2.10 (m, 1H), 2.47 
(dt, J = 9.6, 6.0 Hz, 1H), 2.70 (t, J = 5.6 Hz, 1H), 3.31 – 3.38 (m, 1H), 3.64 (s, 3H), 3.66 (s, 
3H), 3.76 (s, 3H), 6.12 (s, 2H), 6.76 (d, J = 7.6 Hz, 1H), 6.94 (d, J = 7.6 Hz, 1H).   
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3.2.15. Preparation of (E)-crotyl trichlorosilane 
CuCl (0.55 g, 5.5 mmol) was weighed out under a stream of nitrogen and placed into a flame 
dried flask containing powdered 4Å MS.  Et2O (40 mL) was added to the flask via syringe. 
Crotyl chloride (1 g, 11.0 mmol) was added in one portion, followed by Hünigs base (4.8 mL, 
27.6 mmol) in one portion. The mixture was cooled to 0°C and HSiCl3 (2.2 mL, 22.1 mmol) 
was added slowly via syringe. The mixture was allowed to warm to room temperature and 
left to stir overnight or until the starting material was consumed (monitored by 1H NMR). 
The reaction has been observed changing colours to a range including yellow, green, blue, 
brown or also remaining an off white colour. Once the reaction was complete stirring was 
stopped and any solid particles were left to settle. The solution was transferred to an 
anhydrous distillation kit to using a cannula. Any Et2O was removed under a stream of 
nitrogen, then the crotyl trichlorosilane was distilled off under vacuum and heating. The pure 
silane was used immediately. 
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(E)-But-2-enyltrichlorosilane (2.50).107 Clear liquid: 1H NMR (400 MHz; CDCl3) δ1.69 (d, 
J = 4.4 Hz, 3H, H-4), 2.23 (d, J = 7.6, 2H, H-1), 5.35 (1H, m), 5.57 (1H, m). 
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3.2.16. Preparation of Allyl Transfer Reagent 2.5170b 
To a solution of METHOX (0.1 g, 0.3 mmol) in freshly distilled MeCN (30 mL) was added i-
Pr2NEt (11.4 g, 88.0 mmol) and p-tolualdehyde (0.7 g, 5.9 mmol). The reaction vessel was 
cooled to −40 °C and freshly prepared crotyl trichlorosilane 2.50 (2.2 g, 11.7 mmol) was 
added dropwise via syringe. The reaction was maintained at −40 °C until consumption of the 
starting material was observed by TLC. After consumption of the starting material, the 
reaction was quenched with water and extracted with ethyl acetate. The combined organic 
layers were washed with sat. NaHCO3 (30 mL) and brine (30 mL), then dried with MgSO4. 
The solvent was evaporated to yield the crude product as a yellow oil. Column 
chromatography was used to purify the compound using 95:5 petroleum ether: ethyl acetate. 
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(1S,2S)-2-Methyl-1-p-tolylbut-3-en-1-ol (2.51).70b Pale yellow oil (79%): 1H NMR (400 
MHz; CDCl3) δ 0.87 (d, J = 6.8 Hz, 3H, H-5), 2.08 – 2.18 (m, OH), 2.34 (s, 3H, H-6), 2.43 – 
2.52 (m, 1H, H-2), 4.31 (d, J = 8.0 Hz, H-1), 5.15 – 5.22 (m, 2H), 5.81 (ddd, J = 17.2, 10.4, 
8.0 Hz, 1H, H-3), 7.13 – 7.23 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 16.6 (CH3, C-5), 21.1 
(CH3, C-6), 46.2 (CH, C-2), 77.8 (CH, C-1), 116.6 (CH2, C-4), 126.8 (CH × 2, Ph), 128.9 
(CH × 2, Ph), 137.3 (C), 139.5 (C), 140.9 (CH, C-3); IR (NaCl) ν 3415, 2975, 2926, 2870, 
1638, 1514, 1455, 1416, 1030, 1017, 913, 812 cm-1; HRMS (ESI) 199.1092 (C12H16ONa 
requires 199.1093); chiral GC (Supelco γ-DEX column, oven for 2 min at 100 °C, then 0.5 
°C min-1) showed 84% ee (tR = 49.5 min, tS = 50.0 min). 
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3.2.17. Synthesis of Allylic N-alkyloxy and N-aryloxy Carbamates101 
To a flask of N,N-carbonyldiimidazole (1.7 g, 10.4 mmol) in MeCN (c.a. 5 mL/mmol) under 
an atmosphere of N2, the allylic alcohol was added (0.5 g, 6.9 mmol) and the mixture stirred 
at room temperature until all of the allylic alcohol is used up (c.a. 3 h). Imidazole (1.9 g, 27.7 
mmol) and hydroxylamine derivative (2.9g, 34.7 mmol) were added and the mixture stirred 
for a further 12 h. The solvent was removed in vacuo to yield a white solid, this was 
partitioned between EtOAc (20 mL) and 1M HCl (20 mL) and extracted further with more 
EtOAc (20 mL). The combined organic fractions were dried with MgSO4, filtered and the 
solvent removed in vacuo to yield the allylic carbamate.  Compounds were purified by 
column chromatography (3:2, petroleum ether: EtOAc). 
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(E)-But-2-enyl methoxycarbamate (2.83b). Colourless oil (97%): 1H NMR (400 MHz; 
CDCl3) δ 1.72 (d, J = 6.4 Hz, 3H, H-4), 3.73 (s, 3H, H-5), 4.58 (d, J = 6.4 Hz, 2H, H-1), 5.55 
– 5.65 (m, 1H, H-2), 5.77 – 5.87 (m, 1H, H-3), 8.00 (s, 1H, NH); 13C NMR (100 MHz, 
CDCl3) δ 17.7 (CH3, C-4), 64.5 (CH3, C-5), 66.4 (CH2, C-1), 124.9 (CH, C-2), 131.8 (CH, C-
3), 157.6 (CO); IR (NaCl) ν 3272, 2941, 1723, 1484, 1338, 1256, 1117, 1032, 968, 772, 560 
cm-1; HRMS (ESI) 168.0630 (C6H11NO3Na requires 168.0631). 
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(E)-But-2-enyl benzyloxycarbamate (2.83a). Colourless oil (97%): 1H NMR (400 MHz; 
CDCl3) δ 1.71 (d, J = 6.4 Hz, 3H, H-4), 4.56 (d, J = 6.4 Hz, 2H, H-1), 4.86 (s, 2H, H-5), 5.53 
– 5.63 (m, 1H, H-2), 5.75 – 5.85 (m, 1H, H-3), 7.32 – 7.40 (m, 5H), 7.53 (br. S, 1H, NH); 13C 
NMR (100 MHz, CDCl3) δ 17.8 (CH3, C-4), 66.5 (CH2, C-1), 78.6 (CH2, C-5), 124.9 (CH, C-
2), 128.5 (CH × 2, Ph), 128.6 (CH, Ph), 129.2 (CH × 2, Ph), 132.0 (CH, C-3), 135.5 (C), 
157.4 (CO); IR (NaCl) ν 3261, 2939, 1716, 1454, 1257, 1109, 969, 745, 698 cm-1; HRMS 
(ESI) 244.0938 (C12H15NO3Na requires 244.0944). 
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3.2.18. Synthesis of Allylic N-tosyl Carbamate102 
p-Tosyl isocyanate (5.6 g, 28.3 mmol) was added slowly to a cooled to 0°C solution of allylic 
alcohol (2 g, 25.7 mmol) in CH2Cl2 (20 mL), and the resulting solution was allowed to warm 
to room temperature. The mixture was stirred for c.a. 3 h, after which the solvent was 
removed in vacuo to yield the carbamate, which was used without further purification. 
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(E)-But-2-enyl tosylcarbamate (2.83c).108 Viscous colourless oil (98%): 1H NMR (400 
MHz; CDCl3) δ 1.68 (ddt, J = 6.4, 1.6, 1.0 Hz, 3H, H-4), 2.44 (s, 3H, H-5), 4.49 (dt, J = 6.8, 
1.0 Hz, 2H, H-1), 5.44 – 5.52 (m, 1H, H-2), 5.70 – 5.79 (m, 1H, H-3), 7.34 (d, J = 8.0 Hz, 
2H), 7.93 (d, J = 8.0 Hz, 2H), 8.05 (br. s, 1H, NH); 13C NMR (100 MHz, CDCl3) δ 17.8 
(CH3, C-4), 21.7 (CH3, C-5), 67.6 (CH2, C-1), 123.9 (CH, C-2), 128.4 (CH × 2, Ph), 129.6 
(CH × 2, Ph), 132.9 (CH, C-3), 135.5 (C), 145.1 (C), 150.5 (CO); IR (NaCl) ν 3241, 1748, 
1597, 1447, 1348, 1220, 1161, 1090, 967, 856, 663, 583, 547 cm-1; HRMS (ESI) 292.0610 
(C12H15NO4SNa requires 292.0614). 
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3.2.19. Cyclisation of N-alkyloxy, N-aryloxy and N-tosyl Carbamates – Optimal 
Conditions. 
To an oven dried flask was added Pd(OAc)2 (8.3 mg, 0.037  mmol), Cu(OTf)2 (0.4 g, 1.11 
mmol) and ground pH 7 buffer tablet (0.1 g). NEt(i-Pr)2 (50 mg, 0.37  mmol) and MeCN (2 
mL) were added and the mixture stirred. Oxygen was bubbled through the mixture for 2-3 
minutes, then a balloon of O2 was applied. To the flask was added the desired carbamate (0.1 
g, 0.37 mmol) in MeCN (1 mL). The mixture was stirred and heated to 60 °C for 72 h. Upon 
completion, the reaction mixture was partitioned between EtOAc (10 mL) and sat. NaHCO3 
(10 mL), separated and the aqueous fraction extracted again with EtOAc (10 mL). The 
combined organic fractions were washed with brine (10 mL) and dried with MgSO4, filtered 
and the solvent removed in vacuo. The resultant brown oil was purified by column 
chromatography (10:1, light petroleum: EtOAc). 
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3-Methoxy-4-vinyloxazolidin-2-one (2.84b). Clear colourless oil (14%): 1H NMR (400 
MHz; CDCl3) δ 3.74 (s, 3H, H-8), 3.90 (t, J = 8.4 Hz, 1H, H-5), 4.20 – 4.28 (m, 1H, H-4), 
4.29 (t, J = 7.6 Hz, 1H, H-5), 5.36 (d, J = 10.0 Hz, 1H, H-7), 5.43 (d, J = 17.2 Hz, 1H, H-7), 
5.78 (ddd, J = 17.2, 10.0, 8.4 Hz, 1H, H-6); 13C NMR (100 MHz, CDCl3) δ 62.6 (CH, C-4), 
64.5 (CH3, C-8), 65.6 (CH2, C-5), 122.6 (CH2, C-7), 132.7 (CH, C-6), 158.8 (CO); IR (NaCl) 
ν 3323, 2941, 1784, 1383, 1313, 1210, 1082, 1023, 795, 763 cm-1; HRMS (ESI) 166.0480 
(C6H9NO3Na requires 166.0475). 
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N-(But-3-en-2-yl)-O-methylhydroxylamine (2.85b). Colourless oil (15%): 1H NMR (400 
MHz; CDCl3) δ 1.26 (d, J = 7.2 Hz, 3H, H-1), 3.65 (s, 3H, H-5), 4.50 – 4.59 (m, 1H, H-2), 
5.08 (dt, J = 10.4, 1.2 Hz, 1H, H-4), 5.13 (dt, J = 17.6, 1.2 Hz, 1H, H-4), 5.87 (ddd, J = 17.6, 
10.4, 6.4 Hz, 1H, H-3); 13C NMR (100 MHz, CDCl3) δ 16.4 (CH3, C-1), 57.5 (CH, C-2), 64.4 
(CH3, C-5), 116.2 (CH2, C-4), 137.2 (CH, C-3), 157.6 (CO); IR (NaCl) ν 2976, 2939, 1734, 
1710, 1389, 1282, 1089, 1064, 967, 925, 768 cm-1; HRMS (ESI) 123.0666 (C5H10NONa 
requires 123.0655). 
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3-(Benzyloxy)-4-vinyloxazolidin-2-one (2.84a). Colourless oil (20%): 1H NMR (400 MHz; 
CDCl3) δ 3.85 (t, J = 8.4 Hz, 1H, H-5), 4.10 (q, J = 8.4 Hz, 1H, H-4), 4.24 (t, J = 8.4 Hz, 1H, 
H-5), 4.84 (d, J = 10.6 Hz, 1H, H-8), 4.95 (d, J = 10.6 Hz, 1H, H-8), 5.24 (d, J = 10.0 Hz, 1H, 
H-7), 5.31 (d, J = 17.0 Hz, 1H, H-7), 5.53 (ddd, J = 17.0, 10.0, 8.4 Hz, 1H, H-6), 7.26 – 7.36 
(m, 5H); HRMS (ESI) 242.0785 (C12H13NO3Na requires 242.0788). 
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O-Benzyl-N-(but-3-en-2-yl)hydroxylamine (2.85a). Colourless oil (18%): 1H NMR (400 
MHz; CDCl3) δ 1.26 (d, J = 6.8 Hz, 3H, H-1), 4.54 – 4.63 (m, 1H, H-2), 4.80 (s, 1H, H-5), 
4.81 (s, 1H, H-5), 5.09 (d, J = 10.4 Hz, 1H, H-4), 5.15 (d, J = 17.2 Hz, 1H, H-4), 5.90 (ddd, J 
= 17.2, 10.4, 6.0 Hz, 1H, H-3), 7.25 – 7.35 (m, 5H); HRMS (ESI) 200.1047 (C12H15NONa 
requires 200.1046). 
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3-Tosyl-4-vinyloxazolidin-2-one (2.84c).18 Colourless oil (65%): 1H NMR (400 MHz; 
CDCl3) δ 2.45 (s, 3H, H-8), 4.05 (dd, J = 8.4, 4.0 Hz, 1H, H-5), 4.50 (t, J = 8.4 Hz, 1H, H-5), 
4.92 (td, J = 8.4, 4.0 Hz, 1H, H-4), 5.39 (d, J = 10.0 Hz, 1H, H-7), 5.49 (d, J = 16.8 Hz, 1H), 
5.82 (ddd, J = 16.8, 10.0, 8.4 Hz, 1H, H-6), 7.34 (d, J = 8.0 Hz, 2H), 7.93 (d, J = 8.0 Hz, 2H); 
13C NMR (100 MHz, CDCl3) δ 21.7 (CH3, C-8), 59.6 (CH, C-4), 68.1 (CH2, C-5), 120.9 
(CH2, C-7), 128.7 (CH × 2, Ph), 129.7 (CH × 2, Ph), 133.6 (CH, C-6), 135.0 (C), 145.6 (C), 
151.9 (CO); IR (NaCl) ν 3303, 1783, 1373, 1173, 1124, 1054, 815, 756, 665, 602 cm-1; 
HRMS (ESI) 290.0453 (C12H13NO4SNa requires 290.0457). 
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N-(But-3-en-2-yl)-4-methylbenzenesulfonamide (2.85c).109 Colourless oil (25%): 1H NMR 
(400 MHz; CDCl3) δ 1.18 (d, J = 6.8 Hz, 3H, H-1), 2.43 (s, 3H, H-5), 3.86 – 3.96 (m, 1H, H-
2), 4.99 (dt, J = 10.4, 1.2 Hz, 1H, H-4), 5.06 (dt, J = 17.2, 1.2 Hz, 1H, H-4), 5.64 (ddd, J = 
17.2, 10.4, 6.0 Hz, 1H, H-3), 7.29 (d, J = 7.8 Hz, 2H), 7.75 (d, J = 7.8 Hz, 2H); 13C NMR 
(100 MHz, CDCl3) δ 21.5 (CH3, C-1), 21.6 (CH3, C-5), 51.6 (CH, C-2), 115.2 (CH2, C-4), 
127.2 (CH × 2, Ph), 129.6 (CH × 2, Ph), 138.0 (C), 139.0 (CH, C-3), 143.8 (C); IR (NaCl) ν 
3278, 2925, 1736, 1598, 1360, 1327, 1158, 1091, 814, 672 cm-1; HRMS (ESI) 248.0711 
(C11H15NO2SNa requires 248.0716). 
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5. Appendix 
5.1. Crystal Data for 2.63 
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Crystal data 
C19H26N2O4 F(000) = 372 
Mr = 346.42 Dx = 1.207 Mg m-3 
Monoclinic, P21 Mo Kα radiation, λ = 0.71073 Å 
a = 11.1404 (18) Å Cell parameters from 4923 reflections 
b = 8.0196 (13) Å θ = 3.1–28.1° 
c = 11.1622 (18) Å µ = 0.09 mm-1 
β = 107.072 (2)° T = 150 K 
V = 953.3 (3)  Å3 Block, colourless 
Z = 2 0.41 × 0.29 × 0.25 mm 
 
Data collection 
Bruker APEX 2 CCD diffractometer 4049 reflections with I> 2σ(I) 
Radiation source: fine-focus sealed tube Rint = 0.058 
ω rotation with narrow frames scans θmax = 28.4°, θmin = 1.9° 
Absorption correction: multi-scan  
TWINABS v2012/1, Sheldrick, G.M., (2012) 
h = -14→14 
Tmin = 0.966, Tmax = 0.979 k = -10→10 
17201 measured reflections l = -14→14 
4577 independent reflections  
 
 
 
177 
 
Refinement 
Refinement on F2 Secondary atom site location: difference Fourier map 
Least-squares matrix: full Hydrogen site location: difference Fourier map 
R[F2> 2σ(F2)] = 0.038 Only H-atom coordinates refined 
wR(F2) = 0.096 w = 1/[σ2(Fo2) + (0.0567P)2]     
where P = (Fo2 + 2Fc2)/3 
S = 1.08 (∆/σ)max< 0.001 
4577 reflections ∆〉max = 0.20 e Å-3 
327 parameters ∆〉min = -0.16 e Å-3 
16 restraints Absolute structure: Flack x determined using 1663 quotients 
[(I+)-(I-)]/[(I+)+(I-)] (Parsons and Flack (2004), Acta Cryst. 
A60, s61). Flack x via hole-in-one method gives 0.230(999).  
Primary atom site location: structure-invariant 
direct methods 
Flack parameter: 1.0 (7). Could not be reliably determined. 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters 
(Å2) 
 x y z Uiso*/Ueq 
N1 0.19893 (15) 0.9726 (2) 0.32609 (15) 0.0221 (3) 
N2 0.25192 (14) 0.8306 (2) 0.28546 (15) 0.0219 (3) 
C3 0.36959 (18) 0.8747 (3) 0.25585 (18) 0.0240 (4) 
H3 0.440 (2) 0.827 (3) 0.319 (2) 0.018 (5)* 
C4 0.3745 (2) 1.0655 (3) 0.2721 (2) 0.0307 (5) 
H4A 0.461 (2) 1.104 (3) 0.303 (2) 0.026 (6)* 
H4B 0.337 (2) 1.119 (4) 0.200 (3) 0.038 (7)* 
C5 0.30169 (19) 1.0958 (3) 0.3672 (2) 0.0271 (4) 
H5 0.271 (2) 1.207 (3) 0.358 (2) 0.023 (6)* 
C6 0.3824 (2) 1.0612 (3) 0.4993 (2) 0.0350 (5) 
H6 0.458 (2) 1.127 (4) 0.521 (3) 0.046 (8)* 
C7 0.3580 (3) 0.9571 (4) 0.5790 (2) 0.0420 (6) 
H7A 0.280 (3) 0.896 (4) 0.564 (3) 0.050 (8)* 
H7B 0.416 (2) 0.944 (3) 0.658 (2) 0.034 (7)* 
C8 0.36914 (17) 0.8173 (3) 0.12673 (18) 0.0237 (4) 
C9 0.4686 (2) 0.7237 (3) 0.1118 (2) 0.0316 (5) 
H9 0.538 (2) 0.697 (3) 0.184 (3) 0.032 (6)* 
C10 0.4712 (2) 0.6746 (3) -0.0067 (2) 0.0388 (5) 
H10 0.537 (3) 0.611 (4) -0.015 (3) 0.046 (8)* 
C11 0.3745 (2) 0.7209 (3) -0.1111 (2) 0.0373 (5) 
H11 0.380 (3) 0.678 (4) -0.188 (3) 0.048 (8)* 
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C12 0.2750 (2) 0.8136 (3) -0.0975 (2) 0.0336 (5) 
H12 0.207 (3) 0.846 (4) -0.168 (3) 0.042 (7)* 
C13 0.27169 (19) 0.8605 (3) 0.02092 (19) 0.0270 (4) 
H13 0.204 (2) 0.924 (3) 0.030 (2) 0.026 (6)* 
C14 0.08331 (18) 1.0278 (3) 0.24990 (18) 0.0239 (4) 
O1 0.04204 (14) 1.1641 (2) 0.26171 (15) 0.0341 (4) 
O2 0.02419 (13) 0.90933 (19) 0.17165 (15) 0.0317 (4) 
C15 -0.10419 (19) 0.9454 (3) 0.0936 (2) 0.0350 (5) 
H15 -0.132 (3) 1.044 (4) 0.131 (3) 0.043 (8)* 
C16 -0.1009 (3) 0.9788 (5) -0.0366 (3) 0.0575 (8) 
H16A -0.192 (2) 0.991 (6) -0.086 (3) 0.086* 
H16B -0.071 (4) 0.875 (4) -0.069 (4) 0.086* 
H16C -0.054 (3) 1.085 (4) -0.046 (4) 0.086* 
C17 -0.1821 (3) 0.7979 (5) 0.1054 (3) 0.0557 (8) 
H17A -0.181 (4) 0.778 (6) 0.192 (4) 0.090 (14)* 
H17B -0.156 (4) 0.695 (6) 0.067 (4) 0.085 (13)* 
H17C -0.273 (3) 0.817 (5) 0.059 (3) 0.070 (10)* 
C18 0.24242 (17) 0.6777 (3) 0.33648 (17) 0.0225 (4) 
O3 0.30908 (13) 0.56129 (18) 0.32784 (14) 0.0284 (3) 
O4 0.14892 (13) 0.67313 (18) 0.38916 (13) 0.0257 (3) 
C19 0.1221 (2) 0.5097 (3) 0.4342 (2) 0.0288 (4) 
H19 0.136 (2) 0.428 (3) 0.376 (2) 0.027 (6)* 
C20 -0.0122 (3) 0.5174 (3) 0.4362 (3) 0.0425 (6) 
H20A -0.072 (3) 0.538 (4) 0.349 (2) 0.057 (9)* 
H20B -0.019 (3) 0.599 (4) 0.503 (3) 0.059 (9)* 
H20C -0.039 (3) 0.410 (3) 0.465 (3) 0.054 (9)* 
C21 0.2141 (3) 0.4760 (4) 0.5615 (3) 0.0513 (7) 
H21A 0.304 (3) 0.484 (4) 0.560 (3) 0.049 (8)* 
H21B 0.195 (3) 0.562 (4) 0.616 (3) 0.041 (7)* 
H21C 0.200 (4) 0.370 (5) 0.593 (4) 0.076 (11)* 
 
Geometric parameters (Å, º) 
N1—C14 1.391 (2) C12—H12 0.95 (3) 
N1—N2 1.417 (2) C13—H13 0.95 (2) 
N1—C5 1.479 (3) C14—O1 1.208 (3) 
N2—C18 1.369 (3) C14—O2 1.327 (2) 
N2—C3 1.486 (2) O2—C15 1.469 (2) 
C3—C8 1.512 (3) C15—C16 1.488 (4) 
C3—C4 1.539 (3) C15—C17 1.496 (4) 
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C3—H3 0.96 (2) C15—H15 0.98 (3) 
C4—C5 1.532 (3) C16—H16A 1.01 (2) 
C4—H4A 0.97 (2) C16—H16B 1.01 (2) 
C4—H4B 0.90 (3) C16—H16C 1.02 (2) 
C5—C6 1.511 (3) C17—H17A 0.98 (4) 
C5—H5 0.95 (3) C17—H17B 1.01 (4) 
C6—C7 1.305 (4) C17—H17C 1.00 (4) 
C6—H6 0.96 (3) C18—O3 1.214 (2) 
C7—H7A 0.96 (3) C18—O4 1.338 (2) 
C7—H7B 0.94 (3) O4—C19 1.466 (2) 
C8—C9 1.388 (3) C19—C20 1.504 (3) 
C8—C13 1.393 (3) C19—C21 1.512 (3) 
C9—C10 1.388 (3) C19—H19 0.97 (3) 
C9—H9 0.97 (3) C20—H20A 1.02 (2) 
C10—C11 1.386 (4) C20—H20B 1.01 (2) 
C10—H10 0.91 (3) C20—H20C 1.00 (2) 
C11—C12 1.379 (3) C21—H21A 1.01 (3) 
C11—H11 0.94 (3) C21—H21B 0.98 (3) 
C12—C13 1.385 (3) C21—H21C 0.95 (4) 
    
C14—N1—N2 117.27 (15) C12—C13—H13 119.8 (14) 
C14—N1—C5 118.05 (17) C8—C13—H13 119.6 (15) 
N2—N1—C5 106.19 (14) O1—C14—O2 126.05 (19) 
C18—N2—N1 119.75 (15) O1—C14—N1 122.36 (18) 
C18—N2—C3 119.16 (16) O2—C14—N1 111.45 (17) 
N1—N2—C3 110.92 (15) C14—O2—C15 117.27 (17) 
N2—C3—C8 112.53 (16) O2—C15—C16 108.44 (19) 
N2—C3—C4 102.35 (17) O2—C15—C17 106.3 (2) 
C8—C3—C4 113.90 (18) C16—C15—C17 114.2 (3) 
N2—C3—H3 109.1 (13) O2—C15—H15 106.4 (16) 
C8—C3—H3 110.2 (13) C16—C15—H15 111.6 (16) 
C4—C3—H3 108.4 (14) C17—C15—H15 109.3 (16) 
C5—C4—C3 103.38 (18) C15—C16—H16A 104 (2) 
C5—C4—H4A 111.8 (13) C15—C16—H16B 108 (2) 
C3—C4—H4A 110.7 (15) H16A—C16—H16B 106 (3) 
C5—C4—H4B 110.1 (17) C15—C16—H16C 114 (2) 
C3—C4—H4B 111.9 (19) H16A—C16—H16C 109 (3) 
H4A—C4—H4B 109 (2) H16B—C16—H16C 115 (3) 
N1—C5—C6 111.40 (19) C15—C17—H17A 112 (3) 
N1—C5—C4 101.42 (16) C15—C17—H17B 111 (2) 
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C6—C5—C4 111.28 (19) H17A—C17—H17B 112 (4) 
N1—C5—H5 111.6 (14) C15—C17—H17C 111 (2) 
C6—C5—H5 111.9 (14) H17A—C17—H17C 105 (3) 
C4—C5—H5 108.8 (15) H17B—C17—H17C 106 (3) 
C7—C6—C5 126.8 (2) O3—C18—O4 125.93 (19) 
C7—C6—H6 121.4 (18) O3—C18—N2 122.12 (17) 
C5—C6—H6 111.8 (18) O4—C18—N2 111.87 (16) 
C6—C7—H7A 123.9 (19) C18—O4—C19 116.00 (16) 
C6—C7—H7B 119.5 (16) O4—C19—C20 105.77 (17) 
H7A—C7—H7B 117 (2) O4—C19—C21 109.40 (19) 
C9—C8—C13 118.89 (19) C20—C19—C21 113.3 (2) 
C9—C8—C3 120.01 (18) O4—C19—H19 106.7 (15) 
C13—C8—C3 121.08 (18) C20—C19—H19 113.1 (14) 
C10—C9—C8 120.6 (2) C21—C19—H19 108.3 (15) 
C10—C9—H9 120.2 (15) C19—C20—H20A 111.6 (17) 
C8—C9—H9 119.2 (15) C19—C20—H20B 109.3 (18) 
C11—C10—C9 119.8 (2) H20A—C20—H20B 115 (3) 
C11—C10—H10 120.8 (18) C19—C20—H20C 111.2 (18) 
C9—C10—H10 119.4 (18) H20A—C20—H20C 106 (3) 
C12—C11—C10 120.2 (2) H20B—C20—H20C 103 (3) 
C12—C11—H11 124.6 (19) C19—C21—H21A 111.9 (17) 
C10—C11—H11 115.1 (19) C19—C21—H21B 104.0 (17) 
C11—C12—C13 120.0 (2) H21A—C21—H21B 112 (3) 
C11—C12—H12 121.8 (17) C19—C21—H21C 111 (2) 
C13—C12—H12 118.3 (17) H21A—C21—H21C 110 (3) 
C12—C13—C8 120.6 (2) H21B—C21—H21C 108 (3) 
    
C14—N1—N2—C18 -100.6 (2) C3—C8—C9—C10 -178.0 (2) 
C5—N1—N2—C18 124.97 (18) C8—C9—C10—C11 0.7 (4) 
C14—N1—N2—C3 114.44 (18) C9—C10—C11—C12 -0.8 (4) 
C5—N1—N2—C3 -20.04 (19) C10—C11—C12—C13 0.0 (4) 
C18—N2—C3—C8 87.0 (2) C11—C12—C13—C8 1.1 (3) 
N1—N2—C3—C8 -127.73 (17) C9—C8—C13—C12 -1.2 (3) 
C18—N2—C3—C4 -150.30 (17) C3—C8—C13—C12 177.1 (2) 
N1—N2—C3—C4 -5.06 (19) N2—N1—C14—O1 -164.79 (19) 
N2—C3—C4—C5 27.0 (2) C5—N1—C14—O1 -35.7 (3) 
C8—C3—C4—C5 148.78 (17) N2—N1—C14—O2 19.3 (2) 
C14—N1—C5—C6 143.74 (18) C5—N1—C14—O2 148.38 (17) 
N2—N1—C5—C6 -82.21 (19) O1—C14—O2—C15 -1.2 (3) 
C14—N1—C5—C4 -97.8 (2) N1—C14—O2—C15 174.51 (18) 
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N2—N1—C5—C4 36.3 (2) C14—O2—C15—C16 105.0 (3) 
C3—C4—C5—N1 -38.8 (2) C14—O2—C15—C17 -131.7 (2) 
C3—C4—C5—C6 79.8 (2) N1—N2—C18—O3 -162.53 (16) 
N1—C5—C6—C7 -11.1 (3) C3—N2—C18—O3 -20.4 (3) 
C4—C5—C6—C7 -123.5 (3) N1—N2—C18—O4 20.6 (2) 
N2—C3—C8—C9 -128.1 (2) C3—N2—C18—O4 162.73 (16) 
C4—C3—C8—C9 116.0 (2) O3—C18—O4—C19 -3.2 (3) 
N2—C3—C8—C13 53.7 (3) N2—C18—O4—C19 173.52 (16) 
C4—C3—C8—C13 -62.3 (3) C18—O4—C19—C20 -156.27 (18) 
C13—C8—C9—C10 0.4 (3) C18—O4—C19—C21 81.3 (2) 
 
Hydrogen-bond geometry (Å, º) 
D—H···A D—H H···A D···A D—H···A 
C19—H19···O1i 0.97 (3) 2.53 (3) 3.343 (3) 141.4 (18) 
 
Symmetry code:  (i) x, y-1, z. 
Computing details 
Data collection: Bruker APEX 2; cell refinement: Bruker SAINT; data reduction: Bruker 
SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to 
refine structure: SHELXL2012 (Sheldrick, 2012); molecular graphics: Bruker SHELXTL; 
software used to prepare material for publication: Bruker SHELXTL. 
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix. The cell esds are taken into account individually 
in the estimation of esds in distances, angles and torsion angles; correlations between esds in 
cell parameters are only used when they are defined by crystal symmetry. An approximate 
(isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. 
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5.2. NOE Spectra for 2.63 
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5.3. NOE Spectra for 2.56a 
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